

HEDIS Benchmarks

and Coding Guidelines for Quality Care

Electronic Clinical Data Systems







Iowa | Iowa Health Link

https://provider.wellpoint.com/ia

Coverage provided by Wellpoint Iowa, Inc. IAWP-CD-069503-24-CPN69339 | January 2025





Table of contents

Electronic Clinical Data Systems	4	
Follow-Up Care for Children Prescribed ADHD Medication (ADD-E)	6	
Adult Immunization Status (AIS-E)	7	
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E)	9	
Unhealthy Alcohol Use Screening and Follow-Up (ASF-E)		
Blood Pressure Control for Patients with Hypertension (BPC-E)		
Cervical Cancer Screening (CCS-E)		
Childhood Immunization Status (CIS-E)		
Colorectal Cancer Screening (COL-E)		
Documented Assessment After Mammogram (DBM-E)		
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-		
Depression Remission or Response for Adolescents and Adults (DRR-E)		
Follow-Up After Abnormal Mammogram Assessment (FMA-E)		
Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)		
Immunizations for Adolescents (IMA-E)		
Postpartum Depression Screening and Follow-Up (PDS-E)		
Prenatal Depression Screening and Follow-up (PND-E)		
Prenatal Immunization Status (PRS-E)		
Social Need Screening and Intervention (SNS-E)		
Appendix		
Adult Immunization Status (AIS-E)		37
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E)		
Unhealthy Alcohol Use Screening and Follow-Up (ASF-E)		
Breast Cancer Screening (BCS-E)		
Blood Pressure Control for Patients With Hypertension (BPC-E)		
Cervical Cancer Screening (CCS-E)		
Childhood Immunization Status (CIS-E)		59
Colorectal Cancer Screening (COL-E)		
Documented Assessment After Mammogram (DBM-E)		
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E)		
Depression Remission or Response for Adolescents and Adults (DRR-E)		
Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)		
Follow-Up After Abnormal Mammogram Assessment (FMA-E)		
Postpartum Depression Screening and Follow-Up (PDS-E)		
Prenatal Depression Screening and Follow-up (PND-E) Prenatal Immunization Status (PRS-E)		
Additional codes		
Social Need Screening and Intervention (SNS-E)		

Page 3 of 117

Electronic Clinical Data Systems

HEDIS[®] is a widely used set of performance measures developed and maintained by NCQA. These are used to drive improvement efforts surrounding best practices.

The HEDIS quality measures reported using the Electronic Clinical Data Systems (ECDS) inspire innovative use of electronic clinical data to document high-quality patient care that demonstrates commitment to evidence-based practices. Organizations that report HEDIS using ECDS encourage the electronic exchange of the information needed to provide high-quality services, ensuring that the information reaches the right people at the right time:

- ECDS reporting is part of the National Committee for Quality Assurance's (NCQA) larger strategy to enable a digital quality system and is aligned with the industry's move to digital measures.
- The ECDS reporting standard provides a method to collect and report structured electronic clinical data for HEDIS quality measurement and improvement.
- According to the NCQA, the HEDIS hybrid data collection (medical record collection) will be phasedout in the coming years.
- Health plans and healthcare providers will need to take advantage of electronic data streams to ensure accurate reporting of measures that require data not typically found in claims.
- CPT[®] Category II codes can be used for performance measurement. The use of the CPT II decreases the need for record abstraction and chart review.
- CVX codes (vaccine administered code set) represent the type of product used in an immunization. Every immunization that used a given type of product will have the same CVX, regardless of who received it.
- Logical Observation Identifiers Names and Codes (LOINC) and SNOMED CT codes (supports the development of comprehensive high-quality clinical content in electronic health records) do not appear on claims and are quickly becoming vital to HEDIS reporting, especially for ECDS measures:
 - LOINC codes while typically associated with lab data, there are several behavioral health screenings that can only be represented by LOINC codes for the purposes of HEDIS reporting and can be extracted from electronic medical record (EMR) systems.
 - SNOMED CT codes represent both diagnoses and procedures as well as clinical findings.
 SNOMED CT codes are the industry standard for classifying clinical data in EMR systems and can be extracted from EMR systems.
 - Because LOINC codes and SNOMED CT codes can only be obtained through supplemental data feeds, it is important that health plans and the provider community embrace the sharing of these EMR data to ensure the quality of care our members are receiving.

HEDIS[®] is a registered trademark of the National Committee for Quality Assurance (NCQA).

Helpful tips:

- Utilize this booklet as a reference to understand the ECDS measures and the coding associated with electronic data transmission.
- Contact your health plan representative to establish an electronic data transfer with the plan if your organization does not already have one.

Page 4 of 117

- Make full use of CPT II codes to submit care quality findings, many HEDIS gaps could be closed via claims if CPT II codes were fully utilized.
- Ensure the EMR systems are set up to link the clinical and behavior health entries to LOINC codes and SNOMED CT codes:
 - Ensure that the extracts are inclusive of LOINC codes for BH screenings among other things and SNOMED CT codes.

Our Supplemental Data team is here to help.

For additional support in submitting supplemental data for ECDS measures, send inquiries to supplementaldata@wellpoint.com.

Page 5 of 117

Follow-Up Care for Children Prescribed ADHD Medication (ADD-E)

This measure looks at the percentage of children ages 6 to 12 newly prescribed attentiondeficit/hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 300-day (10-month) period, one of which was within 30 days of when the first ADHD medication was dispensed during the measurement year.

Two rates are reported:

- Initiation phase: the percentage of members 6 to 12 years of age with a prescription dispensed for ADHD medication, who had one follow-up visit with a practitioner with prescribing authority during the 30-day initiation phase.
- Continuation and maintenance (C&M) phase: the percentage of members 6 to 12 years of age with a prescription dispensed for ADHD medication, who remained on the medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two follow-up visits with a practitioner within 270 days (9 months) after the initiation phase ended.

Record your efforts:

When prescribing a new ADHD medication:

- Be sure to schedule a follow-up visit right away within 30 days of ADHD medication initially prescribed or restarted after a 120-day break.
- Schedule follow-up visits while members are still in the office.
- Have your office staff call members at least three days before appointments.
- After the initial follow-up visits, schedule at least two more office visits in the next nine months to monitor patients' progress.
- Be sure that follow-up visits include the diagnosis of ADHD.

Exclusions:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year
- Members who die any time during the measurement year
- Members with a diagnosis of narcolepsy any time during the member's history through the end of the measurement period. Do not include laboratory claims (claims with POS code 81)

Page 6 of 117

Adult Immunization Status (AIS-E)

This measure looks at the percentage of members 19 years of age and older who are up to date on recommended routine vaccines for influenza, tetanus, and diphtheria (Td) or tetanus, diphtheria, and acellular pertussis (Tdap), zoster and pneumococcal and hepatitis B during the measurement year.

Record your efforts:

Document the required age vaccines were received according to the time interval specified in the measure:

• Members who received an influenza vaccine on or between July 1 of the year prior to the measurement period and June 30 of the measurement period

or

- Members with anaphylaxis due to the influenza vaccine any time before or during the measurement period
- Members who received at least one Td vaccine or one Tdap vaccine between 9 years prior to the start of the measurement period and the end of the measurement period

or

- Members with a history of at least one of the following contraindications any time before or during the measurement period:
 - Anaphylaxis due to the diphtheria, tetanus, or pertussis vaccine.
 - Encephalitis due to the diphtheria, tetanus, or pertussis vaccine.
- Members who received 2 doses of the herpes zoster recombinant vaccine at least 28 days apart, on [Date] through the end of the measurement period

or

- Members with anaphylaxis due to the herpes zoster vaccine any time before or during the measurement period.
- Members who received at least one dose of an adult pneumococcal vaccine) on or after their 19th birthday and before or during the measurement period or members with anaphylaxis due to the pneumococcal vaccine any time before or during the measurement period

or

- Members with anaphylaxis due to the pneumococcal vaccine any time before or during the measurement period.
- Members who received at least three doses of the childhood hepatitis B vaccine with different dates of service on or before their 19th birthday:

Page 7 of 117

- One of the three vaccinations can be a newborn hepatitis B vaccination (ICD-10-PCS code 3E0234Z) during the 8-day period that begins on the date of birth and ends 7 days after the date of birth.
- Members who received a hepatitis B vaccine series on or after their 19th birthday, before or during the measurement period, including either of the following:
 - At least two doses of the recommended two-dose adult hepatitis B vaccine administered at least 28 days apart; or
 - At least three doses of any other recommended adult hepatitis B vaccine administered on different days of service.
- Members who had a hepatitis B surface antigen, hepatitis B surface antibody or total antibody to hepatitis B core antigen test, with a positive result any time before or during the measurement period. Any of the following meet criteria:
- A test result greater than 10 mIU/mL:
 - A test with a finding of immunity.
- Members with a history of hepatitis B illness any time before or during the measurement period. Do not include laboratory claims (POS 81).
- Members with anaphylaxis due to hepatitis B any time before or during the measurement period.

Exclusions:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year

Page 8 of 117

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E)

This measure looks at the percentage of children and adolescents 1 to 17 years of age who had two or more antipsychotic prescriptions and had metabolic testing during the measurement year. Three rates are reported:

- The percentage of children and adolescents on antipsychotics who received blood glucose testing (blood glucose or HbA1c)
- The percentage of children and adolescents on antipsychotics who received cholesterol testing (LDL-C or cholesterol)
- The percentage of children and adolescents on antipsychotics who received both blood glucose and cholesterol testing.

Record your efforts:

- Members who received at least one test for blood glucose or HbA1c during the measurement period
- Members who received at least one test for LDL-C or cholesterol during the measurement period
- Members who were compliant for both the blood glucose and cholesterol indicators:
 - At least one test for blood glucose or HbA1c
 - At least one test for LDL-C or cholesterol

Exclusions:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year

Page 9 of 117

Unhealthy Alcohol Use Screening and Follow-Up (ASF-E)

This measure looks at the percentage of members 18 years of age and older who were screened for unhealthy alcohol use using a standardized instrument and, if screened positive, received appropriate follow-up care during the measurement year:

- Unhealthy Alcohol Use Screening: the percentage of members who had a systematic screening for unhealthy alcohol use
- Follow-Up Care on Positive Screen: the percentage of members receiving brief counseling or other follow-up care within 60 days (2 months) of screening positive for unhealthy alcohol use

Record your efforts:

A standard assessment instrument that has been normalized and validated for the adult patient population to include *AUDIT*, *AUDIT-C*, and a *Single-Question Screen*. Screening requires completion of one or more instruments. The threshold for a positive finding is indicated below for each instrument:

Screening instrument	Total score LOINC codes	Positive finding
Alcohol Use Disorders Identification Test (AUDIT) Screening	75624-7	Total score ≥ 8
Instrument		
Alcohol Use Disorders Identification Test Consumption	75626-2	Total score ≥ 4 for men
(AUDIT-C) Screening Instrument		Total score ≥ 3 for women
Single-question screen (for men):	88037-7	Response ≥1
"How many times in the past year have you had 5 or more		
drinks in a day?"		
Single-question screen (for women and all adults older than	75889-6	Response ≥1
65 years):		
"How many times in the past year have you had 4 or more		
drinks in a day?"		

Any of the following on or up to 60 days after the first positive screen:

- Feedback on alcohol use and harms
- Identification of high-risk situations for drinking and coping strategies
- Increase the motivation to reduce drinking
- Development of a personal plan to reduce drinking
- Documentation of receiving alcohol misuse treatment

Exclusions:

HEDIS ECDS Coding Booklet 2025

Page 10 of 117

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year
- Members with alcohol use disorder that starts during the year prior to the measurement period. Do not include laboratory claims (claims with POS code 81).
- Members with history of dementia any time during the member's history through the end of the measurement period. Do not include laboratory claims (claims with POS code 81).

Page 11 of 117

Breast Cancer Screening (BCS-E)

This HEDIS measure looks at members 50 to 74 years of age who were recommended for routine breast cancer screening and had a mammogram to screen for breast cancer from October 1, two years prior to the measurement period through the end of the measurement period.

Record your efforts:

Include documentation of all types and methods of mammograms including:

- Screening
- Diagnostic
- Film
- Digital
- Digital breast tomosynthesis

In establishing health history with new members, please make sure you ask about when members last mammogram was performed, document at a minimum, year performed in your health history.

Gaps in care are not closed by the following, as they are performed as an adjunct to mammography:

- Breast ultrasounds
- MRIs
- Biopsies

Exclusions:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.
- Members who had a bilateral mastectomy or both right and left unilateral mastectomies any time during the member's history through the end of the measurement period. Any of the following meet the criteria for bilateral mastectomy:
 - Bilateral mastectomy
 - Unilateral mastectomy with a bilateral modifier
 - Unilateral mastectomy found in clinical data with a bilateral qualifier value
 - History of bilateral mastectomy
- Members who had gender-affirming chest surgery with a diagnosis of gender dysphoria any time during the member's history through the end of the measurement period.
- Members 66 years of age and older as of December 31 of the measurement year (all product lines) with frailty and advanced illness. Members must meet *both* frailty and advanced illness criteria to be excluded.
- Members receiving palliative care any time during the measurement year
- Members who had an encounter for palliative anytime during the measurement year. Do not include laboratory claims (claims with POS code 81).

Blood Pressure Control for Patients with Hypertension (BPC-E)

This measure looks at the percentage of members 18 to 85 years of age who had a diagnosis of hypertension (HTN) and whose most recent blood pressure (BP) was <140/90 mm Hg during the measurement period.

Record your efforts:

Members who are 18-85 years old as of the last day of the measurement period who meet either of the following criteria:

- At least two outpatient visits, telephone visits, e-visits or virtual check-ins on different dates of service with a diagnosis of hypertension on or between January 1 of the year prior to the measurement period and June 30 of the measurement period.
- At least one outpatient visit, telephone visit, e-visit or virtual check-in with a diagnosis of hypertension and at least one dispensed antihypertensive medication on or between January 1 of the year prior to the measurement period and June 30 of the measurement period.

Exclusions:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement period.
- Members who die any time during the measurement period
- Members receiving palliative care any time during the measurement period.
- Members who had an encounter for palliative care (ICD-10-CM code Z51.5) any time during the measurement period. Do not include laboratory claims (claims with POS code 81).
- Members with a nonacute inpatient admission during the measurement period. To identify nonacute inpatient admissions:
 - Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
 - Confirm the stay was for nonacute care based on the presence of a nonacute code the claim.
 - Identify the admission date for the stay
- Members with a diagnosis that indicates end-stage renal disease (ESRD) any time during the member's history on or prior to the last day of the measurement period. Do not include laboratory claims (claims with POS code 81).
- Members with a procedure that indicates ESRD: dialysis or kidney transplant any time during the member's history on or prior to the last day of the measurement period.

Page 13 of 117

- Members with a diagnosis of pregnancy (Pregnancy Value Set) any time during the measurement period. Do not include laboratory claims (claims with POS code 81).
- Members 66 to 80 years of age as of the last day of the measurement period (all product lines) with frailty and advanced illness. Members must meet both frailty and advanced illness criteria to be excluded:
 - Frailty. At least two indications of with different dates of service during the measurement period. Do not include laboratory claims (claims with POS code 81).
 - Advanced Illness. Either of the following during the measurement period or the year prior to the measurement period:
 - Advanced illness on at least two different dates of service. Do not include laboratory claims (claims with POS code 81).
 - Dispensed dementia medication.
- Members 81 years of age and older as of the last day of the measurement period (all product lines) with at least two indications of frailty with different dates of service during the measurement period. Do not include laboratory claims (claims with POS code 81).

Page 14 of 117

Cervical Cancer Screening (CCS-E)

This measure looks at the percentage of members 21-64 years of age who were recommended for routine cervical cancer screening and were screened for cervical cancer using any of the following criteria:

- Members 21 to 64 years of age who were recommended for routine cervical cancer screening and had cervical cytology performed within the last 3 years.
- Members 30 to 64 years of age who were recommended for routine cervical cancer screening and had cervical high-risk human papillomavirus (hrHPV) testing performed within the last 5 years.
- Members 30 to 64 to years of age who were recommended for routine cervical cancer screening and had cervical cytology/high-risk human papillomavirus (hrHPV) cotesting within the last 5 years.

Record your efforts:

Make sure your medical records reflect:

- The date when the cervical cytology was performed.
- The results or findings
- Notes in patient's chart if patient has a history of hysterectomy:
 - Complete details if it was a complete, total, or radical abdominal, vaginal, or unspecified hysterectomy with no residual cervix; also, document history of cervical
 - agenesis or acquired absence of cervix. Include, at a minimum, the year the surgical procedure was performed.

Exclusions:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year
- Hysterectomy with no residual cervix any time during the member's history through December 31 of the measurement year
- Cervical agenesis or acquired absence of cervix any time during the member's history through the end of the measurement period. Do not include laboratory claims (claims with POS code 81).
- Members receiving palliative care any time during the measurement period.
- Members who had an encounter for palliative care any time during the measurement period. Do not include laboratory claims (claims with POS code 81).
- Members with Sex Assigned at Birth of Male at any time during the patient's history.

Page 15 of 117

Childhood Immunization Status (CIS-E)

The percentage of children turning 2 years of age who had who had appropriate doses of the following vaccines on or before their second birthday:

- At least 4 diphtheria, tetanus, and acellular pertussis, *DTaP* vaccine with different dates of service. Do not count a vaccination administered prior to 42 days after birth.
 - Anaphylaxis due to the diphtheria, tetanus or pertussis vaccine
 - Encephalitis due to the diphtheria, tetanus or pertussis vaccine
- At least 3 polio, *IPV* vaccine with different dates of service. Do not count a vaccination administered prior to 42 days after birth.
 - Anaphylaxis due to the IPV vaccine
- At least 1 measles, mumps and rubella, *MMR* vaccine (can only be given on or between first and second birthday to close the gap)
 - All of the following any time on or before the child's second birthday (on the same or different date of service). Do not include laboratory claims (claims with POS code 81):
 - History of measles illness
 - History of mumps illness
 - History of rubella illness
 - Anaphylaxis due to the MMR vaccine on or before the child's second birthday.
- At least 3 haemophilus influenza type B, *Hib* vaccine with different dates of service. Do not count a vaccination administered prior to 42 days after birth.
 - Anaphylaxis due to the HiB vaccine
- At least 3 hepatitis B, *HepB* vaccine (One of the three vaccinations can be a newborn hepatitis B vaccination during the eight-day period that begins on the date of birth and ends 7 days after the date of birth.)
 - History of hepatitis B illness Do not include laboratory claims (claims with POS code 81).
 - Anaphylaxis due to hepatitis B vaccine
- At least 1 chicken pox, VZV vaccine with a date of service on or between first and second birthdays:
 - History of varicella zoster (for example, chicken pox) illness on or before the child's second birthday. Do not include laboratory claims (claims with POS code 81).
 - Anaphylaxis due to the VZV vaccine (SNOMED CT code 471341000124104) on or before the child's second birthday
- At least 4 pneumococcal conjugate, *PCV* vaccine with different dates of service. Do not count a vaccination administered prior to 42 days after birth.
 - Anaphylaxis due to the pneumococcal vaccine
- At least 1 hepatitis A, *HepA* vaccine with a date of service on or between first and second birthday:
 - History of hepatitis A illness on or before the child's second birthday. Do not include laboratory claims (claims with POS code 81).
 - Anaphylaxis due to the hepatitis A vaccine (SNOMED CT code 471311000124103) on or before the child's second birthday.
- At least 2 two-dose rotavirus, *RV* vaccine, on different dates of service on or before the child's second birthday. Do not count a vaccination administered prior to 42 days after birth.

Page 16 of 117

- At least three doses of the three-dose rotavirus, *RV* vaccine on different dates of service on or before the child's second birthday. Do not count a vaccination administered prior to 42 days after birth.
- At least one dose of the two-dose rotavirus, *RV* vaccine and at least two doses of the three-dose rotavirus, *RV* vaccine all on different dates of service, on or before the child's second birthday. Do not count a vaccination administered prior to 42 days after birth.
 - Anaphylaxis due to the rotavirus vaccine (SNOMED CT code 428331000124103) on or before the child's second birthday.
- At least 2 influenza, *Flu* vaccine with different dates of service. Do not count a vaccination administered prior to 180 days after birth.
 - An influenza vaccination recommended for children 2 years and older (for example, LAIV) administered on the child's second birthday meets criteria for one of the two required vaccinations.
 - Anaphylaxis due to the influenza vaccine

Record your efforts:

Once you give our members their needed immunizations, let us and the state know by:

- Recording the immunizations in your state registry.
- Documenting the immunizations (historic and current) within medical records to include:
 - A note indicating the name of the specific antigen and the date of the immunization.
 - The certificate of immunization prepared by an authorized health care provider or agency.
 - Parent refusal, documented history of anaphylactic reaction to serum/vaccinations, illnesses, or seropositive test result.
 - The date of the first hepatitis B vaccine given at the hospital and name of the hospital if available.
 - A note that the *member is up to date* with all immunizations but does not list the dates of all immunizations and the names of the immunization agents does not constitute sufficient evidence of immunization for HEDIS reporting.

Exclusions:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.
- Members who had a contraindication to a childhood vaccine on or before their second birthday.

Page 17 of 117

Colorectal Cancer Screening (COL-E)

This measure looks at the percentage of members 45 to 75 years of age who had appropriate screening for colorectal cancer.

Record your efforts:

- Members with one or more screenings for colorectal cancer. Any of the following meet criteria:
 - Fecal occult blood test (FOBT) during the measurement period
 - Flexible sigmoidoscopy during the measurement period or the 4 years prior to the measurement period
 - Colonoscopy during the measurement period or the 9 years prior to the measurement period
 - CT colonography during the measurement period or the 4 years prior to the measurement period
 - Stool DNA (sDNA) with fecal immunochemical test (FIT) test during the measurement period or the 2 years prior to the measurement period

Exclusions:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.
- Members 66 years of age and older as of December 31 of the measurement year (all product lines) with frailty and advanced illness. Members must meet BOTH frailty and advanced illness criteria to be excluded.
- Members receiving palliative care any time during the measurement year.
- Members who had an encounter for palliative care any time during the measurement year. Do not include laboratory claims (claims with POS code 81).
- Members who had colorectal cancer any time during the member's history through December 31 of the measurement year. Do not include laboratory claims (claims with POS code 81).
- Members who had a total colectomy any time during the member's history through December 31 of the measurement period.

HEDIS ECDS Coding Booklet 2025

Page 18 of 117

Documented Assessment After Mammogram (DBM-E)

This measure looks at the percentage of episodes of mammograms documented in the form of a BI-RADS assessment within 14 days of the mammogram for members 40–74 years of age.

Record your efforts:

The National Comprehensive Cancer Network (NCCN) provides breast cancer screening follow-up and diagnostic guidelines based on the ACR's BI-RADS assessment categories.

- BI-RADS 0: Incomplete- Need Additional Imaging Evaluation and/or Prior Mammograms for Comparison, as needing additional imaging.
- Patients with BI-RADS Category 1: Negative, and Category 2: Benign, are recommended for continued routine screening.
- Patients with BI-RADS Category 3: Probably Benign, are recommended for mammography surveillance.
- Patients with BI-RADS Categories 4: Suspicious, and Category 5: Highly Suggestive of Malignancy, should be managed using core needle biopsy, also called percutaneous core breast biopsy, as the preferred method for tissue diagnosis.
- Patients with Category 6: Known Biopsy- Proven

nccn.org/

Exclusions:

- Members who die any time during the measurement period.
- Members who use hospice services or elect to use a hospice benefit any time during the measurement period.

Page 19 of 117

Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E)

This measure looks at the percentage of members 12 years of age and older with a diagnosis of major depression or dysthymia who had an outpatient encounter with a *Patient Health Questionnaire-9* (*PHQ-9*) score present in their record in the same assessment period as the encounter.

Record your efforts:

The identifiers and descriptors for each organization's coverage used to define members' eligibility for measure reporting. Allocation for reporting is based on eligibility during the participation period.

The measurement period is divided into three assessment periods with specific dates of service:

- Assessment Period 1: January 1 to April 30
- Assessment Period 2: May 1 to August 31
- Assessment Period 3: September 1 to December 31

The measure allows the use of two *PHQ-9* assessments. Selection of the appropriate assessment should be based on the member's age:

- PHQ-9: 12 years of age and older
- PHQ-9 Modified for Teens: 12 to 17 years of age

The *PHQ-9* assessment does not need to occur during a face-to-face encounter; it may be completed over the telephone or through a web-based portal.

Exclusions:

- Members with any of the following at any time during member's history through the end measurement period. Do not include laboratory claims (claims with POS code 81):
 - Bipolar disorder
 - Personality disorder
 - Psychotic disorder
 - Pervasive developmental disorder
- Members who use hospice services or elect to use a hospice benefit any time during the measurement period.
- Members who die any time during the measurement year.

Page 20 of 117

Depression Remission or Response for Adolescents and Adults (DRR-E)

This measure looks at the percentage of members 12 years of age and older with a diagnosis of depression and an elevated PHQ-9 score, who had evidence of response or remission within 120 to 240 days (4 to 8 months) of the elevated score during the measurement year.

- Follow-Up PHQ-9. The percentage of members who have a follow-up PHQ-9 score documented within 120 to 240 days (4 to 8 months) after the initial elevated PHQ-9 score.
- Depression Remission. The percentage of members who achieved remission within 120 to 240 days (4 to 8 months) after the initial elevated PHQ-9 score.
- Depression Response. The percentage of members who showed response within 120 to 240 days (4 to 8 months) after the initial elevated PHQ-9 score.

Record your efforts:

The identifiers and descriptors for each organization's coverage used to define members' eligibility for measure reporting. Allocation for reporting is based on eligibility during the participation period:

- May 1 of the year prior to the measurement period through December 31 of the measurement period
- May 1 of the year prior to the measurement period through April 30 of the measurement period
- The 120- to 240-day period after the index episode start date.
- Index episode start date: The earliest date during the intake period when a member has a diagnosis of major depression or dysthymia *and* a *PHQ-9* total score > 9 documented within a 31 day period, including and around (15 days before and 15 days after) an interactive outpatient encounter with a diagnosis of major depression or dysthymia.

The measure allows the use of two *PHQ-9* assessments. Selection of the appropriate assessment should be based on the member's age:

- PHQ-9: 12 years of age and older
- PHQ-9 Modified for Teens: 12 to 17 years of age

The *PHQ-9* assessment does not need to occur during a face-to-face encounter; it may be completed over the telephone or through a web-based portal.

Exclusions:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.

Page 21 of 117

- Members with any of the following any time during the member's history through the end of the measurement period. Do not include laboratory claims (claims with POS code 81):
 - Bipolar disorder
 - Personality disorder
 - Psychotic disorder
 - Pervasive developmental disorder

Page 22 of 117

Follow-Up After Abnormal Mammogram Assessment (FMA-E)

This measure looks at the percentage of episodes for members 40–74 years of age with inconclusive or high-risk BI-RADS assessments who received appropriate follow-up within 90 days of the assessment.

Record your efforts:

High-risk and inconclusive BI-RADS assessment during the Intake Period that received appropriate follow-up. Appropriate follow-up is defined as either of the following:

- A high-risk BI-RADS assessment result, that received a breast biopsy on or within 90 days after the episode date (91 days total).
- An inconclusive BI-RADS assessment (BI-RADS 0: Incomplete Need Additional Imaging Evaluation and/or Prior Mammograms for Comparison), that received a mammogram or ultrasound on or within 90 days after the episode date (91 days total).

The National Comprehensive Cancer Network (NCCN) provides breast cancer screening follow-up and diagnostic guidelines based on the ACR's BI-RADS assessment categories.

- BI-RADS 0: Incomplete- Need Additional Imaging Evaluation and/or Prior Mammograms for Comparison, as needing additional imaging.
- Patients with BI-RADS Category 1: Negative, and Category 2: Benign, are recommended for continued routine screening.
- Patients with BI-RADS Category 3: Probably Benign, are recommended for mammography surveillance.
- Patients with BI-RADS Categories 4: Suspicious, and Category 5: Highly Suggestive of Malignancy, should be managed using core needle biopsy, also called percutaneous core breast biopsy, as the preferred method for tissue diagnosis.
- Patients with Category 6: Known Biopsy- Proven

nccn.org/

Exclusions:

HEDIS ECDS Coding Booklet 2025

Page 23 of 117

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.

Page 24 of 117

Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)

This measure looks at the percentage of members 12 years of age and older who were screened for clinical depression using a standardized instrument and, if screened positive, received follow-up care during the measurement year:

- Depression Screening. The percentage of members who were screened for clinical depression using a standardized instrument.
- Follow-Up on Positive Screen. The percentage of members who received follow-up care within 30 days of a positive depression screen finding.

Record your efforts:

The identifiers and descriptors for each organization's coverage used to define members' eligibility for measure reporting. Allocation for HEDIS reporting is based on eligibility during the participation period.

This measure requires the use of an age-appropriate screening instrument. The member's age is used to select the appropriate depression screening instrument.

Depression screening instrument:

• A standard assessment instrument that has been normalized and validated for the appropriate patient population. Eligible screening instruments with thresholds for positive findings include:

Total score LOINC codes	Positive finding
44261-6	Total score ≥ 10
89204-2	Total score ≥ 10
55758-7	Total score ≥ 3
89208-3	Total score ≥ 8
89205-9	Total score ≥ 17
99046-5	Total score ≥ 10
71965-8	Total score (T score) ≥ 60
	LOINC codes 44261-6 89204-2 55758-7 89208-3 89205-9 99046-5

1 Brief screening instrument. All other instruments are full-length.

2 Proprietary; may be cost or licensing requirement associated with use.

Instruments for adults (18+ years)	 Total score LOINC codes 	Positive finding
Patient Health Questionnaire (PHQ-9)®	44261-6	Total score ≥ 10
Patient Health Questionnaire-2 (PHQ-2) ^{®1}	55758-7	Total score ≥ 3
Beck Depression Inventory-Fast Screen (BDI- FS) ^{*1,2}	89208-3	Total score ≥ 8

HEDIS ECDS Coding Booklet 2025

Page 25 of 117

Instruments for adults (18+ years)	 Total score LOINC codes 	Positive finding
Beck Depression Inventory (BDI-II)	89209-1	Total score ≥ 20
Center for Epidemiologic Studies Depression	89205-9	Total score ≥ 17
Scale- Revised (CESD-R)		
Duke Anxiety-Depression Scale (DUKE-AD) ^{®2}	90853-3	Total score ≥ 30
Geriatric Depression Scale Short Form (GDS) ¹	48545-8	Total score ≥ 5
Geriatric Depression Scale Long Form (GDS)	48544-1	Total score ≥ 10
Edinburgh Postnatal Depression Scale (EPDS)	99046-5	Total score ≥ 10
My Mood Monitor (M-3) [®]	71777-7	Total score ≥ 5
PROMIS Depression	71965-8	Total score (T score) ≥ 60
Clinically Useful Depression Outcome Scale	90221-3	Total score ≥ 31

(CUDOS)

1 Brief screening instrument. All other instruments are full-length.

2 Proprietary; may be cost or licensing requirement associated with use.

Exclusions:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.
- Members with a history of bipolar disorder any time during the member's history through the end of the year prior to the measurement period. Do not include laboratory claims (claims with POS code 81).
- Members with depression that starts during the year prior to the measurement period. Do not include laboratory claims (claims with POS code 81).

Page 26 of 117

Immunizations for Adolescents (IMA-E)

This measure reviews members 13 years of age who had one dose of meningococcal vaccine, one tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccine, and have completed the human papillomavirus (HPV) vaccine series by their 13th birthday. The measure calculates a rate for each vaccine and two combination rates.

Vaccines administered on or before their 13th birthday:

- At least one meningococcal vaccine with the date of service on or between 11th and 13th birthdays.
- Anaphylaxis due to the meningococcal vaccine (SNOMED CT code 428301000124106) any time on or before the member's 13th birthday.
- At least one tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccine with a date of service on or between the member's 10th and 13th birthdays
- Anaphylaxis due to the tetanus, diphtheria or pertussis vaccine any time on or before the member's 13th birthday.
- Encephalitis due to the tetanus, diphtheria or pertussis vaccine any time on or before the member's 13th birthday.
- At least two doses of HPV vaccine with on or between the member's 9th and 13th birthdays and with dates of service at least 146 days apart.
- At least three HPV vaccines with different dates of service on or between the member's 9th and 13th birthdays.
- Anaphylaxis due to the HPV vaccine (SNOMED CT code 428241000124101) any time on or before the member's 13th birthday.

Record your efforts:

Immunization information obtained from the medical record:

- A note indicating the name of the specific antigen and the date of the immunization
- A certificate of immunization prepared by an authorized health care provider or agency, including the specific dates and types of immunizations administered
- Document in the medical record parent or guardian refusal

HEDIS ECDS Coding Booklet 2025

Page 27 of 117

Exclusions:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.

Page 28 of 117

Postpartum Depression Screening and Follow-Up (PDS-E)

This measure assesses the percentage of deliveries in which members were screened for clinical depression during the postpartum period, and if screened positive, received follow-up care during the measurement year:

- Depression Screening. The percentage of deliveries in which members were screened for clinical depression using a standardized instrument during the postpartum period (7 to 84 days following the delivery date).
- Follow-Up on Positive Screen. The percentage of deliveries in which members received follow-up care within 30 days of a positive depression screen finding (31 total days).
 - Any of the following on or up to 30 days after the first positive screen:
 - An outpatient, telephone, e-visit or virtual check-in follow-up visit with a diagnosis of depression or other behavioral health condition.
 - A depression care management encounter that documents assessment for symptoms of depression or a diagnosis of depression or other behavioral health condition.
 - A behavioral health encounter, including assessment, therapy, collaborative care or medication management.
 - A diagnosis of encounter for exercise counseling (ICD-10-CM code Z71.82). Do not include laboratory claims (claims with POS code 81).
 - A dispensed antidepressant medication
 - Or
- Documentation of additional depression screening on a full-length instrument indicating either no depression or no symptoms that require follow-up (in other words, a negative screen) on the same day as a positive screen on a brief screening instrument

Record your efforts:

The identifiers and descriptors for each organization's coverage used to define members' eligibility for measure reporting. Allocation for reporting is based on eligibility during the participation period:

- The delivery date through 60 days following the date of delivery
- Include deliveries that occur in any setting
- Determine the delivery date using the date as of the end of the delivery
- If a member has more than one delivery in a 180-day period, include only the first eligible delivery. Then, if applicable include the next delivery that occurs after the 180-day period. Identify deliveries chronologically, including only one per 180-day period.
 - Note: Removal of multiple deliveries in a 180-day period is based on eligible deliveries.
 Assess each delivery for exclusions and participation before removing multiple deliveries in a 180-day period.

Page 29 of 117

A standard assessment instrument that has been normalized and validated for the appropriate patient population. Eligible screening instruments with thresholds for positive findings include:

		<u> </u>
Instruments for adolescents (≤ 17 years)	Total score LOINC codes	Positive finding
Patient Health Questionnaire (PHQ-9) [®]	44261-6	Total score ≥ 10
Patient Health Questionnaire Modified for Teens (PHQ- 9M)®	89204-2	Total score ≥ 10
Patient Health Questionnaire-2 (PHQ-2) ^{*1}	55758-7	Total score ≥ 3
Beck Depression Inventory-Fast Screen (BDI-FS) ^{®1,2}	89208-3	Total score ≥ 8
Center for Epidemiologic Studies Depression Scale-Revised (CESD-R)	89205-9	Total score ≥ 17
Edinburgh Postnatal Depression Scale (EPDS)	99046-5	Total score ≥ 10
PROMIS Depression	71965-8	Total score (T score) ≥ 60
PROMIS Depression Instruments for adults (18+ years)	71965-8 Total score LOINC codes	Total score (T score) ≥ 60 Positive finding
	Total score	
Instruments for adults (18+ years)	Total score LOINC codes	Positive finding
Instruments for adults (18+ years) Patient Health Questionnaire (PHQ-9)®	Total score LOINC codes 44261-6	Positive finding Total score ≥ 10
Instruments for adults (18+ years) Patient Health Questionnaire (PHQ-9) [®] Patient Health Questionnaire-2 (PHQ-2) ^{®1}	Total score LOINC codes 44261-6 55758-7	Positive finding Total score ≥ 10 Total score ≥ 3
Instruments for adults (18+ years) Patient Health Questionnaire (PHQ-9)* Patient Health Questionnaire-2 (PHQ-2)*1 Beck Depression Inventory-Fast Screen (BDI-FS)*1,2	Total score LOINC codes 44261-6 55758-7 89208-3	Positive finding Total score ≥ 10 Total score ≥ 3 Total score ≥ 8
Instruments for adults (18+ years)Patient Health Questionnaire (PHQ-9)*Patient Health Questionnaire-2 (PHQ-2)*1Beck Depression Inventory-Fast Screen (BDI-FS)*1,2Beck Depression Inventory (BDI-II)Center for Epidemiologic Studies Depression Scale-Revised	Total score LOINC codes 44261-6 55758-7 89208-3 89209-1	Positive findingTotal score ≥ 10Total score ≥ 3Total score ≥ 8Total score ≥ 20
Instruments for adults (18+ years) Patient Health Questionnaire (PHQ-9)* Patient Health Questionnaire-2 (PHQ-2)*1 Beck Depression Inventory-Fast Screen (BDI-FS)*1,2 Beck Depression Inventory (BDI-II) Center for Epidemiologic Studies Depression Scale-Revised (CESD-R)	Total score LOINC codes 44261-6 55758-7 89208-3 89209-1 89205-9	Positive findingTotal score ≥ 10 Total score ≥ 3 Total score ≥ 8 Total score ≥ 20 Total score ≥ 17
Instruments for adults (18+ years)Patient Health Questionnaire (PHQ-9)*Patient Health Questionnaire-2 (PHQ-2)*1Beck Depression Inventory-Fast Screen (BDI-FS)*1,2Beck Depression Inventory (BDI-II)Center for Epidemiologic Studies Depression Scale-Revised(CESD-R)Duke Anxiety-Depression Scale (DUKE-AD)*2	Total score LOINC codes 44261-6 55758-7 89208-3 89209-1 89205-9 90853-3	Positive findingTotal score ≥ 10 Total score ≥ 3 Total score ≥ 8 Total score ≥ 20 Total score ≥ 17 Total score ≥ 30
Instruments for adults (18+ years)Patient Health Questionnaire (PHQ-9)*Patient Health Questionnaire-2 (PHQ-2)*1Beck Depression Inventory-Fast Screen (BDI-FS)*1,2Beck Depression Inventory (BDI-II)Center for Epidemiologic Studies Depression Scale-Revised(CESD-R)Duke Anxiety-Depression Scale (DUKE-AD)*2Edinburgh Postnatal Depression Scale (EPDS)	Total score LOINC codes 44261-6 55758-7 89208-3 89209-1 89205-9 90853-3 99046-5	Positive findingTotal score ≥ 10 Total score ≥ 3 Total score ≥ 20 Total score ≥ 17 Total score ≥ 30 Total score ≥ 10

1 Brief screening instrument. All other instruments are full-length.

2 Proprietary; may be cost or licensing requirement associated with use.

Exclusions:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.

HEDIS ECDS Coding Booklet 2025

Page 30 of 117

Page 31 of 117

Prenatal Depression Screening and Follow-up (PND-E)

This measure assesses the percentage of deliveries in which members were screened for clinical depression while pregnant and, if screened positive, received follow-up care during the measurement year:

- Depression Screening. The percentage of deliveries in which members were screened for clinical depression during pregnancy using a standardized instrument.
- Follow-Up on Positive Screen. The percentage of deliveries in which members received follow-up care within 30 days of a positive depression screen finding.

Record your efforts:

The identifiers and descriptors for each organization's coverage used to define members' eligibility for measure reporting. Allocation for reporting is based on eligibility during the participation period:

- 28 days prior to the delivery date through the delivery date
- A pregnancy episode in which the delivery date occurs during the measurement period
- Include deliveries that occur in any setting.
- Determine the delivery date using the date as of the end of the delivery.
- If a member has more than one delivery in a 180-day period, include only the first eligible delivery. Then, if applicable include the next delivery that occurs after the 180-day period. Identify deliveries chronologically, including only one per 180-day period.
 - Note: Removal of multiple deliveries in a 180-day period is based on eligible deliveries.
 Assess each delivery for exclusions and participation before removing multiple deliveries in a 180-day period.

A standard assessment instrument that has been normalized and validated for the appropriate patient population. Eligible screening instruments with thresholds for positive findings include:

Instruments for adolescents (≤ 17 years)	Total score LOINC codes	Positive finding
Patient Health Questionnaire (PHQ-9)®	44261-6	Total score ≥ 10
Patient Health Questionnaire Modified for Teens (PHQ- 9M) [*]	89204-2	Total score ≥ 10
Patient Health Questionnaire-2 (PHQ-2) ^{®1}	55758-7	Total score ≥ 3
Beck Depression Inventory-Fast Screen (BDI-FS) ^{®1,2}	89208-3	Total score ≥ 8
Center for Epidemiologic Studies Depression Scale- Revised (CESD-R)	89205-9	Total score ≥ 17
Edinburgh Postnatal Depression Scale (EPDS)	99046-5	Total score ≥ 10
PROMIS Depression	71965-8	Total score (T score) ≥ 60
Instruments for adults (18+ years)	Total score LOINC codes	Positive finding
Patient Health Questionnaire (PHQ-9)®	44261-6	Total score ≥ 10
Patient Health Questionnaire-2 (PHQ-2) ^{®1}	55758-7	Total score ≥ 3
Beck Depression Inventory-Fast Screen (BDI-FS) ^{*1,2}	89208-3	Total score ≥ 8

HEDIS ECDS Coding Booklet 2025

Page 32 of 117

Instruments for adults (18+ years)	Total score LOINC codes	Positive finding
Beck Depression Inventory (BDI-II)	89209-1	Total score ≥ 20
Center for Epidemiologic Studies Depression Scale- Revised (CESD-R)	89205-9	Total score ≥ 17
Duke Anxiety-Depression Scale (DUKE-AD) ^{®2}	90853-3	Total score ≥ 30
Edinburgh Postnatal Depression Scale (EPDS)	99046-5	Total score ≥ 10
My Mood Monitor (M-3) [®]	71777-7	Total score ≥ 5
PROMIS Depression	71965-8	Total score (T score) ≥ 60
Clinically Useful Depression Outcome Scale (CUDOS)	90221-3	Total score ≥ 31

1 Brief screening instrument. All other instruments are full-length.

2 Proprietary; may be cost or licensing requirement associated with use.

Exclusions:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.
- Deliveries that occurred at less than 37 weeks gestation. Length of gestation in weeks is identified by one of two methods:
 - Gestational age assessment (SNOMED CT code 412726003; value <37 weeks), or
 - Gestational age diagnosis

Page 33 of 117

Prenatal Immunization Status (PRS-E)

This measure assesses the percentage of deliveries in the measurement period (January 1 to December 31) in which women had received influenza and tetanus, diphtheria toxoids, and acellular pertussis (Tdap) vaccinations.

Record your efforts:

The identifiers and descriptors for each organization's coverage used to define members' eligibility for measure reporting. Allocation for reporting is based on eligibility during the participation period:

- 28 days prior to the delivery date through the delivery date
- A pregnancy episode in which the delivery date occurs during the measurement period
- Include deliveries that occur in any setting.
- Determine the delivery date using the date as of the end of the delivery.
- If a member has more than one delivery in a 180-day period, include only the first eligible delivery. Then, if applicable, include the next delivery that occurs after the 180-day period. Identify deliveries chronologically, including only one per 180-day period.
 - Note: Removal of multiple deliveries in a 180-day period is based on eligible deliveries.
 Assess each delivery for exclusions and participation before removing multiple deliveries in a 180-day period.

Exclusions:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.
- Deliveries that occurred at less than 37 weeks gestation. Length of gestation in weeks is identified by one of two methods:
 - Gestational age assessment (SNOMED CT code 412726003; value <37 weeks), or
 - Gestational age diagnosis (Weeks of Gestation Less Than 37 Value Set).

Page 34 of 117

Social Need Screening and Intervention (SNS-E)

This measure assesses the percentage of members who were screened, using prespecified instruments, at least once during the measurement period (January 1-December 31) for unmet food, housing and transportation needs, and received a corresponding intervention if they screened positive:

- Food Screening. The percentage of members who were screened for food insecurity.
- Food Intervention. The percentage of members who received a corresponding intervention within 30 days (1 month) of screening positive for food insecurity.
- Housing Screening. The percentage of members who were screened for housing instability, homelessness or housing inadequacy.
- Housing Intervention. The percentage of members who received a corresponding intervention within 30 days (1 month) of screening positive for housing instability, homelessness or housing inadequacy.
- Transportation Screening. The percentage of members who were screened for transportation insecurity.
- Transportation Intervention. The percentage of members who received a corresponding intervention within 30 days (1 month) of screening positive for transportation insecurity.

Record your efforts:

- Food insecurity: Uncertain, limited, or unstable access to food that is: adequate in quantity and in nutritional quality; culturally acceptable; safe and acquired in socially acceptable ways.
- Housing instability: Currently consistently housed but experiencing any of the following circumstances in the past 12 months: being behind on rent or mortgage, multiple moves, cost burden or risk of eviction.
- Homelessness: Currently living in an environment that is not meant for permanent human habitation (for example, cars, parks, sidewalks, abandoned buildings, on the street), not having a consistent place to sleep at night, or because of economic difficulties, currently living in a shelter, motel, temporary or transitional living situation.
- Housing inadequacy: Housing does not meet habitability standards.
- Transportation insecurity: Uncertain, limited or no access to safe, reliable, accessible, affordable, and socially acceptable transportation infrastructure and modalities necessary for maintaining one's health, well-being, or livelihood.

Page 35 of 117

Eligible screening instruments with thresholds for positive findings include:

Food insecurity instruments	Screening item LOINC codes	Positive finding LOINC codes
Accountable Health Communities (AHC) Health-	88122-7	LA28397-0
Related Social Needs (HRSN) Screening Tool		LA6729-3
	88123-5	LA28397-0
		LA6729-3
American Academy of Family Physicians (AAFP)	88122-7	LA28397-0
Social Needs Screening Tool		LA6729-3
	88123-5	LA28397-0
		LA6729-3
American Academy of Family Physicians (AAFP)	88122-7	LA28397-0
Social Needs Screening Tool—short form		LA6729-3
	88123-5	LA28397-0
		LA6729-3
Health Leads Screening Panel®1	95251-5	LA33-6
Hunger Vital Sign™1 (HVS)	88124-3	LA19952-3
Protocol for Responding to and Assessing Patients' Assets, Risks and Experiences [PRAPARE]®1	93031-3	LA30125-1
Safe Environment for Every Kid (SEEK) ^{®1}	95400-8	LA33-6
	95399-2	LA33-6
U.S. Household Food Security Survey (U.S. FSS)	95264-8	LA30985-8
		LA30986-6
U.S. Adult Food Security Survey (U.S. FSS)	95264-8	LA30985-8
		LA30986-6
U.S. Child Food Security Survey (U.S. FSS)	95264-8	LA30985-8
		LA30986-6
U.S. Household Food Security Survey–Six-Item	95264-8	LA30985-8
Short Form (U.S. FSS)		LA30986-6
We Care Survey	96434-6	LA32-8
WellRx Questionnaire	93668-2	LA33-6

Page 36 of 117

Housing instability and homelessness instruments	Screening item LOINC codes	Positive finding LOINC codes
Accountable Health Communities (AHC) Health- Related Social Needs (HRSN) Screening Tool	71802-3	LA31994-9 LA31995-6
American Academy of Family Physicians (AAFP) Social Needs Screening Tool	99550-6	LA33-6
American Academy of Family Physicians (AAFP) Social Needs Screening Tool—short form	71802-3	LA31994-9 LA31995-6
Children's Health Watch Housing Stability Vital	98976-4	LA33-6
Signs™1	98977-2	≥3
	98978-0	LA33-6
Health Leads Screening Panel ^{®1}	99550-6	LA33-6
Protocol for Responding to and Assessing Patients' Assets, Risks and Experiences (PRAPARE) ^{*1}	93033-9	LA33-6
Assets, hisks und Experiences (FNAFANE)	71802-3	LA30190-5
We Care Survey	96441-1	LA33-6
WellRx Questionnaire	93669-0	LA33-6

Housing inadequacy instruments	Screening item LOINC codes	Positive finding LOINC codes
Accountable Health Communities (AHC) Health-	96778-6	LA31996-4
Related Social Needs (HRSN) Screening Tool		LA28580-1
		LA31997-2
		LA31998-0
		LA31999-8
		LA32000-4
		LA32001-2
American Academy of Family Physicians (AAFP)	96778-6	LA32691-0
Social Needs Screening Tool		LA28580-1
		LA32693-6
		LA32694-4
		LA32695-1
		LA32696-9

HEDIS ECDS Coding Booklet 2025

Page 37 of 117

Housing inadequacy instruments	Screening item LOINC codes	Positive finding LOINC codes
		LA32001-2
American Academy of Family Physicians (AAFP)	96778-6	LA31996-4
Social Needs Screening Tool—short form		LA28580-1
		LA31997-2
		LA31998-0
		LA31999-8
		LA32000-4
		LA32001-2
Norwalk Community Health Center Screening Tool [NCHC]	99134-9	LA33-6
	99135-6	LA31996-4
		LA28580-1
		LA31997-2
		LA31998-0
		LA31999-8
		LA32000-4
		LA32001-2

Transportation insecurity instruments	Screening item LOINC codes	Positive finding LOINC codes
Accountable Health Communities (AHC) Health- Related Social Needs (HRSN) Screening Tool	93030-5	LA33-6
American Academy of Family Physicians (AAFP) Social Needs Screening Tool	99594-4	LA33-6
American Academy of Family Physicians (AAFP) Social Needs Screening Tool—short form	99594-4	LA33093-8 LA30134-3
Comprehensive Universal Behavior Screen (CUBS)	89569-8	LA29232-8 LA29233-6 LA29234-4
Health Leads Screening Panel ^{®1}	99553-0	LA33-6
Inpatient Rehabilitation Facility - Patient Assessment Instrument (IRF-PAI)—version 4.0 [CMS Assessment]	93030-5	LA30133-5 LA30134-3

Page 38 of 117

Transportation insecurity instruments	Screening item LOINC codes	Positive finding LOINC codes
Outcome and assessment information set (OASIS) form—version E—Discharge from Agency [CMS Assessment]	93030-5	LA30133-5 LA30134-3
Outcome and assessment information set (OASIS) form—version E—Resumption of Care [CMS Assessment]	93030-5	LA30133-5 LA30134-3
Outcome and assessment information set (OASIS) form—version E—Start of Care [CMS Assessment]	93030-5	LA30133-5 LA30134-3
Protocol for Responding to and Assessing Patients' Assets, Risks and Experiences (PRAPARE) ^{®1}	93030-5	LA30133-5 LA30134-3
PROMIS ^{®1}	92358-1	LA30024-6 LA30026-1 LA30027-9
WellRx Questionnaire	93671-6	LA33-6

1 Proprietary; may be cost or licensing requirement associated with use.

Note: The SNS-E screening numerator counts only screenings that use instruments in the measure specification as identified by the associated LOINC code(s). Allowed screening instruments and LOINC codes for each social need domain are listed above.

Exclusions:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year
- Members who die any time during the measurement year

HEDIS ECDS Coding Booklet 2025

Page 39 of 117

Page 40 of 117

Appendix

Coding for ECDS measures

There are many approved NCQA codes used to identify the services included in the measures listed below. The following are just a few of the approved codes. Please see the NCQA website for a complete list ncqa.org/.

Follow-Up Care for Children Prescribed ADHD Medication (ADD-E)

Description	CPT/HCPCS/POS
Outpatient POS	POS
	03: School
	05: Indian Health Service Free-standing Facility
	07 - Tribal 638 Free-standing Facility
	09 - Prison / Correctional Facility
	11: Office
	12: Home
	13: Assisted Living Facility
	14: Group Home
	15: Mobile Unit
	16: Temporary Lodging
	17: Walk-in Retail Clinic
	18: Place of Employment-Worksite
	19: Off Campus-Outpatient Hospital
	20: Urgent Care Facility
	22: On-Campus Outpatient Hospital
	33: Custodial Care Facility
	49: Independent Clinic
	50: Federally Qualified Health Center
	71: Public Health Clinic
	72: Rural Health Clinic
Health and Behavioral Assessment or	СРТ
Intervention	96156
Online Assessments	СРТ
	99422HCPCS
	G0071: Payment for communication technology-based services
	for 5 minutes or more of a virtual (non-face-to-face)
	communication between an rural health clinic (RHC) or federally
	qualified health center (FQHC) practitioner and RHC or FQHC

Page 41 of 117

Description	CPT/HCPCS/POS
	video and/or images by an RHC or FQHC practitioner, occurring in lieu of an office visit; RHC or FQHC only G2251: Brief communication technology-based service, e.g.for example, virtual check-in, by a qualified health carehealthcare professional who cannot report evaluation and management services, provided to an established patient, not originating from a related service provided within the previous 7 days nor leading to a service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of clinical discussion G2252: Brief communication technology-based service, e.g.for example virtual check-in, by a physician or other qualified health carehealthcare professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of
	medical discussion
Telehealth POS	POS 02: Telehealth Provided Other than in Patient's Home 10: Telehealth Provided in Patient's Home
Visit Setting Unspecified	СРТ
	90791, 90792, 90832, 90833, 90834, 90836, 90837, , 90839, 90840, , 90847, , 90853, 90875, 90876, 99221, 99222, 99223, 99231, 99232, 99233, 99238, 99239, 99252, 99253, 99254, 99255

Note: The codes listed are informational only; this information does not guarantee reimbursement.

Immunization	CPT/HCPCS/CVX/SNOMED CTSNOMED CT
Adult Influenza Vaccine	СРТ
procedure	0, 90653, , , 90658, 90661, 90662, , 90674, , 90686, 90688, 90689, 90694, 90756
	SNOMED CTSNOMED CT
	86198006: Administration of vaccine product containing only Influenza virus
	antigen (procedure)
Adult Influenza	CVX
Immunization	88: influenza virus vaccine, unspecified formulation
	135: influenza, high dose seasonal, preservative-free
	140: Influenza, seasonal, injectable, preservative free
	141: Influenza, seasonal, injectable
	144: seasonal influenza, intradermal, preservative free

Adult Immunization Status (AIS-E)

Page 42 of 117

Immunization	CPT/HCPCS/CVX/SNOMED CTSNOMED CT
	150: Influenza, injectable, quadrivalent, preservative free
	153: Influenza, injectable, Madin Darby Canine Kidney, preservative free
	155: Seasonal, trivalent, recombinant, injectable influenza vaccine, preservative
	free
	158: influenza, injectable, quadrivalent, contains preservative
	166: influenza, intradermal, quadrivalent, preservative free, injectable
	168: Seasonal trivalent influenza vaccine, adjuvanted, preservative free
	171: Influenza, injectable, Madin Darby Canine Kidney, preservative free, quadrivalent
	185: Seasonal, quadrivalent, recombinant, injectable influenza vaccine, preservative free
	186: Influenza, injectable, Madin Darby Canine Kidney, quadrivalent with preservative
	197: influenza, high-dose seasonal, quadrivalent, 0.7mL dose, preservative free
	205: influenza, seasonal vaccine, quadrivalent, adjuvanted, 0.5mL dose, preservative free
Adult Pneumococcal	CVX
Immunization	33: pneumococcal polysaccharide vaccine, 23 valent
	109: pneumococcal vaccine, unspecified formulation
	133: pneumococcal conjugate vaccine, 13 valent
	152: Pneumococcal Conjugate, unspecified formulation
	215: Pneumococcal conjugate vaccine 15-valent (PCV15), polysaccharide CRM197
	conjugate, adjuvant, preservative free
	216: Pneumococcal conjugate vaccine 20-valent (PCV20), polysaccharide CRM197
	conjugate, adjuvant, preservative free
Adult Pneumococcal Vaccine	СРТ
Procedure	90670, 90671, 90677, 90732
	HCPCS
	G0009: Administration of pneumococcal vaccine
	SNOMED CTSNOMED CT
	12866006: Administration of vaccine product containing only Streptococcus
	pneumoniae antigen (procedure)
	394678003: Administration of booster dose of vaccine product containing only
	Streptococcus pneumoniae antigen (procedure)
	871833000: Subcutaneous injection of pneumococcal vaccine (procedure)
	1119366009: Administration of vaccine product containing only Streptococcus pneumoniae Danish serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F capsular polysaccharide antigens (procedure)
	1119367000: Administration of vaccine product containing only Streptococcus
	pneumoniae Danish serotype 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,

Page 43 of 117

Immunization	CPT/HCPCS/CVX/SNOMED CTSNOMED CT
	17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F capsular polysaccharide antigens
	(procedure)
	1119368005: Administration of vaccine product containing only Streptococcus
	pneumoniae Danish serotype 4, 6B, 9V, 14, 18C, 19F, and 23F capsular
	polysaccharide antigens conjugated (procedure)
	1296904008: Administration of vaccine product containing only Streptococcus pneumoniae Danish serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F
	capsular polysaccharide antigens conjugated (procedure)
	434751000124102: Pneumococcal conjugate vaccination (procedure)
Influenza Virus LAIV Vaccine	СРТ
Procedure	90660, 90672
	SNOMED CTSNOMED CT
	787016008: Administration of vaccine product containing only Influenza virus
Influenza Virus LAIV	antigen in nasal dose form (procedure)
Immunization	CVX 111: influenza virus vaccine, live, attenuated, for intranasal use
Infinitization	149: influenza, live, intranasal, quadrivalent
Td Vaccine Procedure	СРТ
	90714
	SNOMED CTSNOMED CT
	73152006: Administration of vaccine product containing only Clostridium tetani and Corynebacterium diphtheriae antigens (procedure)
	312869001: Administration of vaccine product containing only Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure)
	395178008: Administration of first dose of vaccine product containing only
	Clostridium tetani and low dose Corynebacterium diphtheriae antigens (procedure)
	395179000: Administration of second dose of vaccine product containing only
	Clostridium tetani and low dose Corynebacterium diphtheriae antigens (procedure)
	395180002: Administration of third dose of vaccine product containing only
	Clostridium tetani and low dose Corynebacterium diphtheriae antigens (procedure)
	395181003: Administration of booster dose of vaccine product containing only Clostridium tetani and low dose Corynebacterium diphtheriae antigens (procedure)

Page 44 of 117

Immunization	CPT/HCPCS/CVX/SNOMED CTSNOMED CT
	414619005: Administration of vaccine product containing only Clostridium tetani and low dose Corynebacterium diphtheriae and inactivated Human poliovirus antigens (procedure)
	416144004: Administration of third dose of vaccine product containing only Clostridium tetani and low dose Corynebacterium diphtheriae and inactivated Human poliovirus antigens (procedure)
	416591003: Administration of first dose of vaccine product containing only Clostridium tetani and low dose Corynebacterium diphtheriae and inactivated Human poliovirus antigens (procedure)
	417211006: Administration of first booster of vaccine product containing only Clostridium tetani and low dose Corynebacterium diphtheriae and inactivated Human poliovirus antigens (procedure)
	417384007: Administration of second booster of vaccine product containing only Clostridium tetani and low dose Corynebacterium diphtheriae and inactivated Human poliovirus antigens (procedure)
	417615007: Administration of second dose of vaccine product containing only Clostridium tetani and low dose Corynebacterium diphtheriae and inactivated Human poliovirus antigens (procedure)
	866161006: Administration of booster dose of vaccine product containing only Clostridium tetani and Corynebacterium diphtheriae antigens (procedure)
	866184004: Administration of second dose of vaccine product containing only Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 866185003: Administration of first dose of vaccine product containing only
	Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 866186002: Administration of vaccine product containing only Clostridium tetani
	and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 866227002: Administration of booster dose of vaccine product containing only Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure)
	868266002: Administration of second dose of vaccine product containing only Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure)
	868267006: Administration of first dose of vaccine product containing only Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure)
	868268001: Administration of third dose of vaccine product containing only Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure)
	870668008: Administration of third dose of vaccine product containing only Clostridium tetani and Corynebacterium diphtheriae antigens (procedure)
	ed are informational only, not clinical guidelines or standards of medical care, and do not guarantee e and related decisions of treatment are the sole responsibility of the provider. This information does not

Page 45 of 117

Immunization	CPT/HCPCS/CVX/SNOMED CTSNOMED CT
	 870669000: Preschool administration of vaccine product containing only Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 870670004: Preschool administration of vaccine product containing only Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 871828004: Administration of vaccine product containing only Clostridium tetani and low dose Corynebacterium diphtheriae antigens (procedure) 632481000119106: Administration of vaccine product containing only Clostridium tetani and Corynebacterium diphtheriae antigens, less than 7 years of age (procedure)
Td Immunization	CVX 09: tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use (2 Lf
	of tetanus toxoid and 2 Lf of diphtheria toxoid) 113: tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use (5 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid) 115: tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, adsorbed 138: tetanus and diphtheria toxoids, not adsorbed, for adult use 139: Td(adult) unspecified formulation
Tdap Vaccine Procedure	CPT 90715 SNOMED CTSNOMED CT 390846000: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755006: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412756007: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 428251000124104: Tetanus, diphtheria, and acellular pertussis vaccination (procedure) 571571000119105: Administration of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure)

Page 46 of 117

Immunization	CPT/HCPCS/CVX/SNOMED CTSNOMED CT
Herpes Zoster Live Vaccine	СРТ
Procedure	90736
	SNOMED CTSNOMED CT
	871898007: Administration of vaccine product containing only live attenuated
	Human alphaherpesvirus 3 antigen (procedure)
	871899004: Administration of vaccine product containing only live attenuated
	Human alphaherpesvirus 3 antigen via subcutaneous route (procedure)
Herpes Zoster Recombinant	СРТ
Vaccine Procedure	90750
	SNOMED CTSNOMED CT
	722215002: Administration of vaccine product containing only Human
	alphaherpesvirus 3 antigen for shingles (procedure)
CDC Race and Ethnicity	1002-5: American Indian or Alaska Native
	2028-9: Asian
	2054-5: Black or African American
	2076-8: Native Hawaiian or Other Pacific Islander
	2106-3: White
	2135-2: Hispanic or Latino
	2186-5: Not Hispanic or Latino
Note: The codes listed are informational only: this information does not guarantee reimbursement.	

Note: The codes listed are informational only; this information does not guarantee reimbursement.

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E)

Description	CPT/CAT II/LOINC/SNOMED CTSNOMED CT
Cholesterol Lab Test	СРТ
	82465, 83718, , 84478
	LOINC
	2085-9: Cholesterol in HDL [Mass/volume] in Serum or Plasma
	2093-3: Cholesterol [Mass/volume] in Serum or Plasma
	2571-8: Triglyceride [Mass/volume] in Serum or Plasma
	3043-7: Triglyceride [Mass/volume] in Blood
	9830-1: Cholesterol. Total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma
	SNOMED CTSNOMED CT
	14740000: Triglycerides measurement (procedure)
	28036006: High density lipoprotein cholesterol measurement (procedure)
	77068002: Cholesterol measurement (procedure)
	104583003: High density lipoprotein/total cholesterol ratio measurement
	(procedure)
	104584009: Intermediate density lipoprotein cholesterol measurement (procedure)
	([

Page 47 of 117

Description	CPT/CAT II/LOINC/SNOMED CTSNOMED CT
Description	104586006: Cholesterol/triglyceride ratio measurement (procedure)
	104784006: Lipids, triglycerides measurement (procedure)
	104990004: Triglyceride and ester in high density lipoprotein measurement
	(procedure)
	104991000: Triglyceride and ester in intermediate density lipoprotein
	measurement (procedure)
	121868005: Total cholesterol measurement (procedure)
	166832000: Serum high density lipoprotein cholesterol measurement
	(procedure)
	166838001: Serum fasting high density lipoprotein cholesterol measurement
	(procedure)
	166839009: Serum random high density lipoprotein cholesterol measurement
	(procedure)
	166849007: Serum fasting triglyceride measurement (procedure)
	166850007: Serum random triglyceride measurement (procedure)
	167072001: Plasma random high density lipoprotein cholesterol measurement
	(procedure)
	167073006: Plasma fasting high density lipoprotein cholesterol measurement
	(procedure)
	167082000: Plasma triglyceride measurement (procedure)
	167083005: Plasma random triglyceride measurement (procedure)
	167084004: Plasma fasting triglyceride measurement (procedure)
	271245006: Measurement of serum triglyceride level (procedure)
	275972003: Cholesterol screening (procedure)
	314035000: Plasma high density lipoprotein cholesterol measurement
	(procedure)
	315017003: Fasting cholesterol level (procedure)
	390956002: Plasma total cholesterol level (procedure)
	412808005: Serum total cholesterol measurement (procedure)
	412827004: Fluid sample triglyceride measurement (procedure)
	443915001: Measurement of total cholesterol and triglycerides (procedure)
Cholesterol Test Result or	SNOMED CT
Finding	166830008: Serum cholesterol above reference range (finding)
	166848004: Serum triglycerides above reference range (finding)
	259557002: High density lipoprotein triglyceride (substance)
	365793008: Finding of cholesterol level (finding)
	365794002: Finding of serum cholesterol level (finding)
	365795001: Finding of triglyceride level (finding)
	365796000: Finding of serum triglyceride levels (finding)

Page 48 of 117

Description	CPT/CAT II/LOINC/SNOMED CTSNOMED CT
	439953004: Cholesterol/high density lipoprotein ratio above reference range (finding)
	707122004: Triglyceride in high density lipoprotein subfraction 2 (substance)
	707123009: Triglyceride in high density lipoprotein subfraction 3 (substance)
	1162800007: Cholesterol esters within reference range (finding)
	1172655006: Low density lipoprotein cholesterol below reference range
	(finding)
	1172656007: Low density lipoprotein cholesterol within reference range
	(finding)
Chursen Lab Test	67991000119104: Serum cholesterol outside reference range (finding)
Glucose Lab Test	CPT
	80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951 LOINC
	10450-5: Glucose [Mass/volume] in Serum or Plasma10 hours fasting
	1492-8: Glucose [Mass/volume] in Serum or Plasma1.5 hours post 0.5 g/kg
	glucose IV
	1494-4: Glucose [Mass/volume] in Serum or Plasma1.5 hours post 100 g
	glucose PO
	1496-9: Glucose [Mass/volume] in Serum or Plasma1.5 hours post 75 g glucose
	PO
	1499-3: Glucose [Mass/volume] in Serum or Plasma1 hour post 0.5 g/kg
	glucose IV
	1501-6: Glucose [Mass/volume] in Serum or Plasma1 hour post 100 g glucose PO
	1504-0: Glucose [Mass/volume] in Serum or Plasma1 hour post 50 g glucose
	PO
	1507-3: Glucose [Mass/volume] in Serum or Plasma1 hour post 75 g glucose
	PO
	1514-9: Glucose [Mass/volume] in Serum or Plasma2 hours post 100 g glucose PO
	1518-0: Glucose [Mass/volume] in Serum or Plasma2 hours post 75 g glucose
	PO 1530-5: Glucose [Mass/volume] in Serum or Plasma3 hours post 100 g glucose
	PO
	1533-9: Glucose [Mass/volume] in Serum or Plasma3 hours post 75 g glucose
	PO
	1554-5: Glucose [Mass/volume] in Serum or Plasma12 hours fasting
	1557-8: Fasting glucose [Mass/volume] in Venous blood
	1558-6: Fasting glucose [Mass/volume] in Serum or Plasma
	17865-7: Glucose [Mass/volume] in Serum or Plasma8 hours fasting

Page 49 of 117

Description	CPT/CAT II/LOINC/SNOMED CTSNOMED CT
	20436-2: Glucose [Mass/volume] in Serum or Plasma2 hours post dose glucose
	20437-0: Glucose [Mass/volume] in Serum or Plasma3 hours post dose glucose
	20438-8: Glucose [Mass/volume] in Serum or Plasma1 hour post dose glucose
	20440-4: Glucose [Mass/volume] in Serum or Plasma1.5 hours post dose
	glucose
	2345-7: Glucose [Mass/volume] in Serum or Plasma
	26554-6: Glucose [Mass/volume] in Serum or Plasma2.5 hours post dose
	glucose
	41024-1: Glucose [Mass/volume] in Serum or Plasma2 hours post 50 g glucose
	PO
	49134-0: Glucose [Mass/volume] in Blood2 hours post dose glucose
	6749-6: Glucose [Mass/volume] in Serum or Plasma2.5 hours post 75 g glucose PO
	9375-7: Glucose [Mass/volume] in Serum or Plasma2.5 hours post 100 g
	glucose PO
	SNOMED CTSNOMED CT
	22569008: Glucose measurement, serum (procedure)
	33747003: Glucose measurement, blood (procedure)
	52302001: Glucose measurement, fasting (procedure)
	72191006: Glucose measurement, plasma (procedure)
	73128004: Glucose measurement, random (procedure)
	88856000: Glucose measurement, 2 hour post prandial (procedure)
	104686004: Glucose measurement, blood, test strip (procedure)
	167086002: Serum random glucose measurement (procedure)
	167087006: Serum fasting glucose measurement (procedure)
	167088001: Serum 2-hr post-prandial glucose measurement (procedure)
	167095005: Plasma random glucose measurement (procedure)
	167096006: Plasma fasting glucose measurement (procedure)
	167097002: Plasma 2-hr post-prandial glucose measurement (procedure)
	250417005: Glucose concentration, test strip measurement (procedure)
	271061004: Random blood glucose measurement (procedure)
	271062006: Fasting blood glucose measurement (procedure)
	271063001: Lunch time blood sugar measurement (procedure)
	271064007: Supper time blood sugar measurement (procedure)
	271065008: Bedtime blood sugar measurement (procedure)
	275810004: BM stix glucose measurement (procedure)
	302788006: Post-prandial blood glucose measurement (procedure)
	302789003: Capillary blood glucose measurement (procedure)
	308113006: Self-monitoring of blood glucose (procedure)
	313474007: 60-minute blood glucose measurement (procedure)

Page 50 of 117

Description	CPT/CAT II/LOINC/SNOMED CTSNOMED CT
	313545000: 120-minute blood glucose measurement (procedure)
	313546004: 90-minute blood glucose measurement (procedure)
	313624000: 150-minute blood glucose measurement (procedure)
	313626003: 60-minute plasma glucose measurement (procedure)
	313627007: 120-minute plasma glucose measurement (procedure)
	313628002: 150-minute plasma glucose measurement (procedure)
	313630000: 60-minute serum glucose measurement (procedure)
	313631001: 120-minute serum glucose measurement (procedure)
	313697000: 90-minute plasma glucose measurement (procedure)
	313698005: 90-minute serum glucose measurement (procedure)
	313810002: 150-minute serum glucose measurement (procedure)
	412928005: Blood glucose series (procedure)
	440576000: 240-minute plasma glucose measurement (procedure)
	443780009: Quantitative measurement of mass concentration of glucose in
	serum or plasma specimen 120 minutes after 75-gram oral glucose challenge
	(procedure)
	444008003: Quantitative measurement of mass concentration of glucose in
	serum or plasma specimen 6 hours after glucose challenge (procedure)
	444127006: Quantitative measurement of mass concentration of glucose in
	postcalorie fasting serum or plasma specimen (procedure)
Glucose Test Result or	SNOMED CT
Finding	166890005: Random blood glucose within reference range (finding)
C C	166891009: Random blood sugar below reference range (finding)
	166892002: Random blood sugar above reference range (finding)
	166914001: Blood glucose 0-1.4 mmol/L (finding)
	166915000: Blood glucose 1.5-2.4 mmol/L (finding)
	166916004: Blood glucose 2.5-4.9 mmol/L (finding)
	166917008: Blood glucose 5-6.9 mmol/L (finding)
	166918003: Blood glucose 7-9.9 mmol/L (finding)
	166919006: Blood glucose 10-13.9 mmol/L (finding)
	166921001: Blood glucose within reference range (finding)
	166922008: Blood glucose outside reference range (finding)
	166923003: Blood glucose 14+ mmol/L (finding)
	442545002: Random blood glucose outside reference range (finding)
	444780001: Glucose in blood specimen above reference range (finding)
	1179458001: Blood glucose below reference range (finding)
HbA1c Lab Test	СРТ
	83036, 83037
	LOINC
	17855-8: Hemoglobin A1c/Hemoglobin. Total in Blood by calculation

Page 51 of 117

Description	
Description	CPT/CAT II/LOINC/SNOMED CTSNOMED CT 17856-6: Hemoglobin A1c/Hemoglobin. Total in Blood by HPLC
	4548-4: Hemoglobin A1c/Hemoglobin. Total in Blood
	4549-2: Hemoglobin A1c/Hemoglobin. Total in Blood by Electrophoresis
	96595-4: Hemoglobin A1c/Hemoglobin. Total in DBS
	SNOMED CT
	43396009: Hemoglobin A1c measurement (procedure)
	313835008: Hemoglobin A1c measurement aligned to the Diabetes Control and
	Complications Trial (procedure)
HbA1c Test Result or	СРТ
Finding	83036, 83037
	CAT II
	3044F: Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM)
	3046F: Most recent hemoglobin A1c level greater than 9.0% (DM)
	3051F: Most recent hemoglobin A1c (HbA1c) level greater than or equal to 7.0%
	and less than 8.0% (DM)
	3052F: Most recent hemoglobin A1c (HbA1c) level greater than or equal to 8.0%
	and less than or equal to 9.0% (DM)
	SNOMED CTSNOMED CT
	451051000124101: Hemoglobin A1c less than 77 percent % indicating good
	diabetic control (finding)
	451061000124104: Hemoglobin A1c greater than nine percent indicating poor
	diabetic control (finding)
LDL-C Lab Test	СРТ
	80061, 83700, 83701, 83704, 83721
	LOINC
	12773-8: Cholesterol in LDL [Units/volume] in Serum or Plasma by
	Electrophoresis
	13457-7: Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation
	18261-8: Cholesterol in LDL [Mass/volume] in Serum or Plasma ultracentrifugate
	18262-6: Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay
	2089-1: Cholesterol in LDL [Mass/volume] in Serum or Plasma
	49132-4: Cholesterol in LDL [Mass/volume] in Serum or Plasma by
	Electrophoresis
	55440-2: Cholesterol.in LDL (real) [Mass/volume] in Serum or Plasma by VAP
	96259-7: Cholesterol in LDL [Mass/volume] in Serum or Plasma by Calculated by
	Martin-Hopkins
	SNOMED CTSNOMED CT
	113079009: Low density lipoprotein cholesterol measurement (procedure)
	166833005: Serum low density lipoprotein cholesterol measurement
	(procedure)

Page 52 of 117

Description	CPT/CAT II/LOINC/SNOMED CTSNOMED CT
	166840006: Serum fasting low density lipoprotein cholesterol measurement
	(procedure)
	166841005: Serum random low density lipoprotein cholesterol measurement
	(procedure)
	167074000: Plasma random low density lipoprotein cholesterol measurement
	(procedure)
	167075004: Plasma fasting low density lipoprotein cholesterol measurement
	(procedure)
	314036004: Plasma low density lipoprotein cholesterol measurement
	(procedure)
LDL-C Test Result or	CAT II
Finding	3048F, 3049F, 3050F
Note: The codes listed are	informational only; this information does not guarantee reimbursement.

Unhealthy Alcohol Use Screening and Follow-Up (ASF-E)

Description	CPT/HCPCS/ICD10CM/ SNOMED CTSNOMED CT
Alcohol Counseling or	СРТ
Other Follow Up Care	99408, 99409
	HCPCS
	H0015: Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education H0050: Alcohol and/or drug services, brief intervention, per 15 minutes H2036: Alcohol and/or other drug treatment program, per diem
	SNOMED CTSNOMED CT
	20093000: Alcohol rehabilitation and detoxification (regime/therapy) 23915005: Combined alcohol and drug rehabilitation and detoxification (regime/therapy)
	24165007: Alcoholism counseling (procedure)
	64297001: Detoxication psychiatric therapy for alcoholism (regime/therapy) 386449006: Substance use treatment: alcohol withdrawal (regime/therapy)
	408945004: Alcohol abuse prevention (procedure)
	408947007: Alcohol abuse prevention education (procedure)
	408948002: Alcohol abuse prevention management (procedure)
	413473000: Counseling about alcohol consumption (procedure)
	707166002: Alcohol reduction program (regime/therapy)
Alcohol Use Disorder	429291000124102: Alcohol brief intervention (procedure)

Page 53 of 117

Description	CPT/HCPCS/ICD10CM/ SNOMED CTSNOMED CT
Description	F10.10: Alcohol abuse, uncomplicated
	F10.120: Alcohol abuse with intoxication, uncomplicated
	F10.121: Alcohol abuse with intoxication delirium
	F10.129: Alcohol abuse with intoxication, unspecified
	F10.130: Alcohol abuse with withdrawal, uncomplicated
	F10.131: Alcohol abuse with withdrawal delirium
	F10.132: Alcohol abuse with withdrawal with perceptual disturbance
	F10.139: Alcohol abuse with withdrawal, unspecified
	F10.14: Alcohol abuse with alcohol-induced mood disorder
	F10.150: Alcohol abuse with alcohol-induced psychotic disorder with delusions
	F10.151: Alcohol abuse with alcohol-induced psychotic disorder with
	hallucinations
	F10.159: Alcohol abuse with alcohol-induced psychotic disorder, unspecified
	F10.180: Alcohol abuse with alcohol-induced anxiety disorder
	F10.181: Alcohol abuse with alcohol-induced sexual dysfunction
	F10.182: Alcohol abuse with alcohol-induced sleep disorder
	F10.188: Alcohol abuse with other alcohol-induced disorder
	F10.20: Alcohol dependence, uncomplicated
	F10.220: Alcohol dependence with intoxication, uncomplicated
	F10.221: Alcohol dependence with intoxication delirium
	F10.229: Alcohol dependence with intoxication, unspecified
	F10.230: Alcohol dependence with withdrawal, uncomplicated
	F10.231: Alcohol dependence with withdrawal delirium
	F10.232: Alcohol dependence with withdrawal with perceptual disturbance
	F10.239: Alcohol dependence with withdrawal, unspecified
	F10.24: Alcohol dependence with alcohol-induced mood disorder
	F10.250: Alcohol dependence with alcohol-induced psychotic disorder with
	delusions
	F10.251: Alcohol dependence with alcohol-induced psychotic disorder with
	hallucinations
	F10.259: Alcohol dependence with alcohol-induced psychotic disorder,
	unspecified
	F10.26: Alcohol dependence with alcohol-induced persisting amnestic disorder
	F10.27: Alcohol dependence with alcohol-induced persisting dementia
	F10.280: Alcohol dependence with alcohol-induced anxiety disorder
	F10.281: Alcohol dependence with alcohol-induced sexual dysfunction
	F10.282: Alcohol dependence with alcohol-induced sleep disorder
	F10.288: Alcohol dependence with other alcohol-induced disorder
	F10.29: Alcohol dependence with unspecified alcohol-induced disorder
	F10.90: Alcohol use, unspecified, uncomplicated

Page 54 of 117

Description	
Description	CPT/HCPCS/ICD10CM/ SNOMED CTSNOMED CT
	F10.920: Alcohol use, unspecified with intoxication, uncomplicated
	F10.921: Alcohol use, unspecified with intoxication delirium
	F10.929: Alcohol use, unspecified with intoxication, unspecified
	F10.930: Alcohol use, unspecified with withdrawal, uncomplicated
	F10.931: Alcohol use, unspecified with withdrawal delirium
	F10.932: Alcohol use, unspecified with withdrawal with perceptual disturbance
	F10.939: Alcohol use, unspecified with withdrawal, unspecified
	F10.94: Alcohol use, unspecified with alcohol-induced mood disorder
	F10.950: Alcohol use, unspecified with alcohol-induced psychotic disorder with
	delusions
	F10.951: Alcohol use, unspecified with alcohol-induced psychotic disorder with
	hallucinations
	F10.959: Alcohol use, unspecified with alcohol-induced psychotic disorder,
	unspecified
	F10.96: Alcohol use, unspecified with alcohol-induced persisting amnestic
	disorder
	F10.97: Alcohol use, unspecified with alcohol-induced persisting dementia
	F10.980: Alcohol use, unspecified with alcohol-induced anxiety disorder
	F10.981: Alcohol use, unspecified with alcohol-induced sexual dysfunction
	F10.982: Alcohol use, unspecified with alcohol-induced sleep disorder
	F10.988: Alcohol use, unspecified with other alcohol-induced disorder
	F10.99: Alcohol use, unspecified with unspecified alcohol-induced disorder
	K29.20: Alcoholic gastritis without bleeding
	K29.21: Alcoholic gastritis with bleeding
	K70.10: Alcoholic hepatitis without ascites
	K70.11: Alcoholic hepatitis with ascites
	SNOMED CTSNOMED CT
	281004: Dementia associated with alcoholism (disorder)
	7052005: Alcohol hallucinosis (disorder)
	7200002: Alcoholism (disorder)
	8635005: Alcohol withdrawal delirium (disorder)
	15167005: Alcohol abuse (disorder)
	18653004: Alcohol intoxication delirium (disorder)
	29212009: Organic mental disorder caused by ingestible alcohol (disorder)
	34938008: Anxiety disorder caused by alcohol (disorder)
	41083005: Sleep disorder caused by ingestible alcohol (disorder)
	42344001: Psychosis caused by ingestible alcohol (disorder)
	53936005: Mood disorder caused by ingestible alcohol (disorder)
	61144001: Alcohol-induced psychotic disorder with delusions (disorder)
	66590003: Alcohol dependence (disorder)

Page 55 of 117

Description	
Description	CPT/HCPCS/ICD10CM/ SNOMED CTSNOMED CT
	69482004: Korsakoff's psychosis (disorder)
	73097000: Alcohol amnestic disorder (disorder)
	78524005: Alcohol-induced sexual dysfunction (finding)
	85561006: Alcohol withdrawal syndrome without complication (disorder)
	87810006: Megaloblastic anemia due to alcoholism (disorder)
	191471000: Korsakov's alcoholic psychosis with peripheral neuritis (disorder)
	191475009: Chronic alcoholic brain syndrome (disorder)
	191476005: Alcohol withdrawal hallucinosis (disorder)
	191478006: Alcoholic paranoia (disorder)
	191480000: Alcohol withdrawal syndrome (disorder)
	191811004: Continuous chronic alcoholism (disorder)
	191812006: Episodic chronic alcoholism (disorder)
	191813001: Chronic alcoholism in remission (disorder)
	191882002: Nondependent alcohol abuse, continuous (disorder)
	191883007: Nondependent alcohol abuse, episodic (disorder)
	191884001: Nondependent alcohol abuse in remission (disorder)
	231467000: Absinthe addiction (disorder)
	268645007: Nondependent alcohol abuse (disorder)
	284591009: Persistent alcohol abuse (disorder)
	713583005: Mild alcohol dependence (disorder)
	713862009: Severe alcohol dependence (disorder)
	714829008: Moderate alcohol dependence (disorder)
	723926008: Perceptual disturbances and seizures co-occurrent and due to
	alcohol withdrawal (disorder)
	723927004: Psychotic disorder caused by alcohol with schizophreniform
	symptoms (disorder)
	723928009: Mood disorder with depressive symptoms caused by alcohol
	(disorder)
	723929001: Mood disorder with manic symptoms caused by alcohol (disorder)
	723930006: Mood disorder with mixed manic and depressive symptoms caused
	by alcohol (disorder)
	97571000119109: Thrombocytopenia co-occurrent and due to alcoholism
	(disorder)
	135311000119100: Insomnia caused by alcohol (disorder)
	288031000119105: Alcohol induced disorder co-occurrent and due to alcohol
	dependence (disorder)
	10741871000119101: Alcohol dependence in pregnancy (disorder)
	10755041000119100: Alcohol dependence in childbirth (disorder)
Note: The codes listed are inf	formational only; this information does not guarantee reimbursement.

Page 56 of 117

Breast Cancer Screening (BCS-E)

Description	CPT/LOINC/SNOMED CTSNOMED CT
Mammography	СРТ
	, , 77063, 77065, 77066, 77067
	LOINC
	24604-1: MG Breast Diagnostic Limited Views
	24605-8: MG Breast Diagnostic
	24606-6: MG Breast Screening
	24610-8: MG Breast Limited Views
	26175-0: MG Breast - bilateral Screening
	26176-8: MG Breast - left Screening
	26177-6: MG Breast - right Screening
	26287-3: MG Breast - bilateral Limited Views
	26289-9: MG Breast - left Limited Views
	26291-5: MG Breast - right Limited Views
	26346-7: MG Breast - bilateral Diagnostic
	26347-5: MG Breast - left Diagnostic
	26348-3: MG Breast - right Diagnostic
	26349-1: MG Breast - bilateral Diagnostic Limited Views
	26350-9: MG Breast - left Diagnostic Limited Views
	26351-7: MG Breast - right Diagnostic Limited Views
	36319-2: MG Breast 4 Views
	36625-2: MG Breast Views
	36626-0: MG Breast - bilateral Views
	36627-8: MG Breast - left Views
	36642-7: MG Breast - left 2 Views
	36962-9: MG Breast Axillary
	37005-6: MG Breast - left Magnification
	37006-4: MG Breast - bilateral MLO
	37016-3: MG Breast - bilateral Rolled Views
	37017-1: MG Breast - left Rolled Views
	37028-8: MG Breast Tangential
	37029-6: MG Breast - bilateral Tangential
	37030-4: MG Breast - left Tangential
	37037-9: MG Breast True lateral
	37038-7: MG Breast - bilateral True lateral
	37052-8: MG Breast - bilateral XCCL
	37053-6: MG Breast - left XCCL
	37539-4: MG Breast Grid Views
	37542-8: MG Breast Magnification Views
	37543-6: MG Breast - bilateral Magnification Views
e codes and measure tins listed -	are informational only, not clinical guidelines or standards of medical care, and do not guarantee
כ כסקבי מווט וווכמינור וונט וואדים א	

Page 57 of 117

Description	CPT/LOINC/SNOMED CTSNOMED CT
	37551-9: MG Breast Spot Views
	37552-7: MG Breast - bilateral Spot Views
	37553-5: MG Breast - left Spot Views compression
	37554-3: MG Breast - bilateral Magnification and Spot
	37768-9: MG Breast - right 2 Views
	37769-7: MG Breast - right Magnification and Spot
	37770-5: MG Breast - right Tangential
	37771-3: MG Breast - right True lateral
	37772-1: MG Breast - right XCCL
	37773-9: MG Breast - right Magnification
	37774-7: MG Breast - right Views
	37775-4: MG Breast - right Rolled Views
	38070-9: MG Breast Views for implant
	38071-7: MG Breast - bilateral Views for implant
	38072-5: MG Breast - left Views for implant
	38090-7: MG Breast - bilateral Air gap Views
	38091-5: MG Breast - left Air gap Views
	38807-4: MG Breast - right Spot Views
	38820-7: MG Breast - right Views for implant
	38854-6: MG Breast - left Magnification and Spot
	38855-3: MG Breast - left True lateral
	39150-8: FFD mammogram Breast Views Post Localization
	39152-4: FFD mammogram Breast Diagnostic
	39153-2: FFD mammogram Breast Screening
	39154-0: FFD mammogram Breast - bilateral Diagnostic
	42168-5: FFD mammogram Breast - right Diagnostic
	42169-3: FFD mammogram Breast - left Diagnostic
	42174-3: FFD mammogram Breast - bilateral Screening
	42415-0: MG Breast - bilateral Views Post Wire Placement
	42416-8: MG Breast - left Views Post Wire Placement
	46335-6: MG Breast - bilateral Single view
	46336-4: MG Breast - left Single view
	46337-2: MG Breast - right Single view
	46338-0: MG Breast - unilateral Single view
	46339-8: MG Breast - unilateral Views
	46342-2: FFD mammogram Breast Views
	46350-5: MG Breast - unilateral Diagnostic
	46351-3: MG Breast - bilateral Displacement Views for Implant
	46354-7: FFD mammogram Breast - right Screening
	46355-4: FFD mammogram Breast - left Screening

Page 58 of 117

Description CPT/LOINC/SNOMED CTSNOMED CT	
46356-2: MG Breast - unilateral Screening	
46380-2: MG Breast - unilateral Views for implant	
48475-8: MG Breast - bilateral Diagnostic for implant	
48492-3: MG Breast - bilateral Screening for implant	
69150-1: MG Breast - left Diagnostic for implant	
69251-7: MG Breast Views Post Wire Placement	
69259-0: MG Breast - right Diagnostic for implant	
72137-3: DBT Breast - right diagnostic	
72138-1: DBT Breast - left diagnostic	
72139-9: DBT Breast - bilateral diagnostic	
72140-7: DBT Breast - right screening	
72141-5: DBT Breast - left screening	
72142-3: DBT Breast - bilateral screening	
86462-9: DBT Breast - unilateral	
86463-7: DBT Breast - bilateral	
91517-3: DBT Breast - right diagnostic for implant	
91518-1: DBT Breast - left diagnostic for implant	
91519-9: DBT Breast - bilateral diagnostic for implant	
91520-7: DBT Breast - right screen for implant	
91521-5: DBT Breast - left screen for implant	
91522-3: DBT Breast - bilateral screen for implant	
103885-0: MG Breast - left Screening for implant	
103886-8: MG Breast - right Screening for implant	
103892-6: DBT Breast screening	
103893-4: MG Breast Screening for implant	
103894-2: MG Breast Diagnostic for implant	
SNOMED CTSNOMED CT	
12389009: Xeromammography (procedure)	
24623002: Screening mammography (procedure)	
43204002: Mammography of bilateral breasts (procedure)	
71651007: Mammography (procedure)	
241055006: Mammogram - symptomatic (procedure)	
241057003: Mammogram coned (procedure)	
241058008: Mammogram magnification (procedure)	
258172002: Stereotactic mammography (procedure)	
439324009: Mammogram in compression view (procedure)
450566007: Digital breast tomosynthesis (procedure)	
709657006: Fluoroscopy of breast (procedure)	
723778004: Digital tomosynthesis of right breast (procedu	
723779007: Digital tomosynthesis of left breast (procedure	2)

Page 59 of 117

Description	CPT/LOINC/SNOMED CTSNOMED CT
	723780005: Digital tomosynthesis of bilateral breasts (procedure) 726551006: Contrast enhanced spectral mammography (procedure) 833310007: Contrast enhanced dual energy spectral mammography (procedure) 866234000: Mammography of breast implant (procedure) 866235004: Mammography of bilateral breast implants (procedure) 866236003: Mammography of left breast implant (procedure) 866237007: Mammography of right breast implant (procedure) 866237007: Mammography of right breast implant (procedure) 384151000119104: Screening mammography of bilateral breasts (procedure)
	392521000119107: Screening mammography of right breast (procedure)
	392531000119105: Screening mammography of left breast (procedure)
	566571000119105: Mammography of right breast (procedure) 572701000119102: Mammography of left breast (procedure)
CDC race and ethnicity	1002-5: American Indian or Alaska Native 2028-9: Asian
	2054-5: Black or African American
	2076-8: Native Hawaiian or Other Pacific Islander
	2106-3: White
	2135-2: Hispanic or Latino
	2186-5: Not Hispanic or Latino

Note: The codes listed are informational only; this information does not guarantee reimbursement.

Blood Pressure Control for Patients With Hypertension (BPC-E)

Description	CPT/CVX/SNOMED CTSNOMED CT
Diastolic Blood Pressure	CAT II
	3079F: Most recent diastolic blood pressure 80-89 mm Hg
	3080F: Most recent diastolic blood pressure greater than or equal to 90 mm Hg
	3078F: Most recent diastolic blood pressure less than 80 mm Hg
	LOINC
	8514-2: Brachial artery - left Diastolic blood pressure
	8515-9: Brachial artery - right Diastolic blood pressure
	8496-2: Brachial artery Diastolic blood pressure
	8462-4 : Diastolic blood pressure
	75995-1: Diastolic blood pressure by Continuous non-invasive monitoring
	89267-9: Diastolic blood pressurelying in L-lateral position
	8453-3: Diastolic blood pressuresitting

Page 60 of 117

Description	CPT/CVX/SNOMED CTSNOMED CT
	8454-1: Diastolic blood pressurestanding
	8455-8: Diastolic blood pressuresupine
	SNOMED CTSNOMED CT
	271650006: Diastolic blood pressure (observable entity)
Diastolic Less Than 90	CAT II
	3079F: Most recent diastolic blood pressure 80-89 mm Hg
	3078F: Most recent diastolic blood pressure less than 80 mm Hg
Systolic and Diastolic	CAT II
Result	3079F: Most recent diastolic blood pressure 80-89 mm Hg
	3080F: Most recent diastolic blood pressure greater than or equal to 90 mm Hg
	3078F: Most recent diastolic blood pressure less than 80 mm Hg
	3075F: Most recent systolic blood pressure 130-139 mm Hg
	3077F: Most recent systolic blood pressure greater than or equal to 140 mm Hg
	3074F: Most recent systolic blood pressure less than 130 mm Hg
	50741. Most recent systeme blood pressure less than 150 min rig
Systolic Blood Pressure	CAT II
	3075F: Most recent systolic blood pressure 130-139 mm Hg
	3077F: Most recent systolic blood pressure greater than or equal to 140 mm
	3074F: Most recent systolic blood pressure less than 130 mm Hg
	LOINC
	8546-4: Brachial artery - left Systolic blood pressure
	8547-2: Brachial artery - right Systolic blood pressure
	8508-4: Brachial artery Systolic blood pressure
	8480-6: Systolic blood pressure
	75997-7: Systolic blood pressure by Continuous non-invasive monitoring
	89268-7: Systolic blood pressurelying in L-lateral position 8459-0: Systolic blood pressuresitting
	8460-8: Systolic blood pressurestanding
	8461-6: Systolic blood pressuresupine
	SNOMED CT
	271649006: Systolic blood pressure (observable entity)
Systolic Less Than 140	CAT II
-,	3075F: Most recent systolic blood pressure 130-139 mm Hg
	3074F: Most recent systolic blood pressure less than 130 mm Hg
Essential Hypertension	
Essential Hypertension	ICD10CM
Essential Hypertension	ICD10CM I10: Essential (primary) hypertension SNOMED CTSNOMED CT

Page 61 of 117

Description	CPT/CVX/SNOMED CTSNOMED CT
	1201005: Benign essential hypertension (disorder)
	71874008: Benign essential hypertension complicating AND/OR reason for care
	during childbirth (disorder)
	23717007: Benign essential hypertension complicating AND/OR reason for care
	during pregnancy (disorder)
	35303009: Benign essential hypertension complicating AND/OR reason for care
	during puerperium (disorder)
	63287004: Benign essential hypertension in obstetric context (disorder)
	59621000: Essential hypertension (disorder)
	18416000: Essential hypertension complicating AND/OR reason for care during
	childbirth (disorder)
	78808002: Essential hypertension complicating AND/OR reason for care during
	pregnancy (disorder)
	9901000: Essential hypertension complicating AND/OR reason for care during
	puerperium (disorder)
	72022006: Essential hypertension in obstetric context (disorder)
	19769006: High-renin essential hypertension (disorder)
	371125006: Labile essential hypertension (disorder)
	46481004: Low-renin essential hypertension (disorder)
	78975002: Malignant essential hypertension (disorder)
	40511000119107: Postpartum pre-existing essential hypertension (disorder)
	429457004: Systolic essential hypertension (disorder)
CDC Race and Ethnicity	1002-5: American Indian or Alaska Native
	2028-9: Asian
	2054-5: Black or African American
	2076-8: Native Hawaiian or Other Pacific Islander
	2106-3: White
	2135-2: Hispanic or Latino
	2186-5: Not Hispanic or Latino

Note: The codes listed are informational only; this information does not guarantee reimbursement.

Cervical	Cancer	Screening	(CCS-E)

Description	CPT/HCPCS/LOINC/SNOMED CTSNOMED CT
Cervical Cytology Lab Test	LOINC
	10524-7: Microscopic observation [Identifier] in Cervix by Cyto stain
	18500-9: Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

Page 62 of 117

19762-4: General categories [Interpretation] of Cervical or vaginal smear or
scraping by Cyto stain
19764-0: Statement of adequacy [Interpretation] of Cervical or vaginal smear or
scraping by Cyto stain
19765-7: Microscopic observation [Identifier] in Cervical or vaginal smear or
scraping by Cyto stain
19766-5: Microscopic observation [Identifier] in Cervical or vaginal smear or
scraping by Cyto stain Narrative
19774-9: Cytology study comment Cervical or vaginal smear or scraping Cyto stain
33717-0 Cervical and/or vaginal cytology study
47527-7: Cytology report of Cervical or vaginal smear or scraping Cyto stain.thin
prep
47528-5: Cytology report of Cervical or vaginal smear or scraping Cyto stain
SNOMED CTSNOMED CT
171149006: Screening for malignant neoplasm of cervix (procedure)
416107004: Cervical cytology test (procedure)
417036008: Liquid based cervical cytology screening (procedure)
440623000: Microscopic examination of cervical Papanicolaou smear (procedure)
448651000124104: Microscopic examination of cervical Papanicolaou smear and
Human papillomavirus deoxyribonucleic acid detection cotesting (procedure)
SNOMED CT
168406009: Severe dyskaryosis on cervical smear cannot exclude invasive
carcinoma (finding)
168407000: Cannot exclude glandular neoplasia on cervical smear (finding)
168408005: Cervical smear - atrophic changes (finding)
168410007: Cervical smear - borderline changes (finding)
168414003: Cervical smear - inflammatory change (finding)
168415002: Cervical smear - no inflammation (finding)
168416001: Cervical smear - severe inflammation (finding)
168424006: Cervical smear - koilocytosis (finding)
250538001: Dyskaryosis on cervical smear (finding)
269957009: Cervical smear result (finding)
269958004: Cervical smear - negative (finding)
269959007: Cervical smear - mild dyskaryosis (finding)
269960002: Cervical smear - severe dyskaryosis (finding)
269961003: Cervical smear - moderate dyskaryosis (finding)
7758U5UU3, Viral changes on cervical smear minning
275805003: Viral changes on cervical smear (finding) 281101005: Smear: no abnormality detected - no endocervical cells (finding)

Page 63 of 117

Description	CPT/HCPCS/LOINC/SNOMED CTSNOMED CT
	310841002: Cervical smear - mild inflammation (finding)
	310842009: Cervical smear - moderate inflammation (finding)
	416030007: Cervicovaginal cytology: Low grade squamous intraepithelial lesion
	(finding)
	416032004: Cervicovaginal cytology normal or benign (finding)
	416033009: Cervicovaginal cytology: High grade squamous intraepithelial lesion or
	carcinoma (finding)
	439074000: Dysplasia on cervical smear (finding)
	439776006: Cervical Papanicolaou smear positive for malignant neoplasm (finding)
	439888000: Abnormal cervical Papanicolaou smear (finding)
	441087007: Atypical squamous cells of undetermined significance on cervical
	Papanicolaou smear (finding)
	441088002: Atypical squamous cells on cervical Papanicolaou smear cannot
	exclude high grade squamous intraepithelial lesion (finding)
	441094005: Atypical endocervical cells on cervical Papanicolaou smear (finding)
	441219009: Atypical glandular cells on cervical Papanicolaou smear (finding)
	441667007: Abnormal cervical Papanicolaou smear with positive human
	papillomavirus deoxyribonucleic acid test (finding)
	700399008: Cervical smear - borderline change in squamous cells (finding)
	700400001: Cervical smear - borderline change in endocervical cells (finding)
	1155766001: Nuclear abnormality in cervical smear (finding)
	62051000119105: Low grade squamous intraepithelial lesion on cervical
	Papanicolaou smear (finding)
	62061000119107: High grade squamous intraepithelial lesion on cervical
	Papanicolaou smear (finding)
	98791000119102: Cytological evidence of malignancy on cervical Papanicolaou
	smear (finding)
High Risk HPV Lab Test	СРТ
	87624, 87625
	HCPCS
	LOINC
	21440-3: Human papilloma virus 16+18+31+33+35+45+51+52+56 DNA [Presence]
	in Cervix by Probe
	30167-1: Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+68
	DNA [Presence] in Cervix by Probe with signal amplification
	38372-9: Human papilloma virus

6+11+16+18+31+33+35+39+42+43+44+45+51+52+56+58+59+68 DNA [Presence] in Cervix by Probe with signal amplification

Page 64 of 117

Description	CPT/HCPCS/LOINC/SNOMED CTSNOMED CT
	59263-4: Human papilloma virus 16 DNA [Presence] in Cervix by Probe with signal
	amplification
	59264-2: Human papilloma virus 18 DNA [Presence] in Cervix by Probe with signal
	amplification
	59420-0: Human papilloma virus
	16+18+31+33+35+39+45+51+52+56+58+59+66+68 DNA [Presence] in Cervix by
	Probe with signal amplification
	69002-4: Human papilloma virus E6+E7 mRNA [Presence] in Cervix by NAA with
	probe detection
	71431-1: Human papilloma virus 31+33+35+39+45+51+52+56+58+59+66+68 DNA
	[Presence] in Cervix by NAA with probe detection
	75694-0: Human papilloma virus 18+45 E6+E7 mRNA [Presence] in Cervix by NAA
	with probe detection
	77379-6 Human papilloma virus 16 and 18 and
	31+33+35+39+45+51+52+56+58+59+66+68 DNA [Interpretation] in Cervix
	77399-4: Human papilloma virus 16 DNA [Presence] in Cervix by NAA with probe
	detection
	77400-0: Human papilloma virus 18 DNA [Presence] in Cervix by NAA with probe
	detection
	82354-2: Human papilloma virus 16 and 18+45 E6+E7 mRNA [Identifier] in Cervix by
	NAA with probe detection
	82456-5: Human papilloma virus 16 E6+E7 mRNA [Presence] in Cervix by NAA with
	probe detection
	82675-0: Human papilloma virus
	16+18+31+33+35+39+45+51+52+56+58+59+66+68 DNA [Presence] in Cervix by
	NAA with probe detection
	95539-3: Human papilloma virus 31 DNA [Presence] in Cervix by NAA with probe
	detection
	SNOMED CTSNOMED CT
	35904009: Human papillomavirus deoxyribonucleic acid detection (procedure)
	44865100012410: Microscopic examination of cervical Papanicolaou smear and
	Human papillomavirus deoxyribonucleic acid detection cotesting (procedure)
	numan paphomavnus deoxynbondciele acid detection cotesting (procedure)
	104132-6: Human papilloma virus 16 and 18 and 31 and 45+33+52+58 and
	35+39+51+56+59+66+68 DNA [Interpretation] in Cervix by NAA with probe
	detection
	104170-6: Human papilloma virus 31+33+52+58 DNA [Presence] in Cervix by NAA
	with probe detection
	1002-5: American Indian or Alaska Native

HEDIS ECDS Coding Booklet 2025

Page 65 of 117

Description	CPT/HCPCS/LOINC/SNOMED CTSNOMED CT
	2028-9: Asian
	2054-5: Black or African American
CDC Race and Ethnicity	2076-8: Native Hawaiian or Other Pacific Islander
	2106-3: White
	2135-2: Hispanic or Latino
	2186-5: Not Hispanic or Latino
Note: The codes listed are informational only; this information does not guarantee reimbursement.	

Childhood Immunization Status (CIS-E)

Description	CPT/HCPCS/SNOMEDSNOMED CT/CVX
DTaP Immunization	CVX
	20: diphtheria, tetanus toxoids and acellular pertussis vaccine
	50: DTaP-Haemophilus influenzae type b conjugate vaccine
	106: diphtheria, tetanus toxoids and acellular pertussis vaccine, 5 pertussis antigens
	107: diphtheria, tetanus toxoids and acellular pertussis vaccine, unspecified formulation
	110: DTaP-hepatitis B and poliovirus vaccine
	120: diphtheria, tetanus toxoids and acellular pertussis vaccine,
	Haemophilus influenzae type b conjugate, and poliovirus vaccine,
	inactivated (DTaP-Hib-IPV)
	146: Diphtheria and Tetanus Toxoids and Acellular Pertussis
	Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate
	(Meningococcal Protein Conjugate), and Hepatitis B
	(Recombinant) Vaccine.
	198: Diphtheria, pertussis, tetanus, hepatitis B, Haemophilus
	Influenza Type b, (Pentavalent)
DTaP Vaccine Procedure	СРТ
	, 90698, , 90723
	SNOMED CTSNOMED CT
	310306005: Administration of first dose of vaccine product
	containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type and Human poliovirus antigens (procedure)
	310307001: Administration of second dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and

Page 66 of 117

Description Cerynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 310308006: Administration of third dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 312370000: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 313383003: Administration of fourth dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 390846000: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 390865008: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 390865008: Administration of vaccine product containing only acellular Bordetella pertussis antigens (procedure) 390914008: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755067: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757033: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757032: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412763002: Administration of first d	Description	CPT/HCPCS/SNOMEDSNOMED CT/CVX
and Human poliovirus antigens (procedure) 310308006: Administration of third dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 312870000: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 313383003: Administration of fourth dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 390846000: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 390865008: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 390865008: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 3909014008: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755006: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412756007: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412756007: Administration of first dose of va		
 310308006: Administration of third dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 312870000: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 313383003: Administration of fourth dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 390846000: Administration of booster dose of vaccine product containing only vacellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 390865008: Administration of booster dose of vaccine product containing only vacellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 390904008: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 390914008: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755007: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412752002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412752002: Administrat		
containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 312870000: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 313383003: Administration of fourth dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 390846000: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 390865008: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 390865008: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 390914008: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755006: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412756002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure		
Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 312870000: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 313383003: Administration of fourth dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 3908460000: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 390865008: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 390865008: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 399014008: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755006: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755007: Administration of stored dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product co		•
and Human poliovirus antigens (procedure) 312870000: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 313383003: Administration of fourth dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 390845000: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 390865008: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 390865008: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 399014008: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755006: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755007: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412752002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium d		
312870000: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 313383003: Administration of fourth dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 390846000: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 390865008: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 399014008: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 412755006: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755007: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412752002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412752002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetan		
Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 313383003: Administration of fourth dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 390846000: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 390865008: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 390914008: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755006: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755007: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412756007: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412750202: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine		
diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 313383003: Administration of fourth dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 390846000: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 390865008: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 399014008: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755006: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755007: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755007: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clos		
poliovirus antigens (procedure) 313383003: Administration of fourth dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 390846000: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 390865008: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 399014008: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755006: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755007: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412756007: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clo		
 313383003: Administration of fourth dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 390846000: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 390865008: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae ant Human poliovirus antigens (procedure) 390914008: Administration of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 399014008: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755006: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412756007: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing on		
containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 390846000: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 390865008: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 390040008: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755006: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412756007: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412756007: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412756002: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412752002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412763007: Administration of first dose of vaccine product containing only acell		
Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) 390846000: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 390865008: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 399014008: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755006: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755007: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412756007: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412752002: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412763007: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridiu		
and Human poliovirus antigens (procedure) 390846000: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 390865008: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 399014008: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755006: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755007: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412756007: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412752002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412763007: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium		
containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 390865008: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 399014008: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755006: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412756007: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412756007: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412763007: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium		and Human poliovirus antigens (procedure)
tetani and Corynebacterium diphtheriae antigens (procedure) 390865008: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 399014008: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755006: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412756007: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412763007: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412763007: Administration of first dose of vaccine product		390846000: Administration of booster dose of vaccine product
390865008: Administration of booster dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 399014008: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755006: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412756007: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412763007: Administration of second dose of vaccine product		containing only acellular Bordetella pertussis and Clostridium
containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 399014008: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755006: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412756007: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412763007: Administration of second dose of vaccine product		tetani and Corynebacterium diphtheriae antigens (procedure)
tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 399014008: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755006: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412756007: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412763007: Administration of second dose of vaccine product		390865008: Administration of booster dose of vaccine product
antigens (procedure) 399014008: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755006: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412756007: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae ant Human poliovirus antigens (procedure) 412763007: Administration of second dose of vaccine product		containing only acellular Bordetella pertussis and Clostridium
399014008: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755006: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412756007: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae ant gens (procedure) 412763007: Administration of second dose of vaccine product		tetani and Corynebacterium diphtheriae and Human poliovirus
Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412755006: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412756007: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae ant Human poliovirus antigens (procedure) 412763007: Administration of second dose of vaccine product		
diphtheriae antigens (procedure) 412755006: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412756007: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 412763007: Administration of second dose of vaccine product		
412755006: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412756007: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae ant gens (procedure) 412763007: Administration of second dose of vaccine product		
containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412756007: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 412763007: Administration of second dose of vaccine product		
tetani and Corynebacterium diphtheriae antigens (procedure) 412756007: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 412763007: Administration of second dose of vaccine product		
412756007: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 412763007: Administration of second dose of vaccine product		
containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 412763007: Administration of second dose of vaccine product		
tetani and Corynebacterium diphtheriae antigens (procedure) 412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 412763007: Administration of second dose of vaccine product		•
412757003: Administration of third dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 412763007: Administration of second dose of vaccine product		
containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 412763007: Administration of second dose of vaccine product		
tetani and Corynebacterium diphtheriae antigens (procedure) 412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 412763007: Administration of second dose of vaccine product		•
412762002: Administration of first dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 412763007: Administration of second dose of vaccine product		
containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 412763007: Administration of second dose of vaccine product		
tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 412763007: Administration of second dose of vaccine product		
antigens (procedure) 412763007: Administration of second dose of vaccine product		
412763007: Administration of second dose of vaccine product		
containing only acendial bordetena pertussis and Clostinulum		•
		containing only accidial boldetena pertussis and clostifulum

Page 67 of 117

Description	CPT/HCPCS/SNOMEDSNOMED CT/CVX
	tetani and Corynebacterium diphtheriae and Human poliovirus
	antigens (procedure)
	412764001: Administration of third dose of vaccine product
	containing only acellular Bordetella pertussis and Clostridium
	tetani and Corynebacterium diphtheriae and Human poliovirus
	antigens (procedure)
	414001002: Administration of vaccine product containing only
	five component acellular Bordetella pertussis and Clostridium
	tetani and Corynebacterium diphtheriae and Haemophilus
	influenzae type b and inactivated whole Human poliovirus
	antigens (procedure)
	414259000: Administration of first dose of vaccine product
	containing only five component acellular Bordetella pertussis,
	Clostridium tetani, Corynebacterium diphtheriae, Haemophilus
	influenzae type b and inactivated whole Human poliovirus
	antigens (procedure)
	414620004: Administration of vaccine product containing only
	acellular Bordetella pertussis five component and Clostridium
	tetani and low dose Corynebacterium diphtheriae and
	inactivated whole Human poliovirus antigens (procedure)
	415507003: Administration of second dose of vaccine product
	containing only five component acellular Bordetella pertussis,
	Clostridium tetani, Corynebacterium diphtheriae, Haemophilus
	influenzae type b and inactivated whole Human poliovirus
	antigens (procedure)
	415712004: Administration of third dose of vaccine product
	containing only five component acellular Bordetella pertussis,
	Clostridium tetani, Corynebacterium diphtheriae, Haemophilus
	influenzae type b and inactivated whole Human poliovirus
	antigens (procedure)
	770608009: Administration of vaccine product containing only
	Bordetella pertussis and Clostridium tetani and Corynebacterium
	diphtheriae and Haemophilus influenzae type b and Hepatitis B
	virus antigens (procedure)
	770616000: Administration of first dose of vaccine product
	containing only Bordetella pertussis and Clostridium tetani and
	Corynebacterium diphtheriae and Haemophilus influenzae type b
	and Hepatitis B virus antigens (procedure)
	770617009: Administration of second dose of vaccine product
	containing only Bordetella pertussis and Clostridium tetani and
	rmational only, not clinical guidelines or standards of medical care, and do not guarantee
	ted decisions of treatment are the sole responsibility of the provider. This information does not garding the appropriate care of members. Your state/provider contract(s), Medicaid, member

Page 68 of 117

Description	CPT/HCPCS/SNOMEDSNOMED CT/CVX
	Corynebacterium diphtheriae and Haemophilus influenzae type
	and Hepatitis B virus antigens (procedure)
	770618004: Administration of third dose of vaccine product
	containing only Bordetella pertussis and Clostridium tetani and
	Corynebacterium diphtheriae and Haemophilus influenzae type
	and Hepatitis B virus antigens (procedure)
	787436003: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacteriun diphtheriae and Haemophilus influenzae type b antigens (procedure)
	866158005: Administration of first dose of vaccine product
	containing only Bordetella pertussis and Clostridium tetani and
	Corynebacterium diphtheriae antigens (procedure)
	866159002: Administration of second dose of vaccine product
	containing only Bordetella pertussis and Clostridium tetani and
	Corynebacterium diphtheriae antigens (procedure)
	866226006: Administration of third dose of vaccine product
	containing only Bordetella pertussis and Clostridium tetani and
	Corynebacterium diphtheriae antigens (procedure)
	868273007: Administration of vaccine product containing only
	Bordetella pertussis and Clostridium tetani and Corynebacteriun
	diphtheriae and Human poliovirus antigens (procedure)
	868274001: Administration of second dose of vaccine product
	containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure)
	868276004: Administration of third dose of vaccine product
	containing only Bordetella pertussis and Clostridium tetani and
	Corynebacterium diphtheriae and Human poliovirus antigens (procedure)
	868277008: Administration of first dose of vaccine product
	containing only Bordetella pertussis and Clostridium tetani and
	Corynebacterium diphtheriae and Human poliovirus antigens
	(procedure)
	1162640003: Administration of vaccine product containing only
	acellular Bordetella pertussis and Clostridium tetani and
	Corynebacterium diphtheriae and Haemophilus influenzae type
	and Hepatitis B virus and inactivated Human poliovirus antigens

Page 69 of 117

Description	CPT/HCPCS/SNOMEDSNOMED CT/CVX
	428251000124104: Tetanus, diphtheria, and acellular pertussis vaccination (procedure) 571571000119105: Administration of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) 572561000119108: Administration of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Hepatitis B virus and inactivated whole Human poliovirus antigens (procedure) 16290681000119103 : Administration of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and inactivated whole Human poliovirus antigens (procedure)
Haemophilus Influenzae Type B (HiB)	CVX
Immunization	 17: Haemophilus influenzae type b vaccine, conjugate unspecified formulation 46: Haemophilus influenzae type b vaccine, PRP-D conjugate 47: Haemophilus influenzae type b vaccine, HbOC conjugate 48: Haemophilus influenzae type b vaccine, PRP-T conjugate 49: Haemophilus influenzae type b vaccine, PRP-OMP conjugate 50: DTaP-Haemophilus influenzae type b conjugate vaccine 51: Haemophilus influenzae type b conjugate and Hepatitis B vaccine 120: diphtheria, tetanus toxoids and acellular pertussis vaccine, Haemophilus influenzae type b conjugate, and poliovirus vaccine, inactivated (DTaP-Hib-IPV) 146: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate (Meningococcal Protein Conjugate), and Hepatitis B (Recombinant) Vaccine. 148: Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine 198: Diphtheria, pertussis, tetanus, hepatitis B, Haemophilus Influenza Type b, (Pentavalent)
Haemophilus Influenzae Type B (HiB) Vaccine Procedure	CPT , 90647, 90648, , 90698, 90748 SNOMED CTSNOMED CT 127787002: Administration of vaccine product containing only Haemophilus influenzae type b antigen (procedure)

Page 70 of 117

Description	CPT/HCPCS/SNOMEDSNOMED CT/CVX
	170343007: Administration of first dose of vaccine product
	containing only Haemophilus influenzae type b antigen
	(procedure)
	170344001: Administration of second dose of vaccine product
	containing only Haemophilus influenzae type b antigen
	(procedure)
	170345000: Administration of third dose of vaccine product
	containing only Haemophilus influenzae type b antigen
	(procedure)
	170346004: Administration of booster dose of vaccine product
	containing only Haemophilus influenzae type b antigen
	(procedure)
	310306005: Administration of first dose of vaccine product
	containing only Bordetella pertussis and Clostridium tetani and
	Corynebacterium diphtheriae and Haemophilus influenzae type b
	and Human poliovirus antigens (procedure)
	310307001: Administration of second dose of vaccine product
	containing only Bordetella pertussis and Clostridium tetani and
	Corynebacterium diphtheriae and Haemophilus influenzae type b
	and Human poliovirus antigens (procedure)
	310308006: Administration of third dose of vaccine product
	containing only Bordetella pertussis and Clostridium tetani and
	Corynebacterium diphtheriae and Haemophilus influenzae type b
	and Human poliovirus antigens (procedure)
	312869001: Administration of vaccine product containing only
	Clostridium tetani and Corynebacterium diphtheriae and
	Haemophilus influenzae type b and Human poliovirus antigens
	(procedure)
	312870000: Administration of vaccine product containing only
	Bordetella pertussis and Clostridium tetani and Corynebacterium
	diphtheriae and Haemophilus influenzae type b and Human
	poliovirus antigens (procedure)
	313383003: Administration of fourth dose of vaccine product
	containing only Bordetella pertussis and Clostridium tetani and
	Corynebacterium diphtheriae and Haemophilus influenzae type b
	and Human poliovirus antigens (procedure)
	414001002: Administration of vaccine product containing only
	five component acellular Bordetella pertussis and Clostridium
	tetani and Corynebacterium diphtheriae and Haemophilus

Page 71 of 117

influenzae type b and inactivated w antigens (procedure) 414259000: Administration of first containing only five component ac Clostridium tetani, Corynebacteriu influenzae type b and inactivated w antigens (procedure) 415507003: Administration of seco containing only five component ac Clostridium tetani, Corynebacteriu influenzae type b and inactivated w antigens (procedure) 415712004: Administration of thirc containing only five component ac Clostridium tetani, Corynebacteriu influenzae type b and inactivated w antigens (procedure) 4159712004: Administration of thirc containing only five component ac Clostridium tetani, Corynebacteriu influenzae type b and inactivated w antigens (procedure) 428975001: Administration of vacc Haemophilus influenzae type b and serogroup C antigens (procedure) 712833000: Administration of seco containing only Haemophilus influe meningitidis serogroup C antigens 712834006: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 770608009: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 770616000: Administration of first cortaining only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc 770617009: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc 770618004: Administration of seco containing only Bordetella pertussi	CVX
414259000: Administration of first containing only five component act Clostridium tetani, Corynebacteriu influenzae type b and inactivated v antigens (procedure) 415507003: Administration of seco containing only five component act Clostridium tetani, Corynebacteriu influenzae type b and inactivated v antigens (procedure) 415712004: Administration of third containing only five component act Clostridium tetani, Corynebacteriu influenzae type b and inactivated v antigens (procedure) 428975001: Administration of vacc Haemophilus influenzae type b and serogroup C antigens (procedure) 712833000: Administration of vacc Haemophilus influenzae type b and serogroup C antigens (procedure) 712834006: Administration of seco containing only Haemophilus influe meningitidis serogroup C antigens 712834006: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 770608009: Administration of vacc Bordetella pertussis and Clostridiur diphtheriae and Haemophilus influe virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc	hole Human poliovirus
containing only five component ac Clostridium tetani, Corynebacteriu influenzae type b and inactivated v antigens (procedure) 415507003: Administration of seco containing only five component ac Clostridium tetani, Corynebacteriu influenzae type b and inactivated v antigens (procedure) 415712004: Administration of thirc containing only five component ac Clostridium tetani, Corynebacteriu influenzae type b and inactivated v antigens (procedure) 428975001: Administration of vacc Haemophilus influenzae type b and serogroup C antigens (procedure) 712833000: Administration of vacc containing only Haemophilus influe meningitidis serogroup C antigens 770608009: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (procedure) 770618004: Administration of seco	
Clostridium tetani, Corynebacteriu influenzae type b and inactivated w antigens (procedure) 415507003: Administration of seco containing only five component acd Clostridium tetani, Corynebacteriu influenzae type b and inactivated w antigens (procedure) 415712004: Administration of third containing only five component acd Clostridium tetani, Corynebacteriu influenzae type b and inactivated w antigens (procedure) 428975001: Administration of vacc Haemophilus influenzae type b and serogroup C antigens (procedure) 712833000: Administration of seco containing only Haemophilus influe meningitidis serogroup C antigens 712834006: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 770608009: Administration of first containing only Baemophilus influe meningitidis serogroup C antigens 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (procedure) 770617009: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc	dose of vaccine product
influenzae type b and inactivated v antigens (procedure) 415507003: Administration of seco containing only five component ac Clostridium tetani, Corynebacteriu influenzae type b and inactivated v antigens (procedure) 415712004: Administration of thirc containing only five component ac Clostridium tetani, Corynebacteriu influenzae type b and inactivated v antigens (procedure) 428975001: Administration of vacc Haemophilus influenzae type b and serogroup C antigens (procedure) 712833000: Administration of seco containing only Haemophilus influe meningitidis serogroup C antigens 712834006: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 770608009: Administration of vacc Bordetella pertussis and Clostridiur diphtheriae and Haemophilus influe virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and I and Hepatitis B virus antigens (proce 770618004: Administration of seco	ellular Bordetella pertussis,
influenzae type b and inactivated v antigens (procedure) 415507003: Administration of seco containing only five component ac Clostridium tetani, Corynebacteriu influenzae type b and inactivated v antigens (procedure) 415712004: Administration of thirc containing only five component ac Clostridium tetani, Corynebacteriu influenzae type b and inactivated v antigens (procedure) 428975001: Administration of vacc Haemophilus influenzae type b and serogroup C antigens (procedure) 712833000: Administration of seco containing only Haemophilus influe meningitidis serogroup C antigens 712834006: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 770608009: Administration of vacc Bordetella pertussis and Clostridiur diphtheriae and Haemophilus influe virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and I and Hepatitis B virus antigens (proce 770618004: Administration of seco	n diphtheriae, Haemophilus
antigens (procedure) 415507003: Administration of seco containing only five component act Clostridium tetani, Corynebacteriu influenzae type b and inactivated v antigens (procedure) 415712004: Administration of third containing only five component act Clostridium tetani, Corynebacteriu influenzae type b and inactivated v antigens (procedure) 428975001: Administration of vacc Haemophilus influenzae type b and serogroup C antigens (procedure) 712833000: Administration of seco containing only Haemophilus influe meningitidis serogroup C antigens 712834006: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 770608009: Administration of vacc Bordetella pertussis and Clostridiur diphtheriae and Haemophilus influe virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proce 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proce 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proce 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proce 770618004: Administration of third and Hepatitis B virus antigens (proce 770618004: Administration of third and Hepatitis B virus antigens (proce 770618004: Administration of third 3000000000000000000000000000000000000	-
415507003: Administration of seco containing only five component ac Clostridium tetani, Corynebacteriu influenzae type b and inactivated v antigens (procedure) 415712004: Administration of thirc containing only five component ac Clostridium tetani, Corynebacteriu influenzae type b and inactivated v antigens (procedure) 428975001: Administration of vacc Haemophilus influenzae type b and serogroup C antigens (procedure) 712833000: Administration of seco containing only Haemophilus influe meningitidis serogroup C antigens 712834006: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 770608009: Administration of vacc Bordetella pertussis and Clostridiur diphtheriae and Haemophilus influe virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proce 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proce 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proce 770618004: Administration of thirc	·
Clostridium tetani, Corynebacteriu influenzae type b and inactivated v antigens (procedure) 415712004: Administration of thirc containing only five component act Clostridium tetani, Corynebacteriu influenzae type b and inactivated v antigens (procedure) 428975001: Administration of vacc Haemophilus influenzae type b and serogroup C antigens (procedure) 712833000: Administration of seco containing only Haemophilus influe meningitidis serogroup C antigens 712834006: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 712834006: Administration of vacc Bordetella pertussis and Clostridiur diphtheriae and Haemophilus influe virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proce 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proce 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proce 770618004: Administration of third	nd dose of vaccine product
Clostridium tetani, Corynebacteriu influenzae type b and inactivated v antigens (procedure) 415712004: Administration of thirc containing only five component act Clostridium tetani, Corynebacteriu influenzae type b and inactivated v antigens (procedure) 428975001: Administration of vacc Haemophilus influenzae type b and serogroup C antigens (procedure) 712833000: Administration of seco containing only Haemophilus influe meningitidis serogroup C antigens 712834006: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 712834006: Administration of vacc Bordetella pertussis and Clostridiur diphtheriae and Haemophilus influe virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc	ellular Bordetella pertussis,
influenzae type b and inactivated w antigens (procedure) 415712004: Administration of third containing only five component acd Clostridium tetani, Corynebacteriuu influenzae type b and inactivated w antigens (procedure) 428975001: Administration of vacc Haemophilus influenzae type b and serogroup C antigens (procedure) 712833000: Administration of seco containing only Haemophilus influe meningitidis serogroup C antigens 712834006: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 770608009: Administration of vacc Bordetella pertussis and Clostridiur diphtheriae and Haemophilus influ virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussis Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc	-
antigens (procedure) 415712004: Administration of third containing only five component acd Clostridium tetani, Corynebacteriu influenzae type b and inactivated w antigens (procedure) 428975001: Administration of vacc Haemophilus influenzae type b and serogroup C antigens (procedure) 712833000: Administration of seco containing only Haemophilus influe meningitidis serogroup C antigens 712834006: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 770608009: Administration of vacc Bordetella pertussis and Clostridiur diphtheriae and Haemophilus influ virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc	
415712004: Administration of third containing only five component acd Clostridium tetani, Corynebacteriuu influenzae type b and inactivated w antigens (procedure) 428975001: Administration of vacc Haemophilus influenzae type b and serogroup C antigens (procedure) 712833000: Administration of seco containing only Haemophilus influe meningitidis serogroup C antigens 712834006: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 770608009: Administration of vacc Bordetella pertussis and Clostridiur diphtheriae and Haemophilus influ virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc	·
containing only five component acc Clostridium tetani, Corynebacteriu influenzae type b and inactivated w antigens (procedure) 428975001: Administration of vacc Haemophilus influenzae type b and serogroup C antigens (procedure) 712833000: Administration of seco containing only Haemophilus influe meningitidis serogroup C antigens 712834006: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 770608009: Administration of vacc Bordetella pertussis and Clostridiur diphtheriae and Haemophilus influ virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and l and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and l and Hepatitis B virus antigens (proc	dose of vaccine product
Clostridium tetani, Corynebacteriu influenzae type b and inactivated w antigens (procedure) 428975001: Administration of vacc Haemophilus influenzae type b and serogroup C antigens (procedure) 712833000: Administration of seco containing only Haemophilus influe meningitidis serogroup C antigens 712834006: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 770608009: Administration of vacc Bordetella pertussis and Clostridiur diphtheriae and Haemophilus influ virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and I and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and I and Hepatitis B virus antigens (proc	-
influenzae type b and inactivated w antigens (procedure) 428975001: Administration of vacc Haemophilus influenzae type b and serogroup C antigens (procedure) 712833000: Administration of seco containing only Haemophilus influe meningitidis serogroup C antigens 712834006: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 770608009: Administration of vacc Bordetella pertussis and Clostridiur diphtheriae and Haemophilus influ virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc	•
antigens (procedure) 428975001: Administration of vacco Haemophilus influenzae type b and serogroup C antigens (procedure) 712833000: Administration of seco containing only Haemophilus influe meningitidis serogroup C antigens 712834006: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 770608009: Administration of vacco Bordetella pertussis and Clostridiur diphtheriae and Haemophilus influ virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and I and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and I and Hepatitis B virus antigens (proc	
428975001: Administration of vacc Haemophilus influenzae type b and serogroup C antigens (procedure) 712833000: Administration of seco containing only Haemophilus influe meningitidis serogroup C antigens 712834006: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 770608009: Administration of vacc Bordetella pertussis and Clostridiur diphtheriae and Haemophilus influ virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and I and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and I and Hepatitis B virus antigens (proc	·
Haemophilus influenzae type b and serogroup C antigens (procedure) 712833000: Administration of seco containing only Haemophilus influe meningitidis serogroup C antigens 712834006: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 770608009: Administration of vacc Bordetella pertussis and Clostridiur diphtheriae and Haemophilus influ virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and I and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and I and Hepatitis B virus antigens (proc 770618004: Administration of third	ine product containing only
serogroup C antigens (procedure) 712833000: Administration of seco containing only Haemophilus influe meningitidis serogroup C antigens 712834006: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 770608009: Administration of vacc Bordetella pertussis and Clostridiur diphtheriae and Haemophilus influ virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and l and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and l and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and l and Hepatitis B virus antigens (proc	
712833000: Administration of seco containing only Haemophilus influe meningitidis serogroup C antigens 712834006: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 770608009: Administration of vacc Bordetella pertussis and Clostridiur diphtheriae and Haemophilus influ virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and I and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and I and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and I and Hepatitis B virus antigens (proc	C
containing only Haemophilus influe meningitidis serogroup C antigens 712834006: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 770608009: Administration of vacc Bordetella pertussis and Clostridiur diphtheriae and Haemophilus influ virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and I and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and I and Hepatitis B virus antigens (proc 770618004: Administration of third	nd dose of vaccine product
meningitidis serogroup C antigens 712834006: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 770608009: Administration of vacc Bordetella pertussis and Clostridiur diphtheriae and Haemophilus influ virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc	-
712834006: Administration of first containing only Haemophilus influe meningitidis serogroup C antigens 770608009: Administration of vacc Bordetella pertussis and Clostridiur diphtheriae and Haemophilus influ virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc	
containing only Haemophilus influe meningitidis serogroup C antigens 770608009: Administration of vacc Bordetella pertussis and Clostridiur diphtheriae and Haemophilus influ virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and I and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and I and Hepatitis B virus antigens (proc	
meningitidis serogroup C antigens 770608009: Administration of vacc Bordetella pertussis and Clostridiur diphtheriae and Haemophilus influ virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and I and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and I and Hepatitis B virus antigens (proc 770618004: Administration of third	-
770608009: Administration of vacc Bordetella pertussis and Clostridiur diphtheriae and Haemophilus influ virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and l and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and l and Hepatitis B virus antigens (proc 770618004: Administration of third	
diphtheriae and Haemophilus influ virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc 770618004: Administration of third	
virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc 770618004: Administration of third	n tetani and Corynebacteriur
virus antigens (procedure) 770616000: Administration of first containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc 770618004: Administration of third	-
containing only Bordetella pertussi Corynebacterium diphtheriae and I and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and I and Hepatitis B virus antigens (proc 770618004: Administration of third	
Corynebacterium diphtheriae and l and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and l and Hepatitis B virus antigens (proc 770618004: Administration of third	dose of vaccine product
Corynebacterium diphtheriae and l and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and l and Hepatitis B virus antigens (proc 770618004: Administration of third	s and Clostridium tetani and
and Hepatitis B virus antigens (proc 770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc 770618004: Administration of third	
770617009: Administration of seco containing only Bordetella pertussi Corynebacterium diphtheriae and l and Hepatitis B virus antigens (proc 770618004: Administration of third	
containing only Bordetella pertussi Corynebacterium diphtheriae and and Hepatitis B virus antigens (proc 770618004: Administration of thire	-
Corynebacterium diphtheriae and l and Hepatitis B virus antigens (proc 770618004: Administration of third	•
and Hepatitis B virus antigens (proc 770618004: Administration of third	
770618004: Administration of third	
	•
e codes and measure tips listed are informational only, not clinical guidelines or standards of medi	
mbursement. All member care and related decisions of treatment are the sole responsibility of the tate or control your clinical decisions regarding the appropriate care of members. Your state/provi	

Page 72 of 117

Description	CPT/HCPCS/SNOMEDSNOMED CT/CVX
	 Corynebacterium diphtheriae and Haemophilus influenzae type b and Hepatitis B virus antigens (procedure) 786846001: Administration of vaccine product containing only Haemophilus influenzae type b and Hepatitis B virus antigens (procedure) 787436003: Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b antigens (procedure) 1119364007: Administration of vaccine product containing only Haemophilus influenzae type b and Neisseria meningitidis serogroup C and Y antigens (procedure) 1162640003: Administration of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Hepatitis B virus and inactivated Human poliovirus antigens (procedure) 16292241000119109 : Administration of booster dose of vaccine product containing only Haemophilus influenzae type b capsular polysaccharide polyribosylribitol phosphate conjugated to Clostridium tetani toxoid protein (procedure)
Hepatitis A Immunization	CVX 31: hepatitis A vaccine, pediatric dosage, unspecified formulation 83: hepatitis A vaccine, pediatric/adolescent dosage, 2 dose schedule 85: hepatitis A vaccine, unspecified formulation
Hepatitis A Vaccine Procedure	CPT SNOMED CTSNOMED CT 17037+D909+D90971:E185331: Administration of first dose of pediatric vaccine product containing only Hepatitis A virus antigen (procedure) 170379004: Administration of second dose of vaccine product containing only Hepatitis A virus antigen (procedure) 170380001: Administration of third dose of vaccine product containing only Hepatitis A virus antigen (procedure) 170381002: Administration of booster dose of vaccine product containing only Hepatitis A virus antigen (procedure)

Page 73 of 117

Description	CPT/HCPCS/SNOMEDSNOMED CT/CVX
	170434002: Administration of first dose of vaccine product
	containing only Hepatitis A and Hepatitis B virus antigens
	(procedure)
	170435001: Administration of second dose of vaccine product
	containing only Hepatitis A and B virus antigens (procedure) 170436000: Administration of third dose of vaccine product
	containing only Hepatitis A and Hepatitis B virus antigens
	(procedure)
	170437009: Administration of booster dose of vaccine product
	containing only Hepatitis A and Hepatitis B virus antigens
	(procedure)
	243789007: Administration of vaccine product containing only
	Hepatitis A virus antigen (procedure)
	312868009: Administration of vaccine product containing only
	Hepatitis A and Hepatitis B virus antigens (procedure)
	314177003: Administration of vaccine product containing only
	Hepatitis A virus and Salmonella enterica subspecies enterica
	serovar Typhi antigens (procedure)
	314178008: Administration of first dose of vaccine product containing only Hepatitis A virus and Salmonella enterica
	subspecies enterica serovar Typhi antigens (procedure)
	314179000: Administration of second dose of vaccine product
	containing only Hepatitis A virus and Salmonella enterica
	subspecies enterica serovar Typhi antigens (procedure)
	394691002: Administration of booster dose of vaccine product
	containing only Hepatitis A virus and Salmonella enterica
	subspecies enterica serovar Typhi antigens (procedure)
	871752004: Administration of second dose of pediatric vaccine
	product containing only Hepatitis A virus antigen (procedure)
	871753009: Administration of third dose of pediatric vaccine
	product containing only Hepatitis A virus antigen (procedure)
	871754003: Administration of booster dose of pediatric vaccine
	product containing only Hepatitis A virus antigen (procedure) 571511000119102: Administration of adult vaccine product
	containing only Hepatitis A virus antigen (procedure)
Hepatitis B Immunization	CVX
	08: hepatitis B vaccine, pediatric or pediatric/adolescent dosage
	44: hepatitis B vaccine, dialysis patient dosage
	45: hepatitis B vaccine, unspecified formulation

Page 74 of 117

Description	CPT/HCPCS/SNOMEDSNOMED CT/CVX
	 51: Haemophilus influenzae type b conjugate and Hepatitis B vaccine 110: DTaP-hepatitis B and poliovirus vaccine 146: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate (Meningococcal Protein Conjugate), and Hepatitis B (Recombinant) Vaccine. 198: Diphtheria, pertussis, tetanus, hepatitis B, Haemophilus Influenza Type b, (Pentavalent)
Hepatitis B Vaccine Procedure	CPT 90723, 90740, 90744, 90747, 90748 HCPCS G0010: Administration of hepatitis b vaccine SNOMED CTSNOMED CT 16584000: Administration of vaccine product containing only Hepatitis B virus antigen (procedure) 170370000: Administration of first dose of vaccine product containing only Hepatitis B virus antigen (procedure) 170371001: Administration of second dose of vaccine product containing only Hepatitis B virus antigen (procedure) 170372008: Administration of third dose of vaccine product containing only Hepatitis B virus antigen (procedure) 170373003: Administration of booster dose of vaccine product containing only Hepatitis B virus antigen (procedure) 170374009: Administration of fourth dose of vaccine product containing only Hepatitis B virus antigen (procedure) 170375005: Administration of fifth dose of vaccine product containing only Hepatitis B virus antigen (procedure) 170375005: Administration of fifth dose of vaccine product containing only Hepatitis B virus antigen (procedure) 170434002: Administration of first dose of vaccine product containing only Hepatitis A and Hepatitis B virus antigens (procedure) 170435001: Administration of second dose of vaccine product containing only Hepatitis A and B virus antigens (procedure) 170436000: Administration of third dose of vaccine product containing only Hepatitis A and B virus antigens (procedure) 170436000: Administration of third dose of vaccine product containing only Hepatitis A and Hepatitis B virus antigens (procedure) 170437009: Administration of booster dose of vaccine product containing only Hepatitis A and Hepatitis B virus antigens (procedure)

Page 75 of 117

Description	CPT/HCPCS/SNOMEDSNOMED CT/CVX
	312868009: Administration of vaccine product containing only
	Hepatitis A and Hepatitis B virus antigens (procedure)
	396456003: Administration of vaccine product containing only
	acellular Bordetella pertussis and Corynebacterium diphtheriae
	and Hepatitis B virus and inactivated whole Human poliovirus
	antigens (procedure)
	416923003: Administration of sixth dose of vaccine product
	containing only Hepatitis B virus antigen (procedure)
	770608009: Administration of vaccine product containing only
	Bordetella pertussis and Clostridium tetani and Corynebacterium
	diphtheriae and Haemophilus influenzae type b and Hepatitis B
	virus antigens (procedure)
	770616000: Administration of first dose of vaccine product
	containing only Bordetella pertussis and Clostridium tetani and
	Corynebacterium diphtheriae and Haemophilus influenzae type b
	and Hepatitis B virus antigens (procedure)
	770617009: Administration of second dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and
	Corynebacterium diphtheriae and Haemophilus influenzae type b
	and Hepatitis B virus antigens (procedure)
	770618004: Administration of third dose of vaccine product
	containing only Bordetella pertussis and Clostridium tetani and
	Corynebacterium diphtheriae and Haemophilus influenzae type b
	and Hepatitis B virus antigens (procedure)
	786846001: Administration of vaccine product containing only
	Haemophilus influenzae type b and Hepatitis B virus antigens
	(procedure)
	1162640003: Administration of vaccine product containing only
	acellular Bordetella pertussis and Clostridium tetani and
	Corynebacterium diphtheriae and Haemophilus influenzae type b
	and Hepatitis B virus and inactivated Human poliovirus antigens
	(procedure)
	572561000119108: Administration of vaccine product containing
	only acellular Bordetella pertussis and Clostridium tetani and
	Corynebacterium diphtheriae and Hepatitis B virus and
	inactivated whole Human poliovirus antigens (procedure)
Inactivated polio vaccine (IPV) immunization	CVX
	10: poliovirus vaccine, inactivated
	89: poliovirus vaccine, unspecified formulation
	110: DTaP-hepatitis B and poliovirus vaccine

HEDIS ECDS Coding Booklet 2025

Page 76 of 117

Description	CPT/HCPCS/SNOMEDSNOMED CT/CVX
	120: diphtheria, tetanus toxoids and acellular pertussis vaccine, Haemophilus influenzae type b conjugate, and poliovirus vaccine, inactivated (DTaP-Hib-IPV)
	146: Diphtheria and Tetanus Toxoids and Acellular Pertussis
	Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate
	(Meningococcal Protein Conjugate), and Hepatitis B
	(Recombinant) Vaccine.
Inactivated polio vaccine (IPV) procedure	СРТ
	, 90698, 90713, 90723
	SNOMED CTSNOMED CT
	310306005: Administration of first dose of vaccine product
	containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b
	and Human poliovirus antigens (procedure)
	310307001: Administration of second dose of vaccine product
	containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b
	and Human poliovirus antigens (procedure)
	310308006: Administration of third dose of vaccine product
	containing only Bordetella pertussis and Clostridium tetani and
	Corynebacterium diphtheriae and Haemophilus influenzae type b
	and Human poliovirus antigens (procedure)
	312869001: Administration of vaccine product containing only
	Clostridium tetani and Corynebacterium diphtheriae and
	Haemophilus influenzae type b and Human poliovirus antigens (procedure)
	312870000: Administration of vaccine product containing only
	Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure)
	313383003: Administration of fourth dose of vaccine product
	containing only Bordetella pertussis and Clostridium tetani and
	Corynebacterium diphtheriae and Haemophilus influenzae type b
	and Human poliovirus antigens (procedure)
	390865008: Administration of booster dose of vaccine product
	containing only acellular Bordetella pertussis and Clostridium
	tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure)
	396456003: Administration of vaccine product containing only
	acellular Bordetella pertussis and Corynebacterium diphtheriae
The codes and measure tips listed are informational on	ly, not clinical guidelines or standards of medical care, and do not guarantee

Page 77 of 117

Description	CPT/HCPCS/SNOMEDSNOMED CT/CVX
	and Hepatitis B virus and inactivated whole Human poliovirus
	antigens (procedure)
	412762002: Administration of first dose of vaccine product
	containing only acellular Bordetella pertussis and Clostridium
	tetani and Corynebacterium diphtheriae and Human poliovirus
	antigens (procedure)
	412763007: Administration of second dose of vaccine product
	containing only acellular Bordetella pertussis and Clostridium
	tetani and Corynebacterium diphtheriae and Human poliovirus
	antigens (procedure)
	412764001: Administration of third dose of vaccine product
	containing only acellular Bordetella pertussis and Clostridium
	tetani and Corynebacterium diphtheriae and Human poliovirus
	antigens (procedure)
	414001002: Administration of vaccine product containing only
	five component acellular Bordetella pertussis and Clostridium
	tetani and Corynebacterium diphtheriae and Haemophilus
	influenzae type b and inactivated whole Human poliovirus
	antigens (procedure)
	414259000: Administration of first dose of vaccine product
	containing only five component acellular Bordetella pertussis,
	Clostridium tetani, Corynebacterium diphtheriae, Haemophilus
	influenzae type b and inactivated whole Human poliovirus
	antigens (procedure)
	414619005: Administration of vaccine product containing only
	Clostridium tetani and low dose Corynebacterium diphtheriae
	and inactivated Human poliovirus antigens (procedure)
	414620004: Administration of vaccine product containing only
	acellular Bordetella pertussis five component and Clostridium
	tetani and low dose Corynebacterium diphtheriae and
	inactivated whole Human poliovirus antigens (procedure)
	415507003: Administration of second dose of vaccine product
	containing only five component acellular Bordetella pertussis,
	Clostridium tetani, Corynebacterium diphtheriae, Haemophilus
	influenzae type b and inactivated whole Human poliovirus
	antigens (procedure)
	415712004: Administration of third dose of vaccine product
	containing only five component acellular Bordetella pertussis,
	Clostridium tetani, Corynebacterium diphtheriae, Haemophilus

Page 78 of 117

Description	CPT/HCPCS/SNOMEDSNOMED CT/CVX
	influenzae type b and inactivated whole Human poliovirus
	antigens (procedure)
	416144004: Administration of third dose of vaccine product
	containing only Clostridium tetani and low dose Corynebacterium
	diphtheriae and inactivated Human poliovirus antigens
	(procedure)
	416591003: Administration of first dose of vaccine product
	containing only Clostridium tetani and low dose Corynebacterium
	diphtheriae and inactivated Human poliovirus antigens
	(procedure)
	417211006: Administration of first booster of vaccine product
	containing only Clostridium tetani and low dose Corynebacterium
	diphtheriae and inactivated Human poliovirus antigens
	(procedure)
	417384007: Administration of second booster of vaccine product
	containing only Clostridium tetani and low dose Corynebacterium
	diphtheriae and inactivated Human poliovirus antigens
	(procedure)
	417615007: Administration of second dose of vaccine product
	containing only Clostridium tetani and low dose Corynebacterium
	diphtheriae and inactivated Human poliovirus antigens
	(procedure)
	866186002: Administration of vaccine product containing only
	Clostridium tetani and Corynebacterium diphtheriae and Human
	poliovirus antigens (procedure)
	866227002: Administration of booster dose of vaccine product
	containing only Clostridium tetani and Corynebacterium
	diphtheriae and Human poliovirus antigens (procedure)
	868266002: Administration of second dose of vaccine product
	containing only Clostridium tetani and Corynebacterium
	diphtheriae and Human poliovirus antigens (procedure)
	868267006: Administration of first dose of vaccine product
	containing only Clostridium tetani and Corynebacterium
	diphtheriae and Human poliovirus antigens (procedure)
	868268001: Administration of third dose of vaccine product
	containing only Clostridium tetani and Corynebacterium
	diphtheriae and Human poliovirus antigens (procedure)
	868273007: Administration of vaccine product containing only
	Bordetella pertussis and Clostridium tetani and Corynebacterium
	diphtheriae and Human poliovirus antigens (procedure)
	y, not clinical guidelines or standards of medical care, and do not guarantee of treatment are the sole responsibility of the provider. This information does not

Page 79 of 117

Description	CPT/HCPCS/SNOMEDSNOMED CT/CVX
Description	 868274001: Administration of second dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 868276004: Administration of third dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 868277008: Administration of first dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 868277008: Administration of first dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 870670004: Preschool administration of vaccine product containing only Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (procedure) 572561000119108: Administration of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Hepatitis B virus and
	inactivated whole Human poliovirus antigens (procedure) 16290681000119103 : Administration of vaccine product containing only acellular Bordetella pertussis and Clostridium
	tetani and Corynebacterium diphtheriae and inactivated whole Human poliovirus antigens (procedure)
Influenza Immunization	CVX 88: influenza virus vaccine, unspecified formulation 140: Influenza, seasonal, injectable, preservative free 141: Influenza, seasonal, injectable 150: Influenza, injectable, quadrivalent, preservative free 153: Influenza, injectable, Madin Darby Canine Kidney, preservative free 155: Seasonal, trivalent, recombinant, injectable influenza vaccine, preservative free 158: influenza, injectable, quadrivalent, contains preservative 161: Influenza, injectable, quadrivalent, preservative free, pediatric 171: Influenza, injectable, Madin Darby Canine Kidney, preservative free, quadrivalent 186: Influenza, injectable, Madin Darby Canine Kidney, quadrivalent with preservative88, 140, 141, 150, 153, 155, 158, 161

HEDIS ECDS Coding Booklet 2025

Page 80 of 117

Description	CPT/HCPCS/SNOMEDSNOMED CT/CVX
Influenza Vaccine Procedure	CPT 90655, , 90661, , 90674, 90685, 90686, 90687,
	90688, 90689, 90756
	HCPCS
	SNOMED CTSNOMED CT
	86198006: Administration of vaccine product containing only
	Influenza virus antigen (procedure)
Influenza Virus LAIV Immunization	CVX
	111: influenza virus vaccine, live, attenuated, for intranasal use
	149: influenza, live, intranasal, quadrivalent
Influenza Virus LAIV Vaccine Procedure	СРТ
	90660, 90672
	SNOMED CTSNOMED CT
	787016008: Administration of vaccine product containing only
	Influenza virus antigen in nasal dose form (procedure)
Measles, Mumps and Rubella (MMR) Immunization	CVX: 03, 94
Measles, Mumps and Rubella (MMR) Vaccine	CPT: 90707, 90710
Procedure	SNOMEDSNOMED CT: 38598009, 170433008, 432636005,
	433733003, 150971000119104, 571591000119106
	572511000119105
Pneumococcal Conjugate Immunization	CVX
	109: pneumococcal vaccine, unspecified formulation
	133: pneumococcal conjugate vaccine, 13 valent
	152: Pneumococcal Conjugate, unspecified formulation
	215: Pneumococcal conjugate vaccine 15-valent (PCV15),
	polysaccharide CRM197 conjugate, adjuvant, preservative free
Pneumococcal Conjugate Vaccine Procedure	СРТ
	90670, 90671
	HCPCS
	SNOMED CTSNOMED CT
	1119368005: Administration of vaccine product containing only
	Streptococcus pneumoniae Danish serotype 4, 6B, 9V, 14, 18C, 19F, and 23F capsular polysaccharide antigens conjugated (procedure)
	1296904008: Administration of vaccine product containing only Streptococcus pneumoniae Danish serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F capsular polysaccharide antigens
	conjugated (procedure)

HEDIS ECDS Coding Booklet 2025

Page 81 of 117

Description	CPT/HCPCS/SNOMEDSNOMED CT/CVX
	434751000124102: Pneumococcal conjugate vaccination
	(procedure)
Rotavirus (3 Dose Schedule) Immunization	CVX
	116: rotavirus, live, pentavalent vaccine
	122: rotavirus vaccine, unspecified formulation
Rotavirus Vaccine (2 Dose Schedule)	СРТ
Procedure	90681
	SNOMED CTSNOMED CT
	434741000124104: Rotavirus vaccination, 2 dose schedule
	(procedure)
Rotavirus Vaccine (3 Dose Schedule)	СРТ
Procedure	SNOMED CTSNOMED CT
	434731000124109: Rotavirus vaccination, 3 dose schedule
	(procedure)
Varicella zoster (VZV) immunization	CVX
	21: varicella virus vaccine
	94: measles, mumps, rubella, and varicella virus vaccine
Varicella zoster (VZV) vaccine procedure	СРТ
	90710, 90716
	SNOMED CTSNOMED CT
	425897001: Administration of first dose of vaccine product
	containing only Human alphaherpesvirus 3 antigen for
	chickenpox (procedure)
	428502009: Administration of second dose of vaccine product
	containing only Human alphaherpesvirus 3 antigen for
	chickenpox (procedure)
	432636005: Administration of vaccine product containing only
	Human alphaherpesvirus 3 and Measles morbillivirus and Mumps
	orthorubulavirus and Rubella virus antigens (procedure)
	433733003: Administration of second dose of vaccine product
	containing only Human alphaherpesvirus 3 and Measles
	morbillivirus and Mumps orthorubulavirus and Rubella virus
	antigens (procedure)
	737081007: Administration of vaccine product containing only
	Human alphaherpesvirus 3 antigen for chickenpox (procedure)
	871898007: Administration of vaccine product containing only
	live attenuated Human alphaherpesvirus 3 antigen (procedure)
	871899004: Administration of vaccine product containing only
	live attenuated Human alphaherpesvirus 3 antigen via
	subcutaneous route (procedure)

Page 82 of 117

Description	CPT/HCPCS/SNOMEDSNOMED CT/CVX
	871909005: Administration of first dose of vaccine product containing only Human alphaherpesvirus 3 and Measles morbillivirus and Mumps orthorubulavirus and Rubella virus antigens (procedure) 572511000119105: Administration of vaccine product containing only live attenuated Measles morbillivirus and Mumps orthorubulavirus and Rubella virus and Human alphaherpesvirus 3 antigens (procedure)
CDC Race and Ethnicity	1002-5: American Indian or Alaska Native 2028-9: Asian 2054-5: Black or African American 2076-8: Native Hawaiian or Other Pacific Islander 2106-3: White 2135-2: Hispanic or Latino 2186-5: Not Hispanic or Latino

Note: The codes listed are informational only; this information does not guarantee reimbursement.

Colorectal Cancer Screening (COL-E)

Description	CPT/HCPCS/LOINC/SNOMED CTSNOMED CT
Colonoscopy	СРТ
	44388, 44389, 44390, 44391, 44392, 44394, 44401, 44402, 44403, 44404, 44405,
	44406, 44407, 44408, 45378, 45379, 45380, 45381, 45382,45384, 45385, 45386,
	45388, 45389, 45390, 45391, 45392, 45393, 45398
	HCPCS
	G0105: Colorectal cancer screening; colonoscopy on individual at high risk
	: Colorectal cancer screening; colonoscopy on individual not meeting criteria for
	high risk
	SNOMED CTSNOMED CT
	8180007: Fiberoptic colonoscopy through colostomy (procedure)
	12350003: Colonoscopy with rigid sigmoidoscope through colotomy (procedure)
	25732003: Fiberoptic colonoscopy with biopsy (procedure)
	34264006: Intraoperative colonoscopy (procedure)
	73761001: Colonoscopy (procedure)
	174158000: Open colonoscopy (procedure)
	174185007: Diagnostic fiberoptic endoscopic examination of colon and biopsy of
	lesion of colon (procedure)
	235150006: Total colonoscopy (procedure)
	235151005: Limited colonoscopy (procedure)

Page 83 of 117

Description	CPT/HCPCS/LOINC/SNOMED CTSNOMED CT
	275251008: Diagnostic endoscopic examination of colon using fiberoptic
	sigmoidoscope (procedure)
	302052009: Endoscopic biopsy of lesion of colon (procedure)
	367535003: Fiberoptic colonoscopy (procedure) [367535003]
	443998000: Colonoscopy through colostomy with endoscopic biopsy of colon
	(procedure)
	444783004: Screening colonoscopy (procedure)
	446521004: Colonoscopy and excision of mucosa of colon (procedure)
	446745002: Colonoscopy and biopsy of colon (procedure)
	447021001: Colonoscopy and tattooing (procedure)
	709421007: Colonoscopy and dilatation of stricture of colon (procedure)
	710293001: Colonoscopy using fluoroscopic guidance (procedure)
	711307001: Colonoscopy using X-ray guidance (procedure)
	789778002: Colonoscopy and fecal microbiota transplantation (procedure)
	1209098000: Fiberoptic colonoscopy with biopsy of lesion of colon (procedure)
	48021000087103: Colonoscopy using cecal retroflexion technique (procedure)
	48031000087101: Colonoscopy using rectal retroflexion technique (procedure)
CT Colonography	СРТ
	74261, 74262, 74263
	LOINC
	60515-4: CT Colon and Rectum W air contrast PR
	72531-7: CT Colon and Rectum W contrast IV and W air contrast PR
	79069-1: CT Colon and Rectum for screening WO contrast IV and W air contrast
	PR
	79071-7: CT Colon and Rectum WO contrast IV and W air contrast PR
	79101-2: CT Colon and Rectum for screening W air contrast PR
	82688-3: CT Colon and Rectum WO and W contrast IV and W air contrast PR
	SNOMED CTSNOMED CT
	418714002: Virtual computed tomography colonoscopy (procedure)
Flexible sigmoidoscopy	CPT
	45330, 45331, 45332, 45333, 45334, 45335, 45337,
	45338, 45340, 45341, 45342, 45346, 45347, 45349, 45350
	HCPCS
	G0104: Colorectal cancer screening; flexible sigmoidoscopy SNOMED CTSNOMED CT
	44441009: Flexible fiberoptic sigmoidoscopy (procedure) 396226005: Flexible fiberoptic sigmoidoscopy with biopsy (procedure)
	425634007: Diagnostic endoscopic examination of lower bowel and sampling for
	bacterial overgrowth using fiberoptic sigmoidoscope (procedure)
FOBT Lab Test	CPT
	UT I

Page 84 of 117

Description	CPT/HCPCS/LOINC/SNOMED CTSNOMED CT
	82270, 82274
	HCPCS
	Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3
	simultaneous
	LOINC
	12503-9: Hemoglobin.gastrointestinal [Presence] in Stool4th specimen
	12504-7: Hemoglobin. Gastrointestinal [Presence] in Stool5th specimen
	14563-1: Hemoglobin. Gastrointestinal [Presence] in Stool1st specimen
	14564-9: Hemoglobin. Gastrointestinal [Presence] in Stool2nd specimen
	14565-6: Hemoglobin. Gastrointestinal [Presence] in Stool3rd specimen
	2335-8: Hemoglobin. Gastrointestinal [Presence] in Stool
	27396-1: Hemoglobin. Gastrointestinal [Mass/mass] in Stool
	27401-9: Hemoglobin. Gastrointestinal [Presence] in Stool6th specimen
	27925-7: Hemoglobin. Gastrointestinal [Presence] in Stool7th specimen
	27926-5: Hemoglobin. Gastrointestinal [Presence] in Stool8th specimen
	29771-3: Hemoglobin.gastrointestinal.lower [Presence] in Stool by Immunoassay
	56490-6: Hemoglobin.gastrointestinal.lower [Presence] in Stool by Immunoassay
	2nd specimen
	56491-4: Hemoglobin.gastrointestinal.lower [Presence] in Stool by Immunoassay
	3rd specimen
	57905-2: Hemoglobin.gastrointestinal.lower [Presence] in Stool by Immunoassay
	1st specimen
	58453-2: Hemoglobin.gastrointestinal.lower [Mass/volume] in Stool by
	Immunoassay
	80372-6: Hemoglobin. Gastrointestinal [Presence] in Stool by Rapid
	immunoassay
	SNOMED CTSNOMED CT
	104435004: Screening for occult blood in feces (procedure)
	441579003: Measurement of occult blood in stool specimen using immunoassay
	(procedure)
	442067009: Measurement of occult blood in two separate stool specimens
	(procedure)
	442516004: Measurement of occult blood in three separate stool specimens
	(procedure)
	442554004: Guaiac test for occult blood in feces specimen (procedure)
	442563002: Measurement of occult blood in single stool specimen (procedure
FOBT Test Result or	SNOMED CT
Finding	59614000: Occult blood in stools (finding)
	167667006: Fecal occult blood: negative (finding)
	389076003: Fecal occult blood: trace (finding)

HEDIS ECDS Coding Booklet 2025

Page 85 of 117

Description	CPT/HCPCS/LOINC/SNOMED CTSNOMED CT
	71711000112103: Occult blood detected in feces by immunoassay (finding)
sDNA FIT Lab Test	СРТ
	81528
	LOINC
	77353-1: Noninvasive colorectal cancer DNA and occult blood screening
	[Interpretation] in Stool Narrative
	77354-9: Noninvasive colorectal cancer DNA and occult blood screening
	[Presence] in Stool
CDC Race and Ethnicity	1002-5: American Indian or Alaska Native
	2028-9: Asian
	2054-5: Black or African American
	2076-8: Native Hawaiian or Other Pacific Islander
	2106-3: White
	2135-2: Hispanic or Latino
	2186-5: Not Hispanic or Latino

Note: The codes listed are informational only; this information does not guarantee reimbursement.

Documented Assessment After Mammogram (DBM-E)

Page 86 of 117

Description	SNOMED CT
BIRADS Assessment	397138000: Mammography assessment (Category 0) - Need additional imaging evaluation (finding)
	397140005: Mammography assessment (Category 1) - Negative (finding)
	397141009: Mammography assessment (Category 2) - Benign finding (finding)
	397143007: Mammography assessment (Category 3) - Probably benign finding, short interval follow-up (finding)
	397144001: Mammography assessment (Category 4) - Suspicious abnormality, biopsy should be considered (finding)
	6121000179106: Mammography assessment (Category 4A) - Suspicious
	abnormality, biopsy should be considered, low suspicion of malignancy (finding) 6131000179108: Mammography assessment (Category 4B) - Suspicious
	abnormality, biopsy should be considered, moderate suspicion of malignancy (finding)
	6141000179100: Mammography assessment (Category 4C) - Suspicious abnormality, biopsy should be considered, high suspicion of malignancy (finding)
	397145000: Mammography assessment (Category 5) - Highly suggestive of malignancy (finding)
	6111000179101: Mammography assessment (Category 6) - known biopsy, proven malignancy (finding)

Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E)

Description	ICD10CM/SNOMED CTSNOMED CT
Major Depression or	ICD10CM
Dysthymia	F32.0: Major depressive disorder, single episode, mild
	F32.1: Major depressive disorder, single episode, moderate
	F32.2: Major depressive disorder, single episode, severe without psychotic
	features
	F32.3: Major depressive disorder, single episode, severe with psychotic features
	F32.4: Major depressive disorder, single episode, in partial remission
	F32.5: Major depressive disorder, single episode, in full remission
	F32.9: Major depressive disorder, single episode, unspecified
	F33.0: Major depressive disorder, recurrent, mild
	F33.1: Major depressive disorder, recurrent, moderate
	F33.2: Major depressive disorder, recurrent severe without psychotic features
	F33.3: Major depressive disorder, recurrent, severe with psychotic symptoms
	F33.40: Major depressive disorder, recurrent, in remission, unspecified
	F33.41: Major depressive disorder, recurrent, in partial remission
	F33.42: Major depressive disorder, recurrent, in full remission

Page 87 of 117

Description	ICD10CM/SNOMED CTSNOMED CT
	F33.9: Major depressive disorder, recurrent, unspecified
	F34.1: Dysthymic disorder
	SNOMED CTSNOMED CT
	832007: Moderate major depression (disorder)
	2506003: Early onset dysthymia (disorder)
	2618002: Chronic recurrent major depressive disorder (disorder)
	3109008: Secondary dysthymia early onset (disorder)
	14183003: Chronic major depressive disorder, single episode (disorder)
	15193003: Severe recurrent major depression with psychotic features, mood-
	incongruent (disorder)
	15639000: Moderate major depression, single episode (disorder)
	18818009: Moderate recurrent major depression (disorder)
	19527009: Single episode of major depression in full remission (disorder)
	19694002: Late onset dysthymia (disorder)
	20250007: Severe major depression, single episode, with psychotic features,
	mood-incongruent (disorder)
	25922000: Major depressive disorder, single episode with postpartum onset
	(disorder)
	28475009: Severe recurrent major depression with psychotic features (disorder)
	30605009: Major depression in partial remission (disorder)
	33078009: Severe recurrent major depression with psychotic features, mood-
	congruent (disorder)
	33135002: Recurrent major depression in partial remission (disorder)
	33736005: Severe major depression with psychotic features, mood-congruent
	(disorder)
	36170009: Secondary dysthymia late onset (disorder)
	36474008: Severe recurrent major depression without psychotic features
	(disorder)
	36923009: Major depression, single episode (disorder)
	38451003: Primary dysthymia early onset (disorder)
	38694004: Recurrent major depressive disorder with atypical features (disorder)
	39809009: Recurrent major depressive disorder with catatonic features
	(disorder)
	40379007: Mild recurrent major depression (disorder)
	42810003: Major depression in remission (disorder)
	42925002: Major depressive disorder, single episode with atypical features
	(disorder)
	46244001: Recurrent major depression in full remission (disorder)
	60099002: Severe major depression with psychotic features, mood-incongruent
	(disorder)
The codes and measure tips lists	ad are informational only not clinical guidelines or standards of medical care, and do not guarantee

Page 88 of 117

Description	ICD10CM/SNOMED CTSNOMED CT
Description	63412003: Major depression in full remission (disorder)
	63778009: Major depressive disorder, single episode with melancholic features
	(disorder)
	66344007: Recurrent major depression (disorder)
	67711008: Primary dysthymia late onset (disorder)
	69392006: Major depressive disorder, single episode with catatonic features
	(disorder)
	70747007: Major depression single episode, in partial remission (disorder)
	71336009: Recurrent major depressive disorder with postpartum onset
	(disorder)
	73867007: Severe major depression with psychotic features (disorder)
	75084000: Severe major depression without psychotic features (disorder)
	76441001: Severe major depression, single episode, without psychotic features
	(disorder)
	77911002: Severe major depression, single episode, with psychotic features,
	mood-congruent (disorder)
	78667006: Dysthymia (disorder)
	79298009: Mild major depression, single episode (disorder)
	83176005: Primary dysthymia (disorder)
	85080004: Secondary dysthymia (disorder)
	87512008: Mild major depression (disorder)
	191604000: Single major depressive episode, severe, with psychosis (disorder)
	191610000: Recurrent major depressive episodes, mild (disorder)
	191611001: Recurrent major depressive episodes, moderate (disorder)
	191613003: Recurrent major depressive episodes, severe, with psychosis
	(disorder)
	231499006: Endogenous depression first episode (disorder)
	268621008: Recurrent major depressive episodes (disorder)
	274948002: Endogenous depression - recurrent (disorder)
	300706003: Endogenous depression (disorder)
	319768000: Recurrent major depressive disorder with melancholic features
	(disorder)
	320751009: Major depression, melancholic type (disorder)
	370143000: Major depressive disorder (disorder)
	430852001: Severe major depression, single episode, with psychotic features
	(disorder)

Depression Remission or Response for Adolescents and Adults (DRR-E)

Page 89 of 117

Description	SNOMED CT
Major Depression or	SNOMED CT
Dysthymia	832007: Moderate major depression (disorder)
	2506003: Early onset dysthymia (disorder)
	2618002: Chronic recurrent major depressive disorder (disorder)
	3109008: Secondary dysthymia early onset (disorder)
	14183003: Chronic major depressive disorder, single episode (disorder)
	15193003: Severe recurrent major depression with psychotic features, mood-
	incongruent (disorder)
	15639000: Moderate major depression, single episode (disorder)
	18818009: Moderate recurrent major depression (disorder)
	19527009: Single episode of major depression in full remission (disorder)
	19694002: Late onset dysthymia (disorder)
	20250007: Severe major depression, single episode, with psychotic features,
	mood-incongruent (disorder)
	25922000: Major depressive disorder, single episode with postpartum onset
	(disorder)
	28475009: Severe recurrent major depression with psychotic features (disorder)
	30605009: Major depression in partial remission (disorder)
	33078009: Severe recurrent major depression with psychotic features, mood-
	congruent (disorder)
	33135002: Recurrent major depression in partial remission (disorder)
	33736005: Severe major depression with psychotic features, mood-congruent
	(disorder)
	36170009: Secondary dysthymia late onset (disorder)
	36474008: Severe recurrent major depression without psychotic features
	(disorder)
	36923009: Major depression, single episode (disorder)
	38451003: Primary dysthymia early onset (disorder)
	38694004: Recurrent major depressive disorder with atypical features (disorder)
	39809009: Recurrent major depressive disorder with catatonic features
	(disorder)
	40379007: Mild recurrent major depression (disorder)
	42810003: Major depression in remission (disorder)
	42925002: Major depressive disorder, single episode with atypical features
	(disorder)
	46244001: Recurrent major depression in full remission (disorder)
	60099002: Severe major depression with psychotic features, mood-incongruent
	(disorder) 62412002: Major depression in full remission (disorder)
	63412003: Major depression in full remission (disorder)

Page 90 of 117

Description	SNOMED CT
	63778009: Major depressive disorder, single episode with melancholic features
	(disorder)
	66344007: Recurrent major depression (disorder)
	67711008: Primary dysthymia late onset (disorder)
	69392006: Major depressive disorder, single episode with catatonic features
	(disorder)
	70747007: Major depression single episode, in partial remission (disorder)
	71336009: Recurrent major depressive disorder with postpartum onset
	(disorder)
	73867007: Severe major depression with psychotic features (disorder)
	75084000: Severe major depression without psychotic features (disorder)
	76441001: Severe major depression, single episode, without psychotic features
	(disorder)
	77911002: Severe major depression, single episode, with psychotic features,
	mood-congruent (disorder)
	78667006: Dysthymia (disorder)
	79298009: Mild major depression, single episode (disorder)
	83176005: Primary dysthymia (disorder)
	85080004: Secondary dysthymia (disorder)
	87512008: Mild major depression (disorder)
	191604000: Single major depressive episode, severe, with psychosis (disorder)
	191610000: Recurrent major depressive episodes, mild (disorder)
	191611001: Recurrent major depressive episodes, moderate (disorder) 191613003: Recurrent major depressive episodes, severe, with psychosis
	(disorder)
	231499006: Endogenous depression first episode (disorder)
	268621008: Recurrent major depressive episode (disorder)
	274948002: Endogenous depression - recurrent (disorder)
	300706003: Endogenous depression (disorder)
	319768000: Recurrent major depressive disorder with melancholic features
	(disorder)
	320751009: Major depression, melancholic type (disorder)
	370143000: Major depressive disorder (disorder)
	430852001: Severe major depression, single episode, with psychotic features
	(disorder)

Note: The codes listed are informational only; this information does not guarantee reimbursement.

Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)

Page 91 of 117

Description	CPT/HCPCS/SNOMED CTSNOMED CT
Depression Case	CPT
Management Encounter	,,,,
	HCPCS
	: Rural health clinic or federally qualified health center (RHC/FQHC) only, psychiatric collaborative care model (psychiatric COCM), 60 minutes or more of clinical staff time for psychiatric COCM services directed by an RHC or FQHC practitioner (physician, NP, PA, or CNM) and including services furnished by a behavioral health care manager and consultation with a psychiatric consultant, per calendar month
	T1016: Case Management, each 15 minutes
	T1017: Targeted Case Management, each 15 minutes
	: Case Management, per month
	: Targeted Case Management; per month
	SNOMED CTSNOMED CT
	182832007: Procedure related to management of drug administration (procedure)
	225333008: Behavior management (regime/therapy)
	385828006: Health promotion management (procedure)
	386230005: Case Management (procedure)
	409022004: Dispensing medication management (procedure)
	410216003: Communication care management (procedure)
	410219005: Personal care management (procedure)
	410328009: Coping skills Case Management (procedure)
	410335001: Exercises Case Management (procedure)
	410346003: Medication action/side effects Case Management (procedure)
	410347007: Medication set-up Case Management (procedure)
	410351009: Relaxation/breathing techniques Case Management (procedure)
	410352002: Rest/sleep Case Management (procedure)
	410353007: Safety Case Management (procedure)
	410354001: Screening Case Management (procedure)
	410356004: Signs/symptoms-mental/emotional Case Management (procedure)
	410360001: Spiritual care Case Management (procedure)
	410363004: Support group Case Management (procedure)
	410364005: Support system Case Management (procedure)
	410366007: Wellness Case Management (procedure)
	416341003: Case Management started (situation)
	416584001: Case Management ended (situation)
	424490002: Medication prescription Case Management (procedure)
	425604002: Case Management follow up (procedure)
	737850002: Day care Case Management (procedure)

Page 92 of 117

Description	CPT/HCPCS/SNOMED CTSNOMED CT
	621561000124106: Psychiatric Case Management (procedure)
	661051000124109: Education about Department of Veterans Affairs Military2VA
	Case Management Program (procedure)
	662081000124106: Assistance with application for Department of Veterans Affairs
	Military2VA Case Management Program (procedure)
	662541000124107: Evaluation of eligibility for Department of Veterans Affairs
	Military2VA Case Management Program (procedure)
	842901000000108: Multidisciplinary Case Management (procedure)
Symptoms of Depression	SNOMED CT
	394924000: Symptoms of depression (finding)
	788976000: Leaden paralysis (finding)
Note: The codes listed are in	oformational only: this information does not guarantee reimbursement

Note: The codes listed are informational only; this information does not guarantee reimbursement.

Follow-Up After Abnormal Mammogram Assessment (FMA-E)

Description	SNOMED CT
High Risk BIRADS	 397144001: Mammography assessment (Category 4) - Suspicious abnormality, biopsy should be considered (finding) 6121000179106: Mammography assessment (Category 4A) - Suspicious abnormality, biopsy should be considered, low suspicion of malignancy (finding) 6131000179108: Mammography assessment (Category 4B) - Suspicious abnormality, biopsy should be considered, moderate suspicion of malignancy (finding) 6141000179100: Mammography assessment (Category 4C) - Suspicious abnormality, biopsy should be considered, high suspicion of malignancy (finding) 6141000179100: Mammography assessment (Category 4C) - Suspicious abnormality, biopsy should be considered, high suspicion of malignancy (finding) 397145000: Mammography assessment (Category 5) - Highly suggestive of
Inconclusive BIRADS	malignancy (finding) 397138000: Mammography assessment (Category 0) - Need additional imaging evaluation (finding)

Immunizations for Adolescents (IMA-E)

Description	CPT/CVX/SNOMED CTSNOMED CT
Meningococcal	CVX
Immunization	32: meningococcal polysaccharide vaccine (MPSV4)
	108: meningococcal ACWY vaccine, unspecified formulation
	114: meningococcal polysaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4P)
	136: meningococcal oligosaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4O)

Page 93 of 117

Description	CPT/CVX/SNOMED CTSNOMED CT
	147: Meningococcal, MCV4, unspecified conjugate formulation(groups A, C, Y and W-135)
	167: meningococcal vaccine of unknown formulation and unknown serogroups
	203: meningococcal polysaccharide (groups A, C, Y, W-135) tetanus toxoid
	conjugate vaccine 0.5mL dose, preservative free
	316: Meningococcal polysaccharide (groups A, C, Y, W) tetanus toxoid conjugate,
	meningococcal B recombinant vaccine, 0.5mL, preservative free
Meningococcal Vaccine	СРТ
Procedure	, 90733, 90734
	SNOMED CTSNOMED CT
	871874000: Administration of vaccine product containing only Neisseria
	meningitidis serogroup A, C, W135 and Y antigens (procedure)
	428271000124109: Meningococcal conjugate vaccination (procedure)
	16298691000119102: Administration of vaccine product containing only Neisseria
	meningitidis serogroup A, C, W135 and Y capsular oligosaccharide conjugated
	antigens (procedure)
Tdap Vaccine Procedure	СРТ
	90715
	SNOMED CTSNOMED CT
	390846000: Administration of booster dose of vaccine product containing only
	acellular Bordetella pertussis and Clostridium tetani and Corynebacterium
	diphtheriae antigens (procedure)
	412755006: Administration of first dose of vaccine product containing only
	acellular Bordetella pertussis and Clostridium tetani and Corynebacterium
	diphtheriae antigens (procedure)
	412756007: Administration of second dose of vaccine product containing only
	acellular Bordetella pertussis and Clostridium tetani and Corynebacterium
	diphtheriae antigens (procedure)
	412757003: Administration of third dose of vaccine product containing only
	acellular Bordetella pertussis and Clostridium tetani and Corynebacterium
	diphtheriae antigens (procedure)
	428251000124104: Tetanus, diphtheria, and acellular pertussis vaccination
	(procedure)
	571571000119105: Administration of vaccine product containing only acellular
	Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae
	antigens (procedure)
HPV Immunization	CVX
	62: Human papilloma virus vaccine, quadrivalent
	118: Human papilloma virus vaccine, bivalent
	137: HPV, unspecified formulation

HEDIS ECDS Coding Booklet 2025

Page 94 of 117

HPV Vaccine Procedure	165: Human Papillomavirus 9-valent vaccine CPT
HPV Vaccine Procedure	СРТ
	90649, 90650, 90651
	SNOMED CTSNOMED CT
	428741008: Administration of first dose of vaccine product containing only
	Human papillomavirus antigen (procedure)
	428931000: Administration of third dose of vaccine product containing only
	Human papillomavirus antigen (procedure)
	429396009: Administration of second dose of vaccine product containing only
	Human papillomavirus antigen (procedure)
	717953009: Administration of vaccine product containing only Human
	papillomavirus 16 and 18 antigens (procedure)
	724332002: Administration of vaccine product containing only Human
	papillomavirus 9 antigen (procedure)
	734152003: Administration of vaccine product containing only Human
	papillomavirus 6, 11, 16 and 18 antigens (procedure)
	761841000: Administration of vaccine product containing only Human
	papillomavirus antigen (procedure)
	1209198003: Administration of vaccine product containing only Human
	papillomavirus 6, 11, 16, 18, 31, 33, 45, 52 and 58 antigen (procedure)
CDC Race and Ethnicity	1002-5: American Indian or Alaska Native
	2028-9: Asian
	2054-5: Black or African American
	2076-8: Native Hawaiian or Other Pacific Islander
	2106-3: White
	2135-2: Hispanic or Latino
	2186-5: Not Hispanic or Latino

Note: The codes listed are informational only; this information does not guarantee reimbursement.

Postpartum Depression Screening and Ponow-Op (PDS-E)		
Description	CPT/ HCPCS/SNOMEDSNOMED CT	
Deliveries	CPT , 59409, 59410, , 59514, 59515, , 59612, 59614, , 59620, 59622 SNOMED CT 2321005: Delivery by Ritgen maneuver (procedure) 199771001: Piper forceps delivery by application to aftercoming head (procedure)	
Depression Case	CPT	
Management Encounter	HCPCS	
	T1016: Case Management, each 15 minutes	

Postpartum Depression Screening and Follow-Up (PDS-E)

Page 95 of 117

Description	CPT/ HCPCS/SNOMEDSNOMED CT
	T1017: Targeted Case Management, each 15 minutes
	Case Management, per month
	Targeted Case Management; per month
	SNOMED CTSNOMED CT
	182832007: Procedure related to management of drug administration
	(procedure)
	225333008: Behavior management (regime/therapy)
	385828006: Health promotion management (procedure)
	386230005: Case Management (procedure)
	409022004: Dispensing medication management (procedure)
	410216003: Communication care management (procedure)
	410219005: Personal care management (procedure)
	410328009: Coping skills Case Management (procedure)
	410335001: Exercises Case Management (procedure)
	410346003: Medication action/side effects Case Management (procedure)
	410347007: Medication set-up Case Management (procedure)
	410351009: Relaxation/breathing techniques Case Management (procedure)
	410352002: Rest/sleep Case Management (procedure)
	410353007: Safety Case Management (procedure)
	410354001: Screening Case Management (procedure)
	410356004: Signs/symptoms-mental/emotional Case Management (procedure)
	410360001: Spiritual care Case Management (procedure)
	410363004: Support group Case Management (procedure)
	410364005: Support system Case Management (procedure)
	410366007: Wellness Case Management (procedure)
	416341003: Case Management started (situation)
	416584001: Case Management ended (situation)
	424490002: Medication prescription Case Management (procedure)
	425604002: Case Management follow up (procedure)
	737850002: Day care Case Management (procedure)
	621561000124106: Psychiatric Case Management (procedure)
	661051000124109: Education about Department of Veterans Affairs Military2VA
	Case Management Program (procedure)
	662081000124106: Assistance with application for Department of Veterans
	Affairs Military2VA Case Management Program (procedure)
	662541000124107: Evaluation of eligibility for Department of Veterans Affairs
	Military2VA Case Management Program (procedure)
	842901000000108: Multidisciplinary Case Management (procedure)
Symptoms of Depression	SNOMED CT
	394924000: Symptoms of depression (finding)

HEDIS ECDS Coding Booklet 2025

Page 96 of 117

Description	CPT/ HCPCS/SNOMEDSNOMED CT
	788976000: Leaden paralysis (finding)
CDC Race and Ethnicity	1002-5: American Indian or Alaska Native
	2028-9: Asian
	2054-5: Black or African American
	2076-8: Native Hawaiian or Other Pacific Islander
	2106-3: White
	2135-2: Hispanic or Latino
	2186-5: Not Hispanic or Latino
Note: The codes listed are i	nformational only; this information does not guarantee reimbursement.

Prenatal Depression Screening and Follow-up (PND-E)

Description	CPT/ HCPCS/SNOMED CTSNOMED CT
Deliveries	СРТ
	59409, 59410, 59510, 59514, 59515, , 59612, 59614, , 59620, 59622
	SNOMED CT
	2321005: Delivery by Ritgen maneuver (procedure)
	199771001: Piper forceps delivery by application to aftercoming head (procedure)
37 weeks gestation	SNOMED CT
	43697006: Gestation period, 37 weeks (finding)
38 weeks gestation	SNOMED CT
	13798002: Gestation period, 38 weeks (finding)
39 weeks gestation	SNOMED CT
	80487005: Gestation period, 39 weeks (finding)
40 weeks gestation	SNOMED CT
	46230007: Gestation period, 40 weeks (finding)
41 weeks gestation	SNOMED CT
	63503002: Gestation period, 41 weeks (finding)
42 weeks gestation	SNOMED CT
	36428009: Gestation period, 42 weeks (finding)
Weeks of Gestation Less	SNOMED CT
Than 37	931004: Gestation period, 9 weeks (finding)
	6678005: Gestation period, 15 weeks (finding)
	15633004: Gestation period, 16 weeks (finding)
	23464008: Gestation period, 20 weeks (finding)
	25026004: Gestation period, 18 weeks (finding)
	26690008: Gestation period, 8 weeks (finding)

Page 97 of 117

Description	CPT/ HCPCS/SNOMED CTSNOMED CT
	37005007: Gestation period, 5 weeks (finding)
	38039008: Gestation period, 10 weeks (finding)
	41438001: Gestation period, 21 weeks (finding)
	44398003: Gestation period, 4 weeks (finding)
	46906003: Gestation period, 27 weeks (finding)
	48688005: Gestation period, 26 weeks (finding)
	50367001: Gestation period, 11 weeks (finding)
	54318006: Gestation period, 19 weeks (finding)
	57907009: Gestation period, 36 weeks (finding)
	62333002: Gestation period, 13 weeks (finding)
	63110000: Gestation period, 7 weeks (finding)
	65035007: Gestation period, 22 weeks (finding)
	65683006: Gestation period, 17 weeks (finding)
	72544005: Gestation period, 25 weeks (finding)
	72846000: Gestation period, 14 weeks (finding)
	74952004: Gestation period, 3 weeks (finding)
	79992004: Gestation period, 12 weeks (finding)
	82118009: Gestation period, 2 weeks (finding)
	86801005: Gestation period, 6 weeks (finding)
	86883006: Gestation period, 23 weeks (finding)
	87178007: Gestation period, 1 week (finding)
	313178001: Gestation less than 24 weeks (finding)
	313179009: Gestation period, 24 weeks (finding)
	428058009: Gestation less than 9 weeks (finding)
	428566005: Gestation less than 20 weeks (finding)
	428567001: Gestation 14 - 20 weeks (finding)
	428930004: Gestation 9- 13 weeks (finding)
Deservesion Cons	
Depression Case	CPT
Management Encounter	HCPCS
	T1016: Case Management, each 15 minutes T1017: Targeted Case Management, each 15 minutes
	Case Management, per month Targeted Case Management; per month
	SNOMED CTSNOMED CT
	182832007: Procedure related to management of drug administration
	(procedure)
	(procedure) 225333008: Behavior management (regime/therapy)
	385828006: Health promotion management (procedure)
	386230005: Case Management (procedure)
	Soz Soos. Case Management (procedure)
The codes and measure tips listed	are informational only, not clinical guidelines or standards of medical care, and do not guarantee

Page 98 of 117

Description	CPT/ HCPCS/SNOMED CTSNOMED CT
Beschption	409022004: Dispensing medication management (procedure)
	410216003: Communication care management (procedure)
	410219005: Personal care management (procedure)
	410328009: Coping skills Case Management (procedure)
	410335001: Exercises Case Management (procedure)
	410346003: Medication action/side effects Case Management (procedure)
	410347007: Medication set-up Case Management (procedure)
	410351009: Relaxation/breathing techniques Case Management (procedure)
	410352002: Rest/sleep Case Management (procedure)
	410353007: Safety Case Management (procedure)
	410354001: Screening Case Management (procedure)
	410356004: Signs/symptoms-mental/emotional Case Management (procedure)
	410360001: Spiritual care Case Management (procedure)
	410363004: Support group Case Management (procedure)
	410364005: Support system Case Management (procedure)
	410366007: Wellness Case Management (procedure)
	416341003: Case Management started (situation)
	416584001: Case Management ended (situation)
	424490002: Medication prescription Case Management (procedure)
	425604002: Case Management follow up (procedure)
	737850002: Day care Case Management (procedure)
	621561000124106: Psychiatric Case Management (procedure)
	661051000124109: Education about Department of Veterans Affairs Military2VA
	Case Management Program (procedure)
	662081000124106: Assistance with application for Department of Veterans
	Affairs Military2VA Case Management Program (procedure)
	662541000124107: Evaluation of eligibility for Department of Veterans Affairs
	Military2VA Case Management Program (procedure)
	842901000000108: Multidisciplinary Case Management (procedure)
Symptoms of Depression	SNOMED CT
	394924000: Symptoms of depression (finding)
	788976000: Leaden paralysis (finding)
CDC Race and Ethnicity	1002-5: American Indian or Alaska Native
	2028-9: Asian
	2054-5: Black or African American
	2076-8: Native Hawaiian or Other Pacific Islander
	2106-3: White
	2135-2: Hispanic or Latino
	2186-5: Not Hispanic or Latino
Note: The codes listed are in	nformational only; this information does not guarantee reimbursement.

Page 99 of 117

Prenatal Immunization Status (PRS-E)

Description	CPT/CVX/SNOMED CTSNOMED CT
Deliveries	CPT
	59409, 59410, , 59514, 59515, , 59612, 59614, , 59620, 59622
	SNOMED CT
	2321005: Delivery by Ritgen maneuver (procedure)
	199771001: Piper forceps delivery by application to aftercoming head (procedure)
37 Weeks Gestation	SNOMED CT
	43697006: Gestation period, 37 weeks (finding)
38 Weeks Gestation	SNOMED CT
	13798002: Gestation period, 38 weeks (finding)
39 Weeks Gestation	SNOMED CT
	80487005: Gestation period, 39 weeks (finding)
40 Weeks Gestation	SNOMED CT
	46230007: Gestation period, 40 weeks (finding)
41 Weeks Gestation	SNOMED CT
	63503002: Gestation period, 41 weeks (finding)
42 Weeks Gestation	SNOMED CT
	36428009: Gestation period, 42 weeks (finding)
Adult Influenza	CVX
Immunization	88: influenza virus vaccine, unspecified formulation
	135: influenza, high dose seasonal, preservative-free
	140: Influenza, seasonal, injectable, preservative free
	141: Influenza, seasonal, injectable
	144: seasonal influenza, intradermal, preservative free
	150: Influenza, injectable, quadrivalent, preservative free
	153: Influenza, injectable, Madin Darby Canine Kidney, preservative free
	155: Seasonal, trivalent, recombinant, injectable influenza vaccine, preservative
	free
	158: influenza, injectable, quadrivalent, contains preservative
	166: influenza, intradermal, quadrivalent, preservative free, injectable
	168: Seasonal trivalent influenza vaccine, adjuvanted, preservative free
	171: Influenza, injectable, Madin Darby Canine Kidney, preservative free,
	quadrivalent
	185: Seasonal, quadrivalent, recombinant, injectable influenza vaccine,
	preservative free
	186: Influenza, injectable, Madin Darby Canine Kidney, quadrivalent with
	preservative
	197: influenza, high-dose seasonal, quadrivalent, 0.7mL dose, preservative free

Page 100 of 117

Description	CPT/CVX/SNOMED CTSNOMED CT
	205: influenza, seasonal vaccine, quadrivalent, adjuvanted, 0.5mL dose,
	preservative free
Adult Influenza Vaccine	СРТ
Procedure	90653,90658, 90661, 90662, 90674, 90682, 90686, 90688, 90689, 90694, 90756
	SNOMED CTSNOMED CT
	86198006: Administration of vaccine product containing only Influenza virus
	antigen (procedure)
Tdap Vaccine Procedure	CPT
	90715
	SNOMED CTSNOMED CT
	390846000: Administration of booster dose of vaccine product containing only
	acellular Bordetella pertussis and Clostridium tetani and Corynebacterium
	diphtheriae antigens (procedure)
	412755006: Administration of first dose of vaccine product containing only
	acellular Bordetella pertussis and Clostridium tetani and Corynebacterium
	diphtheriae antigens (procedure)
	412756007: Administration of second dose of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium
	diphtheriae antigens (procedure)
	412757003: Administration of third dose of vaccine product containing only
	acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure)
	428251000124104: Tetanus, diphtheria, and acellular pertussis vaccination
	(procedure)
	571571000119105: Administration of vaccine product containing only acellular
	Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae
	antigens (procedure)
CDC Race and Ethnicity	1002-5: American Indian or Alaska Native
	2028-9: Asian
	2054-5: Black or African American
	2076-8: Native Hawaiian or Other Pacific Islander
	2106-3: White
	2135-2: Hispanic or Latino
	2186-5: Not Hispanic or Latino

Additional codes	
Description CPT/CAT II/HCPCS	
Prenatal Bundled CPT	
Services HCPCS	

HEDIS ECDS Coding Booklet 2025

Page 101 of 117

Description	CPT/CAT II/HCPCS
	Prenatal care, at-risk enhanced service package (includes h1001-h1004)
Prenatal Visits	СРТ
	99202-99205, 99211-99215, ,
	HCPCS
	Hospital outpatient clinic visit for assessment and management of a patient
	T1015: Clinic visit/encounter, all-inclusive
Stand-Alone Prenatal	СРТ
Visits	CAT II
	Initial prenatal care visit (report at first prenatal encounter with a health care professional providing obstetrical care. Report also date of visit and, in a separate field, the date of the last menstrual period [LMP]) (Prenatal) Prenatal flow sheet documented in medical record by first prenatal visit (documentation includes at minimum blood pressure, weight, urine protein, uterine size, fetal heart tones, and estimated date of delivery). Report also: date of visit and, in a separate field, the date of the last menstrual period [LMP] (Note: If reporting 0501F Prenatal flow sheet, it is not necessary to report 0500F Initial prenatal care visit) (Prenatal) Subsequent prenatal care visit (Prenatal) [Excludes: patients who are seen for a condition unrelated to pregnancy or prenatal care (e.g. for example, an upper respiratory infection; patients seen for consultation only, not for continuing care)] HCPCS H1000: Prenatal care, at-risk assessment Prenatal care, at-risk enhanced service; antepartum management Prenatal care, at risk enhanced service; care coordination Prenatal care, at-risk enhanced service; color dination Prenatal care, at-risk enhanced service; color on prenatal care NOMED CT
	169600002: Antenatal care assessment (procedure)
	169602005: Antenatal care: 10 years plus since last pregnancy (regime/therapy)
	169603000: Antenatal care: primiparous, under 17 years (regime/therapy)
Postpartum Bundles	СРТ
Services	59410, 59515, 59614, 59622
Home Visit Prenatal Monitoring	СРТ
Postpartum Visit	CPT
	57170, 58300, 59430,
	CAT II
	Postpartum care visit

HCPCS

HEDIS ECDS Coding Booklet 2025

Page 102 of 117

Description	CPT/CAT II/HCPCS
	Cervical or vaginal cancer screening; pelvic and clinical breast examination (G0101)
Online Assessments	Cervical or vaginal cancer screening; pelvic and clinical breast examination (G0101) CPT 99422 HCPCS Payment for communication technology-based services for 5 minutes or more of a virtual (non-face-to-face) communication between an rural health clinic (RHC) or federally qualified health center (FQHC) practitioner and RHC or FQHC patient, or 5 minutes or more of remote evaluation of recorded video and/or images by an RHC or FQHC practitioner, occurring in lieu of an office visit; RHC or FQHC only Remote evaluation of recorded video and/or images submitted by an established patient (e.g. for example, store and forward), including interpretation with follow-up with the patient within 24 business hours, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment Brief communication technology-based service, e.g. for example virtual check-in, by a physician or other qualified health carehealthcare professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion Brief communication technology-based service, e.g.for example, virtual check-in, by a qualified health carehealthcare professional who cannot report evaluation and management services, provided to an established patient, not originating from a related service provided within the previous 7 days nor leading to a service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of clinical discussion Brief communication technology-based service, e.g.for example virtual check-in, by a physician or other qualified health carehealthcare professional who can report evaluation and management services, provided to an established patient, not origin

Note: The codes listed are informational only; this information does not guarantee reimbursement.

Social Need Screening and Intervention (SNS-E)		
	Description	CPT/HCPCS/SNOMED CTSNOMED CT
	Food insecurity procedures	441311000124102: Counseling about nutrition using stress management strategy (regime/therapy)

Page 103 of 117

Description	CPT/HCPCS/SNOMED CTSNOMED CT
Description	441321000124105: Counseling about nutrition using stimulus control strategy
	(regime/therapy)
	441331000124108: Counseling about nutrition using cognitive restructuring strategy
	(regime/therapy)
	441341000124103: Counseling about nutrition using relapse prevention strategy
	(regime/therapy)
	441351000124101: Counseling about nutrition using rewards and contingency
	management strategy (regime/therapy)
	445291000124103: Nutrition-related skill education (procedure)
	445301000124102: Content-related nutrition education (procedure)
	445641000124105: Technical nutrition education (procedure)
	461481000124109: Referral to peer support (procedure)
	462481000124102: Referral to Community Action Agency program (procedure)
	462491000124104: Referral to benefits enrollment assistance program (procedure)
	464001000124109: Referral to case manager (procedure)
	464011000124107: Referral to care manager (procedure)
	464021000124104: Referral to care navigator (procedure)
	464031000124101: Referral to food pantry program (procedure)
	464041000124106: Referral to Child and Adult Care Food Program (procedure)
	464051000124108: Referral to Gus Schumacher Nutrition Incentive Program
	(procedure)
	464061000124105: Referral to food prescription program (procedure)
	464071000124103: Referral to garden program (procedure)
	464081000124100: Referral to home-delivered meals program (procedure)
	464091000124102: Referral to medically tailored meal program (procedure)
	464101000124108: Referral to Supplemental Nutrition Assistance Program
	(procedure)
	464111000124106: Referral to Special Supplemental Nutrition Program for Women,
	Infants and Children (procedure)
	464121000124103: Referral to Summer Food Service Program (procedure)
	464131000124100: Referral to community health worker (procedure)
	464141000124105: Referral to Meals on Wheels Program (procedure)
	464151000124107: Referral to congregate meal program (procedure)
	464161000124109: Referral to community resource network program (procedure)
	464171000124102: Referral to Senior Farmers' Market Nutrition Program
	(procedure)
	464181000124104: Referral to Farmers' Market Nutrition Program for Women,
	Infants and Children (procedure)
	464191000124101: Referral to Food Distribution Program on Indian Reservations
	(procedure)
- 1 1 1	

Page 104 of 117

Description CPT/HCPCS/SNOMED CTSNOMED CT
464201000124103: Education about Child and Adult Care Food Program (procedure
464211000124100: Education about Community Meals Program (procedure)
464221000124108: Education about Gus Schumacher Nutrition Incentive Program
(procedure)
464231000124106: Education about food pantry program (procedure)
464241000124101: Education about food prescription program (procedure)
464251000124104: Education about garden program (procedure)
464261000124102: Education about home-delivered meals program (procedure)
464271000124109: Education about medically tailored meal program (procedure)
464281000124107: Education about Special Supplement Nutrition Program for
Women, Infants and Children (procedure)
464291000124105: Education about community resource network program
(procedure)
464301000124106: Education about benefits enrollment assistance program
(procedure)
464311000124109: Education about Community Action Agency program (procedure
464321000124101: Education about Food Distribution Program on Indian
Reservations (procedure)
464331000124103: Education about Farmers' Market Nutrition Program for Womer
Infants and Children (procedure)
464341000124108: Education about Senior Farmers' Market Nutrition Program
(procedure)
464351000124105: Education about congregate meal program (procedure)
464361000124107: Education about Supplemental Nutrition Assistance Program
(procedure)
464371000124100: Education about Summer Food Service Program (procedure)
464381000124102: Provision of prescription for infant formula (procedure)
464401000124102: Provision of fresh fruit and vegetable voucher (procedure
464411000124104: Provision of food voucher (procedure)
464421000124107: Provision of home-delivered meals (procedure)
464431000124105: Provision of medically tailored meals (procedure)
464611000124102: Coordination of care team (procedure)
464621000124105: Evaluation of eligibility for home-delivered meals program
(procedure)
464631000124108: Evaluation of eligibility for Meals on Wheels program
(procedure)
464641000124103: Evaluation of eligibility for medically tailored meals program
(procedure)
464651000124101: Evaluation of eligibility for Senior Farmers' Market Nutrition
Program (procedure)

Page 105 of 117

Description	CPT/HCPCS/SNOMED CTSNOMED CT
	464661000124104: Evaluation of eligibility for Special Supplemental Nutrition
	Program for Women, Infants and Children (procedure)
	464671000124106: Counseling for readiness to implement food insecurity care plan (procedure)
	464681000124109: Counseling for food insecurity care plan participation barriers
	(procedure)
	464691000124107: Counseling for barriers to achieving food security (procedure) 464701000124107: Counseling for readiness to achieve food security goals (procedure)
	464721000124102: Provision of food prescription (procedure)
	467591000124102: Evaluation of eligibility for food pantry program (procedure)
	467601000124105: Evaluation of eligibility for Food Distribution Program on Indian Reservations (procedure)
	467611000124108: Evaluation of eligibility for Farmers' Market Nutrition Program
	for Women, Infants and Children (procedure)
	467621000124100: Evaluation of eligibility for Supplemental Nutrition Assistance
	Program (procedure)
	467631000124102: Evaluation of eligibility for Summer Food Service Program
	(procedure)
	467641000124107: Evaluation of eligibility for Gus Schumacher Nutrition Incentive funded program (procedure)
	467651000124109: Evaluation of eligibility for garden program (procedure)
	467661000124106: Evaluation of eligibility for Community Meal Program
	(procedure)
	467671000124104: Evaluation of eligibility for Child and Adult Care Food Program (procedure)
	467681000124101: Assistance with application for Summer Food Service Program (procedure)
	467691000124103: Assistance with application for Special Supplemental Nutrition
	Program for Women, Infants and Children (procedure)
	467711000124100: Assistance with application for Senior Farmers' Market Nutrition
	Program (procedure)
	467721000124108: Assistance with application for Medically Tailored Meals Program (procedure)
	467731000124106: Assistance with application for Home-Delivered Meals Program (procedure)
	467741000124101: Assistance with Application for Gus Schumacher Nutrition Incentive Program (procedure)
	467751000124104: Assistance with application for garden program (procedure)

Page 106 of 117

Description	CPT/HCPCS/SNOMED CTSNOMED CT
	467761000124102: Assistance with application for food prescription program
	(procedure)
	467771000124109: Assistance with application for food pantry program (procedure)
	467781000124107: Assistance with application for Child and Adult Care Food
	Program (procedure)
	467791000124105: Assistance with application for Food Distribution Program on
	Indian Reservations (procedure)
	467801000124106: Assistance with application for Community Meal Program
	(procedure)
	467811000124109: Assistance with application for Farmers' Market Nutrition
	Program for Women, Infants and Children (procedure)
	467821000124101: Assistance with application for Supplemental Nutrition
	Assistance Program (procedure)
	468401000124109: Evaluation of eligibility for food prescription program
	(procedure)
	470231000124107: Counseling for social determinant of health risk (procedure)
	470241000124102: Assistance with application for national school lunch program
	(procedure)
	470261000124103: Assistance with application for school breakfast program
	(procedure)
	470281000124108: Evaluation of eligibility for school breakfast program (procedure)
	470291000124106: Referral to national school lunch program (procedure)
	470301000124107: Referral to school breakfast program (procedure)
	470311000124105: Education about national school lunch program (procedure)
	470321000124102: Education about school breakfast program (procedure)
	470591000124109: Education about community development financial institution
	(procedure)
	470601000124101: Education about community development corporation
	(procedure)
	470611000124103: Education about area agency on aging program (procedure)
	471111000124101: Referral to community development financial institution
	(procedure)
	471121000124109: Referral to community development corporation (procedure)
	471131000124107: Referral to area agency on aging (procedure)
	472151000124109: Referral to medical legal partnership program (procedure)
	472331000124100: Education about medical legal partnership program (procedure)
	551101000124107: Referral to lawyer (procedure)
Homelessness	СРТ
Procedures	96156, 96160, 96161
	SNOMED CTSNOMED CT

Page 107 of 117

Description	CPT/HCPCS/SNOMED CTSNOMED CT
Description	308440001: Referral to social worker (procedure)
	710824005: Assessment of health and social care needs (procedure)
	711069006: Coordination of care plan (procedure)
	1148446004: Education about legal aid (procedure)
	1148447008: Assessment for housing insecurity (procedure)
	1148812007: Assessment of progress toward goals to achieve housing security
	(procedure) 1148814008: Assessment of goals to achieve housing security (procedure)
	1148817001: Assessment of barriers in housing insecurity care plan (procedure)
	1148818006: Coordination of services to assist with maintaining housing security
	(procedure)
	1162436000: Referral to legal aid (procedure)
	1162437009: Coordination of resources to address housing instability (procedure)
	1230338004: Referral to charitable organization (procedure) 461481000124109: Referral to peer support (procedure)
	462481000124102: Referral to Community Action Agency program (procedure)
	462491000124104: Referral to benefits enrollment assistance program (procedure)
	464001000124109: Referral to case manager (procedure) 464011000124107: Referral to care manager (procedure)
	464021000124107. Referral to care navigator (procedure)
	464131000124100: Referral to community health worker (procedure)
	464161000124100: Referral to community resource network program (procedure)
	464291000124105: Education about community resource network program (procedure)
	464301000124106: Education about benefits enrollment assistance program
	(procedure)
	464311000124109: Education about Community Action Agency program (procedure)
	464611000124109: Coordination of care team (procedure)
	470231000124107: Counseling for social determinant of health risk (procedure)
	470471000124109: Assistance with application for rental assistance program
	(procedure)
	470481000124107: Assistance with application for subsidized housing program
	(procedure)
	470491000124105: Evaluation of eligibility for subsidized housing program
	(procedure)
	470501000124102: Education about subsidized housing program (procedure)
	470501000124102. Education about substitized nousing program (procedure) 470581000124106: Education about healthcare for the homeless program
	(procedure)
	470591000124109: Education about community development financial institution
	(procedure)
	(procedure)
The codes and measure tips I	isted are informational only, not clinical guidelines or standards of medical care, and do not guarantee

Page 108 of 117

Description	CPT/HCPCS/SNOMED CTSNOMED CT
	470601000124101: Education about community development corporation
	(procedure)
	470611000124103: Education about area agency on aging program (procedure)
	470781000124104: Evaluation of eligibility for permanent supportive housing
	program (procedure)
	470791000124101: Assistance with application for permanent supportive housing
	program (procedure)
	470801000124100: Education about permanent supportive housing program
	(procedure)
	470811000124102: Evaluation of eligibility for transitional housing program
	(procedure)
	470821000124105: Education about transitional housing program (procedure)
	470831000124108: Assistance with application for transitional housing program
	(procedure)
	470841000124103: Referral to healthcare for the homeless program (procedure)
	471021000124108: Referral to street outreach program (procedure)
	471031000124106: Education about street outreach program (procedure)
	471041000124101: Referral to rental assistance program (procedure)
	471071000124109: Referral to fair housing assistance program (procedure)
	471081000124107: Referral to Day Shelter program (procedure)
	471091000124105: Referral to Emergency Shelter program (procedure)
	471101000124104: Referral to coordinated entry program (procedure)
	471111000124101: Referral to community development financial institution
	(procedure)
	471121000124109: Referral to community development corporation (procedure)
	471131000124107: Referral to area agency on aging (procedure)
	472031000124103: Evaluation of eligibility for Safe Haven Program (procedure)
	472041000124108: Referral to subsidized housing service (procedure)
	472051000124105: Education about Safe Haven program (procedure)
	472081000124102: Education about rental assistance program (procedure)
	472091000124104: Evaluation of eligibility for rental assistance program (procedure)
	472101000124105: Evaluation of eligibility for Rapid Re-housing program
	(procedure)
	472111000124108: Education about Rapid Re-housing program (procedure)
	472121000124100: Assistance with application for Rapid Re-housing program
	(procedure)
	472131000124102: Provision of rental assistance voucher (procedure)
	472141000124107: Referral to medical respite for homeless program (procedure)
	472151000124109: Referral to medical legal partnership program (procedure)
	472161000124106: Referral to housing support program (procedure)

Page 109 of 117

Description	CPT/HCPCS/SNOMED CTSNOMED CT
	472191000124103: Counseling for readiness to achieve housing security goals
	(procedure)
	472221000124105: Counseling for readiness to implement housing insecurity care
	plan (procedure)
	472241000124103: Counseling for barriers to achieve housing security (procedure)
	472261000124104: Counseling for housing insecurity care plan participation barriers
	(procedure)
	472301000124108: Evaluation of eligibility for medical respite for homeless program
	(procedure)
	472311000124106: Education about medical respite for homeless program
	(procedure)
	472321000124103: Assistance with application for medical respite for homeless
	program (procedure)
	472331000124100: Education about medical legal partnership program (procedure)
	472341000124105: Evaluation of eligibility for Housing with Services program
	(procedure)
	472351000124107: Assistance with application for Housing with Services
	(procedure)
	472361000124109: Education about Housing with Services program (procedure)
	480791000124106: Evaluation of eligibility for Street Outreach program (procedure)
	480801000124107: Assistance with application for Safe Haven program (procedure)
	480811000124105: Evaluation of eligibility for Housing Only program (procedure)
	480821000124102: Education about Housing Only program (procedure)
	480831000124104: Assistance with application for Housing Only program
	(procedure)
	480871000124101: Evaluation of eligibility for healthcare for homeless program
	(procedure)
	480901000124101: Education about fair housing assistance program (procedure)
	480921000124106: Assistance with application to Emergency Shelter program
	(procedure)
	480931000124109: Evaluation of eligibility for Emergency Shelter program
	(procedure)
	480941000124104: Education about Emergency Shelter program (procedure)
	480961000124100: Education about Day Shelter program (procedure)
	480971000124107: Education about Coordinated Entry program (procedure) 480981000124105: Assistance with application for Day Shelter program (procedure)
Housing Instability	551101000124107: Referral to lawyer (procedure)
Housing Instability Procedures	CPT 96156, 96160, 96161
FIULEUUIES	SNOMED CTSNOMED CT

Page 110 of 117

Description	CPT/HCPCS/SNOMED CTSNOMED CT
	308440001: Referral to social worker (procedure)
	710824005: Assessment of health and social care needs (procedure)
	711069006: Coordination of care plan (procedure)
	1148446004: Education about legal aid (procedure)
	1148447008: Assessment for housing insecurity (procedure)
	1148812007: Assessment of progress toward goals to achieve housing security
	(procedure)
	1148814008: Assessment of goals to achieve housing security (procedure)
	1148817001: Assessment of barriers in housing insecurity care plan (procedure)
	1148818006: Coordination of services to assist with maintaining housing security
	(procedure)
	1156869006: Education about tenant rights organization (procedure)
	1162436000: Referral to legal aid (procedure)
	1162437009: Coordination of resources to address housing instability (procedure)
	1230338004: Referral to charitable organization (procedure)
	461481000124109: Referral to peer support (procedure)
	462481000124102: Referral to Community Action Agency program (procedure)
	462491000124104: Referral to benefits enrollment assistance program (procedure)
	464001000124109: Referral to case manager (procedure)
	464011000124107: Referral to care manager (procedure)
	464021000124104: Referral to care navigator (procedure)
	464131000124100: Referral to community health worker (procedure)
	464161000124109: Referral to community resource network program (procedure)
	464291000124105: Education about community resource network program
	(procedure)
	464301000124106: Education about benefits enrollment assistance program
	(procedure)
	464311000124109: Education about Community Action Agency program (procedure) 464611000124102: Coordination of care team (procedure)
	470231000124107: Counseling for social determinant of health risk (procedure)
	470471000124107: Courseing for social determinant of health risk (procedure) 470471000124109: Assistance with application for rental assistance program
	(procedure)
	470481000124107: Assistance with application for subsidized housing program
	(procedure)
	470491000124105: Evaluation of eligibility for subsidized housing program
	(procedure)
	470501000124102: Education about subsidized housing program (procedure)
	470591000124109: Education about community development financial institution
	(procedure)
	(1

Page 111 of 117

Description	CPT/HCPCS/SNOMED CTSNOMED CT
	470601000124101: Education about community development corporation
	(procedure)
	470611000124103: Education about area agency on aging program (procedure)
	471041000124101: Referral to rental assistance program (procedure)
	471051000124104: Referral to Homelessness Prevention program (procedure)
	471061000124102: Referral to mortgage assistance program (procedure)
	471071000124109: Referral to fair housing assistance program (procedure)
	471111000124101: Referral to community development financial institution
	(procedure)
	471121000124109: Referral to community development corporation (procedure)
	471131000124107: Referral to area agency on aging (procedure)
	472021000124101: Referral to tenants' rights organization program (procedure)
	472041000124108: Referral to subsidized housing service (procedure)
	472081000124102: Education about rental assistance program (procedure)
	472091000124104: Evaluation of eligibility for rental assistance program (procedure)
	472131000124102: Provision of rental assistance voucher (procedure)
	472151000124109: Referral to medical legal partnership program (procedure)
	472161000124106: Referral to housing support program (procedure)
	472191000124103: Counseling for readiness to achieve housing security goals
	(procedure)
	472221000124105: Counseling for readiness to implement housing insecurity care
	plan (procedure)
	472241000124103: Counseling for barriers to achieve housing security (procedure)
	472261000124104: Counseling for housing insecurity care plan participation barriers
	(procedure)
	472271000124106: Provision of mortgage assistance voucher (procedure)
	472281000124109: Evaluation of eligibility for mortgage assistance program
	(procedure)
	472291000124107: Education about mortgage assistance program (procedure)
	472331000124100: Education about medical legal partnership program (procedure)
	472381000124104: Provision of emergency housing fund voucher (procedure)
	480841000124109: Education about Homelessness Prevention program (procedure)
	480851000124106: Evaluation of eligibility for Homelessness Prevention program
	(procedure)
	480861000124108: Assistance with application to Homelessness Prevention program
	(procedure)
	480901000124101: Education about fair housing assistance program (procedure)
	551091000124101: Referral to emergency housing fund program (procedure)
	551101000124107: Referral to lawyer (procedure)

Page 112 of 117

Description	CPT/HCPCS/SNOMED CTSNOMED CT
Inadequate Housing	CPT
Procedures	96156, 96160, 96161
	SNOMED CTSNOMED CT
	49919000: Home safety education (procedure)
	308440001: Referral to social worker (procedure)
	710824005: Assessment of health and social care needs (procedure)
	711069006: Coordination of care plan (procedure)
	1148446004: Education about legal aid (procedure)
	1148813002: Assessment of barriers in inadequate housing care plan (procedure)
	1148815009: Assessment of goals to achieve adequate housing (procedure)
	1148823006: Assessment of progress toward goals to achieve adequate housing
	(procedure)
	1162436000: Referral to legal aid (procedure)
	1230338004: Referral to charitable organization (procedure)
	461481000124109: Referral to peer support (procedure)
	462481000124102: Referral to Community Action Agency program (procedure)
	462491000124104: Referral to benefits enrollment assistance program (procedure)
	464001000124109: Referral to case manager (procedure)
	464011000124107: Referral to care manager (procedure)
	464021000124104: Referral to care navigator (procedure)
	464131000124100: Referral to community health worker (procedure)
	464161000124109: Referral to community resource network program (procedure)
	464291000124105: Education about community resource network program
	(procedure)
	464301000124106: Education about benefits enrollment assistance program
	(procedure)
	464311000124109: Education about Community Action Agency program (procedure)
	464611000124102: Coordination of care team (procedure)
	470231000124107: Counseling for social determinant of health risk (procedure)
	470431000124106: Referral to weatherization assistance program (procedure)
	470441000124101: Evaluation of eligibility for weatherization assistance program
	(procedure)
	470451000124104: Education about weatherization assistance program (procedure)
	470461000124102: Assistance with application for weatherization assistance
	program (procedure)
	470591000124109: Education about community development financial institution
	(procedure)
	470601000124101: Education about community development corporation
	(procedure)
	470611000124103: Education about area agency on aging program (procedure)

Page 113 of 117

Description	CPT/HCPCS/SNOMED CTSNOMED CT
Description	471111000124101: Referral to community development financial institution
	(procedure)
	471121000124109: Referral to community development corporation (procedure)
	471131000124107: Referral to area agency on aging (procedure)
	472151000124109: Referral to medical legal partnership program (procedure)
	472201000124100: Counseling for readiness to achieve adequate housing goals
	(procedure)
	472211000124102: Counseling for readiness to implement inadequate housing care
	plan (procedure)
	472231000124108: Counseling for barriers to achieve adequate housing (procedure)
	472251000124101: Counseling for inadequate housing care plan participation
	barriers (procedure)
	472331000124100: Education about medical legal partnership program (procedure)
	472371000124102: Provision of voucher for repair of place of residence (procedure)
	480881000124103: Referral to environmental hazard testing of residence program
	(procedure)
	480891000124100: Evaluation of eligibility for environmental hazard testing of
	residence program (procedure)
	480911000124103: Education about environmental hazard testing of residence
	program (procedure)
	480951000124102: Assistance with application for environmental hazard testing of
	residence program (procedure)
	551041000124105: Referral to housing repair program (procedure)
	551051000124107: Referral for housing repair assessment program (procedure)
	551061000124109: Evaluation of eligibility for housing repair program (procedure)
	551071000124102: Education about housing repair program (procedure)
	551081000124104: Assistance with application for housing repair program
	(procedure)
	551101000124107: Referral to lawyer (procedure)
Transportation	СРТ
Insecurity Procedures	96156, 96160, 96161
	SNOMED CTSNOMED CT
	308440001: Referral to social worker (procedure)
	710824005: Assessment of health and social care needs (procedure)
	711069006: Coordination of care plan (procedure)
	1148446004: Education about legal aid (procedure)
	1162436000: Referral to legal aid (procedure)
	1230338004: Referral to charitable organization (procedure)
	461481000124109: Referral to peer support (procedure)
reimbursement. All member c	sted are informational only, not clinical guidelines or standards of medical care, and do not guarantee care and related decisions of treatment are the sole responsibility of the provider. This information does not decisions regarding the appropriate care of members. Your state/provider contract(s). Medicaid, member

Page 114 of 117

Description	CPT/HCPCS/SNOMED CTSNOMED CT
	462481000124102: Referral to Community Action Agency program (procedure)
	462491000124104: Referral to benefits enrollment assistance program (procedure)
	464001000124109: Referral to case manager (procedure)
	464011000124107: Referral to care manager (procedure)
	464021000124104: Referral to care navigator (procedure)
	464131000124100: Referral to community health worker (procedure)
	464161000124109: Referral to community resource network program (procedure)
	464291000124105: Education about community resource network program
	(procedure)
	464301000124106: Education about benefits enrollment assistance program
	(procedure)
	464311000124109: Education about Community Action Agency program (procedure)
	464611000124102: Coordination of care team (procedure)
	470231000124107: Counseling for social determinant of health risk (procedure)
	470591000124109: Education about community development financial institution
	(procedure)
	470601000124101: Education about community development corporation
	(procedure)
	470611000124103: Education about area agency on aging program (procedure)
	471111000124101: Referral to community development financial institution
	(procedure)
	471121000124109: Referral to community development corporation (procedure)
	471131000124107: Referral to area agency on aging (procedure)
	472151000124109: Referral to medical legal partnership program (procedure)
	472331000124100: Education about medical legal partnership program (procedure)
	551101000124107: Referral to lawyer (procedure)
	551111000124105: Provision of taxi voucher (procedure)
	551121000124102: Referral to taxi voucher program (procedure)
	551141000124109: Evaluation of eligibility for taxi voucher program (procedure)
	551161000124108: Education about taxi voucher program (procedure)
	551191000124100: Assistance with application for taxi voucher program (procedure)
	551201000124102: Referral to fuel voucher program (procedure)
	551211000124104: Evaluation of eligibility for a fuel voucher program (procedure)
	551221000124107: Education about fuel voucher program (procedure)
	551231000124105: Referral to vehicle donation program (procedure) 551241000124100: Assistance with application for fuel voucher program (procedure)
	551251000124100: Assistance with application for rule volucier program (procedure) 551251000124103: Evaluation of eligibility for vehicle donation program (procedure)
	551251000124103: Evaluation of englointy for vehicle donation program (procedure) 551261000124101: Education about vehicle donation program (procedure)
	551271000124101. Education about venicle donation program (procedure) 551271000124108 Assistance with application for vehicle donation program
	(procedure)

Page 115 of 117

Description	CPT/HCPCS/SNOMED CTSNOMED CT
Beschption	551281000124106: Referral to transportation network company program
	(procedure)
	551291000124109: Assistance with application for transportation network company
	program (procedure)
	551301000124105: Education about transportation network company program
	(procedure)
	551311000124108: Evaluation of eligibility for transportation network company
	program (procedure)
	551321000124100: Referral to volunteer driver program (procedure)
	551331000124102: Referral to rideshare program (procedure)
	551341000124107: Referral to public transportation voucher program (procedure)
	551351000124109: Referral to paratransit program (procedure)
	551361000124106: Referral to microtransit program (procedure)
	551371000124104 Referral to Non-Emergency Medical Transportation program
	(procedure)
	551381000124101: Referral to automobile share program (procedure)
	551401000124101: Referral to vehicle repair program (procedure)
	551421000124106: Assistance with application for bicycle share program
	(procedure)
	551431000124109: Referral to bicycle share program (procedure)
	610961000124100: Assistance with application for volunteer driver program
	(procedure)
	610971000124107: Assistance with application for rideshare program (procedure)
	610981000124105: Assistance with application for public transportation voucher
	program (procedure)
	610991000124108: Assistance with application for paratransit program (procedure)
	611001000124109: Assistance with application for microtransit program (procedure)
	611011000124107: Assistance with application for Non-Emergency Medical
	Transportation program (procedure)
	611021000124104: Assistance with application for automobile share program
	(procedure)
	611031000124101: Education about rideshare program (procedure)
	611041000124106: Education about volunteer driver program (procedure)
	611051000124108: Education about microtransit program (procedure)
	611061000124105: Education about public transportation voucher program
	(procedure)
	611071000124103: Education about paratransit program (procedure)
	611081000124100: Education about Non-Emergency Medical Transportation
	program (procedure)
	611101000124108: Education about vehicle repair program (procedure)

Page 116 of 117

Description	CPT/HCPCS/SNOMED CTSNOMED CT
	611121000124103: Education about automobile share program (procedure)
	611281000124107: Counseling for readiness to achieve transportation security
	(procedure)
	611291000124105: Counseling for barriers to achieve transportation security
	(procedure)
	611301000124106: Counseling for readiness for engagement in transportation
	insecurity care plan (procedure)
	611311000124109: Counseling for barriers to engagement in transportation
	insecurity care plan (procedure)
	611321000124101: Assessment of progress toward goals to achieve transportation security (procedure)
	611331000124103: Assessment of goals to achieve transportation security
	(procedure)
	611341000124108: Assessment of barriers in transportation insecurity care plan
	(procedure)
	611351000124105: Assessment for transportation insecurity (procedure)
	611361000124107: Evaluation of eligibility for rideshare program (procedure)
	611371000124100: Evaluation of eligibility for volunteer driver program (procedure)
	611381000124102: Provision of public transportation voucher (procedure)
	611391000124104: Evaluation of eligibility for public transportation voucher program (procedure)
	611401000124102: Evaluation of eligibility for paratransit program (procedure)
	611411000124104: Evaluation of eligibility for microtransit program (procedure)
	611421000124107: Evaluation of eligibility for automobile share program
	(procedure)
	611431000124105: Evaluation of eligibility for vehicle repair program (procedure)
	611441000124100: Evaluation of eligibility for Non-Emergency Medical
	Transportation program (procedure)

Note: The codes listed are informational only; this information does not guarantee reimbursement.

To help make it as easy as possible to keep up with annual changes to HEDIS documentation, we have created a library of HEDIS content for you. You'll find tip sheets with coding information and more for many HEDIS measures and other documentation to help ensure accurate claims coding, which helps ensure accurate reimbursement. Go to *Provider News* to view all communications in the Optimizing HEDIS & STARS category.

Please visit My Diverse Patients for additional information about eLearning experiences on provider cultural competency and health equity.

HEDIS ECDS Coding Booklet 2025

Page 117 of 117

